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Chapter 1 General Introduction 
1.1 Aim and outline of the thesis 
Protein formulation is a crucial part of the therapeutic protein development process.  
One primary aim during protein formulation is to find solution conditions that impede protein 
instability during long-term storage. This instability can be a result of various degradation 
pathways which can be challenging to predict. This is the case with protein aggregation which 
has been a subject of intensive research by both academia and industry.   
 In the context of developing a new therapeutic protein, particularly interesting is the 
application of predictive methods that can rank protein formulations in order of their effect on 
protein aggregation during long-term storage. The use of such predictive methods before the 
start of the stability studies can substantially reduce the effort, costs and risk of failure during 
therapeutic protein development. 
Many techniques for protein characterisation have been developed over the years.  
In recent times, there was also a significant improvement in the instrumentation with a focus 
on sample volume reduction, increased throughput and automation. Although the portfolio of 
stability-indicating techniques for protein formulation studies is continuously expanding, the 
predictions from these techniques are rarely validated with published peer-reviewed long-term 
stability data. The lack of such publicly available information continues to raise questions 
whether the rankings from these techniques are accurate and what would be the best approach 
to select protein formulations for long-term stability studies. Our aim when we started this 
thesis was to, at least partially, answer these questions. 
The topic was approached from three directions. First, I applied some of the  
widely-used contemporary stability-indicating techniques to characterise different liquid 
formulations of several therapeutic proteins. Second, I developed some new concepts for assays 
that can be used for the selection of stable protein formulations. Third, I performed real-time 
long-term stability studies on the above-mentioned protein formulations. In the end, the 
predictions from the established and newly-developed techniques were compared to the long-
term stability data. The outcome and conclusions of this work are summarised in several 
consecutive and logically connected thesis chapters. 
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In Chapter I, I give a brief introduction to different aspects of therapeutic protein 
stability, some techniques for biophysical protein characterisation and discuss several 
considerations during protein formulation development. 
In Chapter II, I apply some contemporary techniques to study the stability of interferon 
alpha2a as a function of pH and ionic strength. Using these techniques, I found a new  
interferon alpha2a formulation that is very stable during long-term storage at 4 ºC and 25 ºC.  
In Chapter III, I discuss some of the disadvantages of stability-indicating techniques 
that require sample heating during measurements. In this context, I explore the application of 
isothermal chemical denaturation as an orthogonal technique for protein formulation studies. 
In Chapter IV, I present a new approach to study the stability of monoclonal antibody 
formulations by assessing the aggregates formed after the protein is diluted from different 
concentrations of a denaturant. I discuss how the latter technique can complement isothermal 
chemical denaturation experiments during protein formulation development. 
In Chapter V, I study the effect of different denaturants and incubation time on the 
unfolding and aggregation of a monoclonal antibody in several formulation conditions. I show 
that the formulation pH influences in a similar way the aggregation of the partially unfolded 
antibody in the presence of a denaturant and the aggregation of the antibody during refolding 
from a denaturant. 
In Chapter VI, a new microdialysis-based isothermal assay, named ReFOLD, is 
presented. The approach assumes that formulation conditions that suppress the aggregation of 
multiple partially unfolded protein species are good conditions for long-term storage of the 
protein. The ReFOLD assay accurately ranks the formulations of two antibodies in order of 
their effect on the protein aggregation during long-term storage at 4 ºC and 25 ºC. 
In Chapter VII, several orthogonal techniques, including the newly-developed 
ReFOLD assay, are used to probe the effect of additives, i.e. sucrose and two arginine salts, on 
the unfolding and aggregation of a monoclonal antibody. There is a good agreement between 
the predictions from these techniques and the long-term stability of the formulations. 
In Chapter VIII, the thesis is concluded with a summary and suggestions for a rational 
approach and use of stability-indicating techniques to select formulation conditions where 
protein aggregation will be suppressed during long-term storage. 
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1.2 Protein stability 
Protein stability is a very general term that can have a different meaning for scientists with 
diverse research and educational background. In the world of therapeutic proteins and protein 
drugs, protein stability is generally related to four stability “types” – the protein conformational 
stability, the colloidal protein stability, the protein chemical stability and the interfacial protein 
stability1. Each of the aforementioned is important and should be high enough to obtain a 
therapeutic protein formulation that is stable during storage for several months or years.  
1.2.1 Conformational stability 
At ambient conditions, most therapeutic proteins exist predominantly in a folded conformation 
which is required for them to attain their specific biological activity2. In solution, the folded 
protein is usually in equilibrium with a fraction of unfolded protein. This equilibrium can be 
described by an equilibrium constant, Keq (Fig 1A). The equilibrium constant is related to the 
fraction of unfolded protein in the solution and to the Gibbs free energy of protein unfolding, 
dG (Fig 1B).  
 
Figure 1. (A) Schematic representation of an equilibrium between a folded and unfolded protein with the 
corresponding equilibrium constant, Keq; (B) The connection between the Gibbs free energy of protein unfolding, 
the equilibrium constant of protein unfolding and fraction of unfolded protein in solution. In the equation, R is the 
universal gas constant, and T is the temperature (293 K in these calculations); (C) Energy landscape representing 
the Gibbs free energy of protein unfolding as the difference between the unfolded and folded protein state; 
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The dG is a direct measure of the conformational stability of a protein and represents the 
difference in the energy of the folded protein conformation and the unfolded polypeptide chain3 
(Fig 1C). Important to note, the Gibbs free energy of protein unfolding differs not only between 
protein molecules, but also depends on parameters like solution pH and temperature4.  
In the context of protein formulation development, a high Gibbs free energy of protein 
unfolding is essential since this will indicate the presence of only a small fraction of unfolded 
protein species which are often prone to form aggregates5,6. 
1.2.2 Colloidal stability 
The colloidal protein stability is related to the weak net interactions between the protein 
molecules in solution1. Such net protein-protein interactions can be either attractive or repulsive 
and arise from the sum of long-range electrostatic, short-range attractive and hard-sphere 
interactions5. The contribution of the different protein interactions can be graphically presented 
and explained with the DLVO (Deryagin-Landau-Verwey-Overbeek) theory for the stability 
of colloids7 (Fig. 2). The weak protein-protein interactions are of high importance during 
formulation development of therapeutic proteins as they have an impact on the protein 
aggregation, solubility, viscosity, phase separation and crystallisation behaviour1,8–13.  
 
Figure 2. Schematic representation of the DLVO theory for the contribution of long-range repulsive electrostatic 
interactions and attractive short-range interactions to the net protein-protein interactions. (A) and (B) present a 
case with net repulsive and net attractive interactions respectively. 
Several parameters can be used to assess the colloidal protein stability. For example, the second 
virial coefficient, B22, is a measure of the net protein-protein interactions in solution
14.  
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In general, a large positive B22 indicates repulsion between the protein molecules which has 
been connected to lower protein aggregation rates for a range of protein formulations5,15–17.  
1.2.3 Chemical stability 
The chemical protein stability is related to chemical degradation. The latter can occur via 
various mechanisms like oxidation, deamination and proteolysis1,18. 
Protein oxidation can be defined as the covalent alteration of the polypeptide chain by direct 
interaction with reactive oxygen species19. In general, amino acids that contain a sulfur atom 
or aromatic rings are more prone to oxidation20. In the context of therapeutic proteins, the 
oxidation of methionine, tryptophan, histidine, phenylalanine and tyrosine has been identified 
as most relevant21. Various factors can accelerate oxidation, the most critical being the presence 
of metal ions, oxygen exposure, light exposure and high temperature1,18,21. Oxidation is less 
affected by solution properties like pH, and the main strategies to suppress this degradation 
pathway are the addition of antioxidants and chelating agents, the reduction of the oxygen and 
light exposure in the primary package, and storage at refrigerated temperature1. 
Deamination is another chemical degradation pathway typical for therapeutic proteins18. 
Deamination usually occurs via hydrolysis of amide side chains of asparagine and glutamine 
residues22. The rate of this hydrolysis is pH-dependent and exhibits a minimum between  
pH 3 and 61. In neutral and slightly acidic solutions, the deamination rate of asparagine is higher 
than the deamination rate of glutamine residues18. Moreover, the process is faster for asparagine 
residues followed by small amino acids in the primary protein structure18. Also, similar to other 
chemical degradation pathways, deamination rate depends on temperature and typically 
follows Arrhenius behaviour23. Knowing some of the factors that accelerate deamination, the 
most important strategies to reduce this degradation pathway are to select an optimal solution 
pH and to store the protein at lower temperature1. 
Proteolysis, also often named hydrolysis, is a chemical degradation pathway which is related 
to the nonenzymatic cleavage of amide bonds24. That degradation mechanism is often observed 
for monoclonal antibodies where hydrolysis in the solvent-exposed hinge region leads to 
fragmentation of the protein and formation of free Fab domains, free Fc domains and one arm 
antibodies. The proteolysis rate of antibodies is pH-dependent and shows a V-shape profile 
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with a minimum at around pH 625. Accordingly, the most often used approaches to suppress 
hydrolysis are the selection of optimal solution pH and storage at refrigerated temperature1. 
There are many other chemical degradation pathways besides the three that were shortly 
discussed above. Examples are asparagine isomerization26, asparagine hydrolysis27, tryptophan 
hydrolysis28, diketopiperazine formation29, glycation30 and disulphide scrambling31. However, 
these degradation pathways typically occur at relevant rates only in certain conditions,  
e.g. extreme pH or presence of reducing sugars. Moreover, similar to other chemical reactions 
these processes usually follow Arrhenius behaviour and their rate is diminished by storage at 
cold temperatures18. 
1.2.4 Interfacial stability 
The interfacial stability of a protein is related to stress that occurs at air-liquid, solid-liquid or 
liquid-liquid interfaces1,32. Such interfaces exist, for example, between the protein solution and 
the primary packaging material, between the protein solution and the air in the container 
headspace or at the surface of silicon oil droplets. Moreover, new and larger interfaces can be 
created when the solution experiences mechanical stress like shaking, agitation or if being 
dropped33,34. Many therapeutic proteins are surface active and tend to accumulate at the 
interfaces mentioned above35–37. Although the phenomena of protein destabilisation at an 
interface are not fully understood, there are several proposed mechanisms which are outside 
the scope of this thesis32,35. Relevant in the context of protein formulation is that in most cases 
interfacial instability is mitigated by the addition of a suitable amount of non-ionic surfactants 
like polysorbates which are nowadays present in most protein drugs on the market38,39. 
1.3 Biophysical techniques for protein characterisation 
There are many ways to classify the techniques used for biophysical characterisation of 
proteins. In the context of this thesis, I summarised some of the latter into four big groups 
depending on their application to study the four aspects of protein stability discussed earlier. 
1.3.1 Techniques and parameters used to assess protein conformational stability 
The conformational stability of a protein can be assessed by non-isothermal and isothermal 
methods. The non-isothermal methods usually apply a linear temperature gradient to cause 
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protein unfolding. The unfolding of the protein is detected by a change in a physical observable 
that depends on the technique (Table 1).  
Table 1. Techniques employing thermal denaturation to assess protein conformational stability  
Techniques Physical observable 
Differential scanning calorimetry40 Change in heat capacity 
Circular dichroism spectroscopy41 Change in ellipticity 
Ultraviolet spectroscopy42 
Change in the molar absorptivity or the peak maximum of the 
ultraviolet absorption protein spectra 
Fourier-transform infrared 
spectroscopy43 
Change in the position and the intensity of the Amide I band in the 
protein Fourier-transform infrared spectra 
Fluorescence spectroscopy  
(extrinsic fluorescence)44 
Change in the fluorescence intensity of a fluorescence dye upon interactions 
with hydrophobic patches exposed during protein unfolding 
Fluorescence spectroscopy  
(intrinsic fluorescence)45 
Change in the intrinsic protein fluorescence intensity or peak maximum due 
to change in the environment of fluorescent amino acids upon unfolding 
 
In cases where the protein does not aggregate during the measurement and the thermal 
unfolding is reversible, these techniques can provide thermodynamic data describing the 
protein conformational stability and the protein unfolding process40. This includes the Gibbs 
free energy of protein unfolding, the enthalpy of the unfolding process, the change in the heat 
capacity upon unfolding and the true protein melting temperature. The true protein melting 
temperature is the temperature at which the ratio of unfolded to folded protein is one,  
i.e. the Gibbs free energy equals zero (Figure 3A). 
The reality is that most therapeutic proteins aggregate during thermal unfolding and the process 
is not reversible4. The latter obstructs the thermodynamic data analysis and extrapolation using 
the Gibbs-Helmholtz equation (Figure 3B) which resolves the entire protein stability curve that 
depicts the protein conformational stability as a function of temperature (Figure 3A). As a result 
of that, the thermal denaturation techniques are usually used to provide only a  
so-called apparent protein melting temperature which is just an approximation of the true 
protein melting temperature in Fig. 3A. Still, the apparent protein melting temperatures have 
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been widely used in industry and academia as a parameter to compare the conformational 
stability of therapeutic proteins in different formulation conditions46–49. 
 
Figure 3. (A) The protein stability curve and (B) the Gibbs-Helmholtz equation describing what is the protein 
conformational stability at different temperatures. 
The conformational stability of a protein in different formulations can also be measured with 
an isothermal method like isothermal chemical denaturation3,4. In this case, the protein in the 
formulation of interest is mixed with increasing concentrations of a denaturant, i.e. guanidine 
hydrochloride or urea. Next, the samples are incubated at a constant temperature long enough 
to reach an equilibrium and a physical observable, e.g. ellipticity or fluorescence, is measured 
to detect at which denaturant concentrations the protein is partially or fully unfolded (Fig. 4A). 
Finally, the isothermal chemical denaturation graph is fitted to a suitable model to extract 
parameters describing the protein conformational stability (Fig. 4B). The fitting models and 
approaches that can be used for this evaluation have been described in detail elsewhere4,50,51.  
Undoubtedly, isothermal chemical denaturation is a valuable technique since the method can 
be performed at any temperature of interest and can directly provide the Gibbs free energy of 
protein unfolding for that temperature without any extrapolations from higher temperatures 
used in the analysis of thermal denaturation data4 (Fig 3). However, the accurate 
thermodynamic analysis of isothermal chemical denaturation data assumes that the protein 
unfolding in the denaturant is reversible and that the samples are in equilibrium at the time of 
the measurement. The latter assumptions are not always valid for therapeutic proteins in 
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different formulations as indicated in some recent publications and discussed later in this 
thesis6,52–55. 
 
Figure 4. (A) Schematic presentation of a protein unfolding curve obtained by isothermal chemical denaturation 
and (B) the protein stability parameters extracted from the analysis of such curve  
1.3.2 Techniques and parameters used to assess protein colloidal stability 
During formulation development, the colloidal stability of a protein is often assessed with light 
scattering techniques that can provide information about the net protein-protein interactions in 
a formulation. For example, static light scattering is used to determine the second virial 
coefficient, B22, which describes the net protein-protein interactions in solution. Unfortunately, 
the accurate determination of the second virial coefficient is tedious regardless of the technique 
which is used to measure it. Therefore, surrogate parameters for B22 more often find application 
to assess the colloidal stability of a protein during formulation development. One such  
widely-used parameter is the interaction parameter kD which can be measured in  
high-throughput fashion in microwell plates. The interaction parameter kD represents the slope 
of the concentration dependence of the protein mutual diffusion coefficient determined with 
dynamic light scattering (Figure 5). Several studies have shown that kD correlates well with the 
second virial coefficient B22, and similarly to B22, a high positive kD will indicate that the 
protein-protein interactions are repulsive56,57. However, kD and B22 can be determined and are 
valid only in dilute protein solutions58. Moreover, measuring kD in some formulations with low 
ionic strength can provide an overestimation of the repulsive protein interactions which should 
be taken into consideration59.  Defining parameters which more accurately describe the  
protein-protein interactions in a broader range of conditions is currently a topic of intensive 
research with both computational and experimental approaches11,58,60,61. 
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Figure 5. Determination of the interaction parameter kD from the change of the protein mutual diffusion 
coefficient determined with dynamic light scattering as a function of the protein concentration 
The aggregation onset temperature is another parameter which is often measured to compare 
the colloidal stability of therapeutic proteins in different formulations47,62,63. This parameter 
can be determined with various light scattering or spectroscopic techniques while the 
temperature of the protein formulation is gradually increased. The aggregation onset 
temperature is often closely related to the protein melting temperature and does not directly 
reflect the magnitude of the net protein-protein interactions. However, formulations with higher 
aggregation onset temperature or formulations that do not aggregate during heating are likely 
to have high colloidal stability. 
Besides the static and dynamic light scattering, there are many more techniques that can be 
used to assess B22 and kD, or other parameter describing the colloidal protein stability.  
Such techniques are analytical ultracentrifugation64, self-interaction chromatography16, small 
angle X-ray scattering65, nuclear magnetic resonance66, self-interaction nanoparticle 
spectroscopy67, precipitation with polyethylene glycol68 and biolayer interferometry69. In the 
context of protein formulation development, the application of the latter techniques is tedious, 
not well established or their integration in formulation studies is not straightforward which 
makes them more rarely used in the early stage therapeutic protein development. 
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1.3.3 Techniques and parameters used to assess protein chemical stability 
The chemical protein stability is usually assessed by a combination of stress or accelerated 
stability studies and suitable analytical techniques70,71. The stress can be, for example, exposure 
to high temperature, oxidants or light72. Such experiments aim to identify what the major 
chemical degradation pathways of a therapeutic protein are and to compare the rate of chemical 
degradation between formulations70,71. The gold standard analytical method which ultimately 
provides the exact type and extent of chemical changes is liquid chromatography coupled to 
mass spectrometry73. However, the latter method can be very tedious, and accordingly many 
other techniques also find application to study the chemical changes of a protein during 
formulation development (Table 2). Such techniques often do not provide information about 
the exact type of chemical changes, but their output can be used for comparison between 
formulations after different stress.  
Table 2. Techniques used in the characterisation of protein chemical degradation 
Technique Output 
Liquid chromatography coupled to 
mass spectrometry74,75 
Amount and exact type* of chemically changed species 
*Note that peptide mapping73 is required in some cases. 
Reversed phase chromatography 
without mass spectrometry76 
Amount of chemically changed species 
Ion exchange chromatography77 Amount of acidic and basic variants 
Isoelectric focusing Amount of acidic and basic variants 
Protein A chromatography74 
Amount of antibody species oxidised at the protein A binding site of 
antibodies 
Hydrophobic interaction 
chromatography78 
Amount of protein species with changed hydrophobicity 
Combination of reducing and non-
reducing gel electrophoresis  
Qualitative or semi-quantitative information about the presence and 
type of covalent bond between aggregates 
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1.3.4 Techniques and parameters used to assess protein interfacial stability 
The interfacial stability of a protein is typically assessed after applying mechanical stress.  
The latter can be shaking, stirring, vibration, freeze-thaw or dropping 1,33,34,79. Next, the stressed 
samples are analysed with orthogonal techniques. Ultraviolet-visible spectroscopy and 
chromatography are typically used to detect a loss of soluble protein which can occur when the 
protein adsorbs and remains at interfaces, or when insoluble protein aggregates form.  
Size exclusion chromatography, field-flow fractionation and light scattering find application to 
study the formation of small soluble aggregates80. The presence of larger aggregates is 
evaluated with techniques like light obscuration, flow imaging microscopy or others35,81. The 
mechanical stress studies aim to investigate the impact of formulation conditions on the 
interfacial protein stability82, often with a focus on the effect of different surfactant 
concentrations34. In addition, it is important to also study the stability of the protein 
formulations in the final primary package as the type of package material, fill volume, 
headspace, etc., can have a significant impact on protein degradation during mechanical stress1. 
1.4 Considerations for liquid protein formulation development 
Finding the optimal formulation for long-term storage of a new therapeutic protein means 
finding a compromise between multiple variables to ensure that all four types of protein 
stability are sufficiently high. This concept is presented schematically in Fig. 6 where the 
change of protein stability is depicted as a function of two imaginary formulation variables. 
Filled areas represent regions where the respective type of stability is high enough for  
long-term storage. Although this figure is an oversimplification of the problem, it is important 
as it illustrates two important things. First, regions, where one type of protein stability is high, 
can be regions where another kind of stability is low. Second, for some proteins, a “sweet spot” 
exists where the formulation conditions satisfy all four types of protein stability. In reality, the 
variables to be considered during formulation development are far more than two and Fig. 6 
quickly becomes multidimensional. Moreover, it is very difficult to draw a line defining the 
threshold between high and low stability. The latter challenges make the development of stable 
protein formulations a very complex task which must be approached from different directions. 
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Figure 6. Schematic presentation of the effect of two imaginary formulation variables on the four aspects of 
protein stability. Filled areas represent conditions where the respective protein stability is high. The area where 
all four types of stability are sufficiently high is denoted as the formulation conditions “sweet spot”.  
1.5 Challenges in predicting protein long-term storage stability  
The accurate prediction of degradation pathways and their rates during long-term storage can 
bring immense improvements to the development process of therapeutic proteins. 
Unfortunately, we are limited by our current knowledge and understanding about the interplay 
between protein structure, formulation and stability. Therefore, we can make good prognosis 
only for some degradation pathways. For example, the rates of most protein chemical changes 
follow Arrhenius behaviour which allows extrapolation and some prediction from data 
obtained at high temperatures18,83. Moreover, the impact of formulation variables on the most 
common chemical degradation mechanisms for proteins is well studied (See section 1.2.3.).  
Other degradation pathways, like protein aggregation, are very difficult to predict. The 
aforementioned can occur via various mechanisms which are extensively discussed 
elsewhere84–88. In general, a protein can aggregate via its native or via its (partially) unfolded 
state. Especially the partially unfolded protein species have been identified as very aggregation-
prone in many studies89–91. Aggregation that occurs through the unfolded or partially unfolded 
protein is often termed non-native aggregation85. The latter typically follows non-Arrhenius 
behaviour which makes the extrapolations from aggregation rates obtained at higher 
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temperatures very difficult92. Moreover, the mechanism and rate of protein aggregation vary 
between proteins, formulations and can also change with temperature93–96.  
The formation and growth of aggregates can be dictated by low conformational or low colloidal 
protein stability8,95,97. It is, therefore, particularly interesting in the context of protein 
formulation development to apply stability-indicating biophysical techniques to assess 
different aspects of protein stability, and by this to predict formulation conditions that will 
impede protein aggregation during storage. The formulation approaches based on stability-
indicating techniques raise two questions. First, which type of protein stability is critical for 
the protein aggregation in a specific case? And second, which parameters or combination of 
parameters describing the conformational and colloidal protein stability provide reliable 
aggregation predictions? Especially the suitability of stability-indicating parameters like the 
protein melting temperature and the protein aggregation onset temperature has been discussed 
in multiple studies, and their prediction power has been recently questioned48,62,63. Therefore, 
it remains an open question which techniques or combination of techniques and which stability-
indicating parameters should be used to select formulations where the aggregation of a 
therapeutic protein is suppressed during long-term storage. 
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2.1 Abstract 
The knowledge and tools to characterise proteins have comprehensively developed in the last 
two decades. Some of these tools are used in formulation development to select formulation 
conditions suitable for long-term storage. However, there is an ongoing debate whether the 
predictions obtained with these tools are in good agreement with the outcome from real-time 
long-term stability studies. In this work, we investigate whether some of the state-of-the-art 
microscale, microvolume and non-destructive biophysical techniques can be applied to 
promptly select formulations that minimise the aggregation of interferon alpha2a during 
storage. Interferon alpha2a was used as a model protein as it is known to form aggregates at 
concentrations over an order of magnitude higher than used in the commercial product.  
We apply a systematic formulation approach in which we investigate the effect of pH and ionic 
strength on protein stability. The predictions from the sample-saving biophysical 
characterisation are validated by long-term stability studies at 4 ⁰C and 25 ⁰C for 12 months on 
selected formulations. Interferon alpha2a shows minimal aggregation in 10 mM sodium acetate 
buffer with pH 4 and low ionic strength. The latter is indicated by the rapid sample-saving 
biophysical characterization and confirmed by the long-term stability data.  
Keywords - Protein stability; Protein Formulation; Protein Aggregation; Therapeutic proteins; 
Protein storage stability; High-throughput protein characterisation; 
Abbreviations - ACF – autocorrelation function from dynamic light scattering data evaluation; 
DLS – dynamic light scattering; HP-SEC – size exclusion chromatography; ICD – isothermal 
chemical denaturation; IFNα2a – recombinant interferon alpha2a; IP350/330 – Inflection point of 
the protein unfolding transition detected by the integrated intrinsic fluorescence intensity ratio 
(FI350nm/FI330nm); RP-HPLC – reversed-phase chromatography; Tagg – protein aggregation 
onset temperature from nanoDSF; Ton – protein aggregation onset temperature from the 
increase in the protein hydrodynamic radius measured by dynamic light scattering; 
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Figure 7. Graphical abstract of Chapter 2 - Effect of pH and ionic strength on the storage stability of IFNα2a 
2.2 Introduction 
The introduction of the first biologics to the market more than three decades ago has 
revolutionised the therapy of many severe diseases98. Unfortunately, this new type of medicines 
brought not only benefits to the patients and the pharmaceutical companies but also many new 
challenges related to their development, production and safety. One common hurdle of 
biologics, in particular of protein-based drugs, is the tendency of proteins to form aggregates 
of various sizes and characteristics85,88,93,99. On the one hand, the formation of large aggregates 
during the shelf-life of a medicine can lead to non-compliance with the tight regulatory limits 
for subvisible and visible particles in parenteral drugs. On the other hand, the protein 
aggregates are considered degradation products according to the ICH guidelines and their 
presence has been related to undesired immunogenic reactions in patients100–103. The reasons 
mentioned above require the adoption of different strategies to minimise the presence and 
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formation of protein aggregates in parenteral drugs. An often-used strategy is the selection of 
formulation conditions (e.g. pH, ionic strength) that impede aggregate formation and growth 
during storage104. One approach to select the optimal formulation conditions for a protein 
would be to prepare dozens of different samples and store them at the temperature of interest 
(e.g. 4 ⁰C) for 1-2 years to see which of them are the most stable. This approach is impractical 
for both time and sample-consumption reasons. A second approach would be to perform 
accelerated stability and stress studies (e.g. at 25 ⁰C and 40 ⁰C) for a few weeks/months to 
select only the most promising formulations that will move on to long-term stability testing. 
This approach, similar to the first one, is also related to a large sample consumption and a 
significant analytical effort. A third approach that has been explored by academia and industry 
for over two decades is to use biophysical techniques that provide data which can facilitate the 
selection of promising formulation conditions1,5. The working principles of the techniques used 
in the third approach have not changed significantly over the years, and most methods rely on 
fluorescence or light scattering measurements. Most efforts to improve these methods have 
been aimed at creating label-free techniques, improving data quality and reproducibility, as 
well as reducing the sample amounts required for measurements and adapting the methods for 
automation. Still, there is an ongoing debate if and to what extent the data obtained from these 
methods is predictive for the stability of the proteins during long-term storage62,105,106.  
Interferon alpha2a (IFNα2a) is a classic example of a protein-based parenteral drug.  
IFNα2a gained first approval by the FDA in the mid-80s and is used to treat patients suffering 
from different types of hepatitis, carcinoma, leukaemia, lymphoma and several other 
conditions107–110.  The benefit of IFNα2a therapy has been repeatedly proven in various clinical 
trials. However, IFNα2a is a protein which is prone to form aggregates and the presence of the 
latter, when formulated with HSA or chemically cross-linked, has been linked to undesired 
immunogenic reactions in mouse models and human patients111,112. Some of these issues led to 
changes in the formulation, removing HSA, of IFNα2a in the mid-90s111,113. More recent work 
on aggregates and immunogenicity suggests the need for chemical modification, not simply 
aggregation, to drive immunogenicity to therapeutic proteins114,115. Still, the goal during the 
formulation development is to find conditions that suppress the formation of protein aggregates 
of any origin. Noteworthy, IFNα2a was developed and characterised in times when the 
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available techniques for protein formulation and analysis were limited in comparison to the 
tools we have nowadays.  
Our goal in this work is to investigate whether some of the modern rapid sample-saving 
techniques can be used to promptly obtain stability-indicating data that can be reliably used in 
formulation development. To do so, we apply a systematic formulation approach, which 
includes three steps: Step 1 - Screen for optimal pH; Step 2 - Screen for the effect of ionic 
strength (i.e. sodium chloride) on the protein stability; Step 3 - Advanced structural 
characterisation; Finally, we study the long-term stability of IFNα2a in different formulations 
after storage at 4 °C and 25 °C to validate the predictions from the rapid, sample-saving 
biophysical characterisation. This work shows how the techniques we explore can be integrated 
into a quick and systematic (pre-)formulation approach which successfully found a liquid 
interferon alpha2a formulation that is very stable during long-term storage. 
2.3 Materials and methods 
2.3.1 Materials 
Interferon alpha2a was kindly provided by Roche Diagnostics GmbH, Penzberg, Germany. 
The bulk solution contains 1.35 g/L protein, 25 mM ammonium acetate buffer with pH 5 and 
120 mM sodium chloride. The protein concentration was measured spectrophotometrically 
using the NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, USA) and  
an A2800,1% = 0.972.  All other chemicals were obtained from Sigma-Aldrich. All solutions 
were prepared with ultrapure water from a Sartorius arium® pro system. All buffers used in 
this work had a concentration of 10 mM and were prepared by combining the respective 
amounts of the 10 mM free acid and 10 mM free base stock solutions with no subsequent pH 
adjustment. The pH after preparation was ±0.1 of the target value. Important to note, the protein 
concentration 1 g/L that we used is higher than the concentration in the commercially available 
products with IFNα2a. Our aim was not to compare the stability of our formulations to the 
commercial products but to use IFNα2a as a model protein for our studies. 
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2.3.2 Sample dialysis and preparation 
2.3.2.1 Screen for the effect of pH (Step 1) 
The buffer of interferon alpha2a for the first formulation step was exchanged in the following 
way – the IFNα2a bulk solution was diluted to 1 g/L, and 100 µL aliquots were filled in 
Pierce™ microdialysis devices with a membrane having 3.5 kDa MWCO. The samples were 
dialysed at 25 ⁰C against 1.6 mL of buffer (10 mM sodium acetate with pH 3.5, 4.0, 4.5, 5.0 or 
5.5; or 10 mM sodium phosphate with pH 6.0, 6.5, 7.0, 7.5 or 8.0). The buffer was exchanged 
every two hours (5 exchanges in total) to ensure a constant concentration gradient across the 
dialysis membrane. After the last change, the samples were left to dialyse overnight. Finally, 
the samples were collected in microcentrifuge tubes and centrifuged at 10.000 x g for 10 
minutes. The following measurements were performed on the supernatant. 
2.3.2.2 Screen for the effect of sodium chloride (Step 2) 
Few millilitres of IFNα2a bulk solution were filled in Spectra/Por® 6-8 kDa MWCO dialysis 
tubing (Spectrum Laboratories Inc., Rancho Dominguez, USA) and dialysed at 20 – 25 °C 
against excess (approximately 1:200) of 10 mM sodium acetate buffer with pH 4 or 5. Two 
buffer exchanges were performed 3 and 8 hours after the beginning. After the last change, 
dialysis was continued for another 16 hours. Stock solutions of sodium chloride (10X) were 
prepared in the respective buffer and spiked into the dialysed IFNα2a to prepare samples 
containing 1 g/L protein in 10 mM sodium acetate with pH 4 or 5 and varying concentrations 
of sodium chloride. 
2.3.2.3 Advanced Protein Characterisation (Step 3) and Long-Term Stability Study 
The IFNα2a buffer was exchanged, and sodium chloride was spiked in the samples to a final 
concentration of 70 mM as described above. Subsequently, the samples were sterile filtered 
with 0.22 µm cellulose acetate filter. For the long-term stability study, the solutions were 
aseptically filled into pre-sterilised DIN2R glass type I vials (2 mL solution in each vial). 
Finally, the vials were crimped with rubber stoppers and stored at 4 ⁰C and 25 ⁰C. At each time 
point (i.e. 0, 3, 6, 9 and 12 months for the storage at 25 ⁰C; and 0, 6 and 12 months for the 
storage at 4 ⁰C), three new vials were opened and used for the analysis of every condition. 
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2.3.3 High-throughput Fluorimetric Analysis of Thermal Protein Unfolding 
nanoDSF® was used to study the protein thermal unfolding and aggregation116,117. The IFNα2a 
solutions were filled into standard glass capillaries (NanoTemper Technologies, Munich, 
Germany) and placed in the Prometheus® NT.48 (NanoTemper Technologies, Munich, 
Germany). A temperature ramp of 1 °C/min was applied from 20 to 95°C. All measurements 
were performed in triplicates. The Prometheus® NT.48 system measures the integrated 
intrinsic protein fluorescence intensity at 330 and 350 nm after excitation at 280 nm in each 
capillary. Simultaneously, the system can detect aggregation/precipitation of the samples with 
a detector which measures the back-reflection intensity of a light beam that passes twice 
through the capillary118. The fluorescence intensity ratio (F350/F330) was plotted against the 
temperature, and the inflection point (IP350/330) of the transition was derived from the maximum 
of the first derivative of each measurement using the PR.ThermControl V2.1 software 
(NanoTemper Technologies, Munich, Germany). Also, the aggregation onset temperature 
(Тagg) from the increase in the signal from the aggregation detection optics was determined 
using the same software. 
2.3.4 Dynamic Light Scattering (DLS) in Micro Well Plates  
Five µL of IFNα2a solution were filled in 1536 well LoBase plate (Aurora Microplates Inc., 
Carlsbad, USA) and the plate was centrifuged at 2200 rpm for 2 minutes using a Heraeus 
Megafuge 40 centrifuge equipped with an M-20 well plate rotor (Thermo Fisher Scientific, 
Wilmington, USA). Next, each well was sealed with 5 µl of silicon oil and centrifuged again 
at 2200 rpm for 2 minutes. The well plate was placed in a DynaPro® DLS plate reader (Wyatt 
Technology Europe, Dernbach, Germany) and 10 acquisitions of 5 seconds at 25 ⁰C were 
collected for each sample. The autocorrelation function (ACF) of each sample was calculated 
from the fluctuation of the light scattering intensity using the Dynamics V7.8 software. 
Cumulant analysis was performed with the same software to derive the apparent coefficient of 
self-diffusion (D) and the polydispersity index (PDI). Next, the apparent protein hydrodynamic 
radius from DLS (Rh) was calculated using the Stokes-Einstein equation using the viscosity of 
the respective sample. The viscosity of the samples was calculated using the solvent tool of the 
Zetasizer software (Malvern, Herrenberg, Germany). Additionally, the viscosity of some 
control samples was measured experimentally with a falling ball viscometer. In all cases, the 
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viscosity of the solutions was ±2 % of the viscosity of pure water. More data on the viscosity 
of the solution and its effect on the calculated Rh can be found in Supplementary data of this 
chapter.  For the temperature ramp experiments, 5 acquisitions of 5 seconds were taken while 
a temperature ramp of 0.1 °C/min was applied from 25 to 80 °C. The aggregation onset 
temperature (Ton) from the increase in the Rh from DLS was determined using the Dynamics 
V7.8 software. All measurements were performed in triplicates. 
2.3.5 Microscale Isothermal Chemical Denaturation (ICD) 
Stock solutions of IFNα2a, buffer and 7 M guanidine hydrochloride (GuHCl) in the respective 
buffer were combined in a non-binding surface 384 well plate (Corning, USA) with the Viaflo 
Assist system (Integra Biosciences, Konstanz, Germany) as earlier described54. Next, the 
samples are incubated for 1 hour at room temperature, filled into standard nanoDSF® glass 
capillaries, and the integrated intrinsic protein fluorescence at 330 and 350 nm was measured 
with the Prometheus® NT.48. The ratio F350/330 was plotted against the denaturant 
concentration, and the curve was fit to a two-state protein unfolding model using the 
PR.ChemControl V1.4.2 software (NanoTemper Technologies, Munich, Germany) to obtain 
the Gibbs free energy of unfolding (∆G), the melting denaturant concentration (Cm) and the m-
value. The experiment was performed in triplicates. 
2.3.6 Circular dichroism (CD) spectroscopy 
Near- and far-UV circular dichroic spectra of IFNα2a solutions with a concentration of 1 g/L 
were collected at 25 ⁰C with a Jasco J-810 spectropolarimeter (JASCO Deutschland GmbH, 
Pfungstadt, Germany). Quartz cuvettes with 10 mm and 0,1 mm wavelength path were used 
for the near-UV and the far-UV measurements respectively. 10 accumulations of each sample 
were taken with a speed of 20 nm/min. The spectrum of the respective buffer was subtracted 
for each sample, the spectra were smoothed using Savitzky-Golay algorithm with 7 smoothing 
points119 and the mean residue ellipticity was calculated as described elsewhere120. 
2.3.7 Fourier-transform Infrared Spectroscopy (FT-IR) 
FT-IR spectra of IFNα2a solutions with a concentration of 1 g/L were collected using a  
Tensor 27 (Bruker Optik GmbH, Ettlingen, Germany) equipped with a BioATR (Attenuated 
Total Reflectance) cell™ II (Harrick) at 25 °C connected to a thermostat (DC30-K20, Thermo 
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Haake). 120 scans with a resolution of 4 cm-1 were used to obtain each spectrum. The data was 
further analysed with the Opus 7.5 (Bruker Optik GmbH) software and presented as a vector-
normalised second-derivative spectrum. The data was smoothed using a Savitzky-Golay 
algorithm with 17 smoothing points119. 
2.3.8 Size Exclusion Chromatography (HP-SEC) 
A Dionex Summit 2 system (Thermo Fisher, Dreieich, Germany) was used for the size 
exclusion chromatography. 25 µg of IFNα2a were injected on a TSKgel G3000SWxl,  
7,8x300 mm, 5 µm column (Tosoh Bioscience, Tokyo, Japan) and the elution of the protein 
was detected at 343 nm after excitation at 280 nm with an RF2000 fluorescence detector 
(Thermo Fisher, Dreieich, Germany). The fluorescence detection to detect IFNα2a aggregates 
with HP-SEC is already successfully used by other groups121. The running buffer consisted of  
50 mM sodium acetate pH 5 with 500 mM arginine hydrochloride.  The chromatograms were 
integrated with Chromeleon V7 (Thermo Fisher, Dreieich, Germany) and the relative area of 
the high molecular species (i.e. small soluble aggregates) was calculated in percentage.  
2.3.9 Flow Imaging Microscopy (FlowCAM) 
The IFNα2a samples on long-term stability study were analysed for the presence of larger 
protein aggregates (subvisible particles) with a FlowCAM® 8100 (Fluid Imaging 
Technologies, Inc., Scarborough, ME, USA). The system was equipped with a  
10x magnification cell (81 µm x 700 µm). Before each measurement, the cleanliness of the cell 
was checked visually. 200 µL of sample were used for the analysis, and the images are collected 
with a flow rate of 0.15 mL/min, an auto image frame rate of 29 frames/second and a sampling 
time of 74 seconds. The following settings were used for particle identification - 3 µm distance 
to the nearest neighbour, particle segmentation thresholds of 13 and 10 for the dark and light 
pixels respectively. The particle size was reported as the equivalent spherical diameter (ESD). 
The VisualSpreadsheet® 4.7.6 software was used for data collection and evaluation.  
2.3.10  Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) 
A Dionex Summit 2 system (Thermo Fisher, Dreieich, Germany) was used for the reversed-
phase high-performance liquid chromatography. The samples were diluted to 0.1 g/L and  
20 µL were injected on a BioBasic C18, 250 x 2.1, 5 µm column (Thermo Fisher, Dreieich, 
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Germany). The sample elution was detected at 214 nm with a UVD170U UV/Vis detector 
(Thermo Fisher, Dreieich, Germany). A gradient of 32 to 48 % eluent B in A in 30 minutes 
was used. Eluent A consisted of 10 % w/v acetonitrile and 0.1 % w/v trifluoracetic acid in 
ultrapure water. Eluent B consisted of 0.1 % w/v trifluoracetic acid in acetonitrile. The flow 
rate was 0.2 mL/min. The column oven temperature was set at 30 ⁰C. The chromatograms were 
integrated with Chromeleon V7 (Thermo Fisher, Dreieich, Germany) and the total relative area 
of all peaks different than the main peak (i.e. impurities) was calculated in percentage. 
2.4 Results and discussion 
2.4.1 Formulation Step 1 – Studying the effect of solution pH on the thermal unfolding, 
aggregation and solubility of IFNα2a 
In this work, we investigate a systematic sample-saving three-step approach to formulate a 
model protein. As a model protein, we use interferon alpha2a, a therapeutically-relevant 
molecule known to form aggregates that can cause clinical complications for the patients. 
During the first formulation step, we studied the effect of the pH on the solubility, thermal 
unfolding and aggregation of IFNα2a. To accomplish this, we used commercially available 
microdialysis devices, which allowed us to dialyse a small solution volume and test a wide 
range of pH values by consuming only a few micrograms of protein. The IFNα2a content in 
the supernatant after microdialysis against buffers with different pH was determined by UV 
spectrophotometry, i.e. with a NanoDrop 2000. The amount of soluble protein is lower at pH 
6.0 and 6.5 indicated by the lower protein concentration and fluorescence intensity (Fig 8).  
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Figure 8. Effect of the pH on the concentration (black bars) and the intrinsic fluorescence of IFNα2a (red circles) 
in the supernatant after microdialysis. The values are mean of triplicates, the error bar is the standard deviation. 
These observations are in good agreement with the results reported by Sharma et al122. We also 
observed that the protein precipitates at pH 5.5 after gentle heating to 35-40 ⁰C (data not 
shown). The low solubility of the protein in this pH range can be explained with the isoelectric 
point of IFNα2a which is around 6. It is common knowledge that the aqueous solubility of 
many proteins is reduced at pH values near the isoelectric point123. Based on these observations, 
we excluded the buffers with pH 5.5-6.5 from further studies. 
Next, we used state-of-the-art microscale and microvolume approaches to study the unfolding, 
aggregation and the apparent hydrodynamic radius Rh of IFNα2a as a function of pH. With an 
increase of pH from 3.5 to 8.0 the protein unfolding transition becomes more cooperative 
(Figure 9A). The highest IP350/330 is measured at pH 4.0 (Figure 9C). Between pH 4.5 and 8.0 
the inflection points (IP350/330) are around 66-67 ⁰C. The lowest IP350/330 is measured at pH 3.5 
(Figure 9C). At pH 3.5 and 4.0 no aggregation during heating is detected with the aggregation 
detection optics, which indicates high colloidal stability of the protein in these conditions 
(Figure 9B). At pH 4.5 or higher, the samples start to form aggregates large enough to cause 
an increase in the signal of the aggregation detector of the Prometheus® NT.48, indicating 
lower protein colloidal stability (Figure 9B). The lowest aggregation temperature Tagg was 
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measured at pH 5 (Figure 9C). At pH 4.5, 7.0, 7.5 and 8.0 IFNα2a shows similar Tagg around 
65-66 ⁰C (Figure 9C). 
 
Figure 9. Effect of pH on IFNα2a unfolding and aggregation – Above: Thermal unfolding traces (A) and 
scattering traces (B) with the corresponding inflection points (IP350/330) and aggregation onset temperatures 
(Tagg) (C) measured with nanoDSF®; Below: The apparent hydrodynamic radius and PDI (D), the temperature 
dependence of the Rh (E) and the calculated aggregation onset temperatures from DLS (F). The values in (D) are 
means of triplicates, and the error bars are the standard deviation. In (C) and (F) each triplicate is shown. 
The apparent hydrodynamic radius of IFNα2a and the polydispersity of the samples measured 
with DLS is highly dependent on the solution pH. The Rh of IFNα2a is lower at pH 4.0 
compared to the samples with higher pH (Figure 9D). The highest Rh was measured in the pH 
range 7 to 8, which indicates that the protein probably forms oligomers in these conditions.  
Therefore, the pH range 7 to 8 was excluded from further studies. At pH 3.5 the DLS 
measurements indicated reproducibly that there is a population of larger particles in the 
samples. The latter is depicted by the high PDI at this pH. The apparent Rh and PDI derived 
from the cumulant fit for this condition are shown just for informational purpose.  The change 
of the Rh during heating is also dependent on the pH (Figure 9E). At pH 4 the onset of 
aggregation Ton measured by DLS is around 60 ⁰C, and after the aggregates reach an Rh of 
about 30 nm, the aggregate growth stops (Figure 9E). The small aggregate size explains why 
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no aggregation is detected with the Prometheus® NT.48 during heating of the IFNα2a samples 
with pH 4.0 (and pH 3.5). At higher pH (i.e. 4.5 and above) the Ton is shifted to a lower 
temperature or a steep increase in the Rh without a plateau is observed (Figure 9E). The 
determined Ton values of IFNα2a with DLS are lowest at pH 4.5 and 5.0 (Figure 9F), which 
indicates lower protein colloidal stability in these conditions compared to pH 4.0. Important to 
note – only 150 µg of protein and less than 15 hours of total instrument measurement time per 
replicate were required to obtain the data for the entire pH screen presented in Figures 8 and 9.  
As additional information for the readers we also compared the thermal unfolding of IFNα2a 
measured by the change of the intrinsic protein fluorescence intensity ratio (from the 
nanoDSF® measurement) and by the change in the protein ellipticity at 293 nm (from circular 
dichroism) and found excellent agreement between the two methods (Supplementary data). 
Further, the inflection point from the change in the intrinsic protein fluorescence ratio during 
the thermal unfolding of IFNα2a at pH 5.0 corresponds well with the melting temperature of 
IFNa2a measured with differential scanning calorimetry (DSC) by Sharma et al124. Noteworthy 
is that cuvette-based, DSC and near-UV CD devices do not allow the simultaneous thermal 
unfolding studies on many samples and require much higher protein amount in comparison to 
the techniques we used in this study. Both nanoDSF® and DLS in microwell plates can be used 
to measure dozens of samples simultaneously.  
2.4.2 Formulation Step 2 – Studying the effect of sodium chloride on the thermal 
unfolding and aggregation of IFNα2a 
During the second formulation step, we focused on the effect of sodium chloride (i.e. ionic 
strength) on the stability of IFNα2a at pH 4.0 and pH 5.0. These two pH values were selected 
since IFNα2a shows very different behaviour – at pH 4.0 IFNα2a undergoes a less cooperative 
thermal unfolding but has high colloidal stability; at pH 5.0 the protein thermal unfolding is 
characterised by a sharp transition, but the colloidal protein stability is low.  
Increasing the sodium chloride concentration from 0 to 120 mM causes a shift in the unfolding 
transitions of IFNα2a to a lower temperature (Figure 10A and 10D). This shift is more 
pronounced at pH 4 (compared to pH 5) where the IP350/330 is around 72-73 ⁰C without sodium 
chloride and around 61 ⁰C in the presence of 120 mM NaCl (Figure 10C). This indicates that 
the addition of sodium chloride has a very unfavourable effect on the protein thermal stability 
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at pH 4.0. For comparison, at pH 5.0 the difference in the IP350/330 with 0 mM or with 120 mM 
sodium chloride is only 1.5-2 ⁰C (Figure 10F).  
 
Figure 10. nanoDSF® evaluation of the effect of sodium chloride on IFNα2a – thermal unfolding traces at pH 4 
(A) and pH 5 (D), scattering traces from the aggregation detection optics at pH 4 (B) and pH 5 (E) and the 
corresponding inflection points and aggregation temperatures at pH 4 (C) and pH 5 (F). In (C) and (F) the value 
from each triplicate is shown. 
The addition of 30 mM or more sodium chloride to the 10 mM sodium acetate buffer with  
pH 4 results in IFNα2a aggregation (i.e. larger aggregates) during heating, which is detectable 
by the Prometheus® NT.48 (Figure 10B). An increase in the NaCl concentration from 30 mM 
to 120 mM shifts the Tagg in the samples with pH 4 to lower temperatures (Figure 10C).  
At pH 5, the sodium chloride has a small influence on the aggregation of IFNα2a during 
heating, and 120 mM NaCl reduce the Tagg with only approximately 2 ⁰C (Figure 10E and 10F). 
At pH 4.0, the protein Rh from DLS increases with the addition of only 10-20 mM NaCl and 
does not change when the salt concentration is further increased (Figure 11A). At pH 5.0 the 
Rh decreases slightly with increasing NaCl concentration (Figure 11A). At pH 4.0 the addition 
of NaCl greatly shifts the protein Ton to lower temperatures (Figure 11B) and causes the 
formation of larger aggregates during heating (Figure 11C). At pH 5.0 the increasing sodium 
chloride concentration causes only a moderate decrease in the IFNα2a Ton (Figure 11B) and 
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does not affect the steepness of the increase in the protein Rh during heating (Figure 11D). 
These observations are in good agreement with the data in Figure 10B and 10E.  Once again, 
it is important to mention that all the data presented in Figures 10 and 11 was obtained with the 
consumption of 300 µg of protein and less than 15 hours of measurement time per replicate. 
 
Figure 11. Effect of sodium chloride on the apparent hydrodynamic radius Rh from DLS of IFNα2a at pH 4 and 
pH 5 (A); the aggregation onset temperature of IFNα2a from DLS at pH 4 and pH 5 (B); the temperature 
dependence of the Rh from DLS of IFNα2a at pH 4 (C) and pH 5 (D). In (A) and (B) each triplicate is shown. 
2.4.3 Formulation Step 3 - Advanced structural characterisation of IFNα2a  
2.4.3.1 Effect of the pH on the conformational stability of IFNα2a 
Interferon alpha2a shows a two-state unfolding behaviour in an isothermal chemical 
denaturation experiment with guanidine hydrochloride (Figure 12). The calculated Gibbs free 
energy of unfolding ∆G is lower (mean value of 29.45 kJ/mol) at pH 4 compared to the ∆G at 
pH 5 (mean value of 40.53 kJ/mol), although the melting denaturant concentration Cm is higher 
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(mean value of 4.5 M GuHCl) at pH 4 compared to pH 5 (mean value of 4.01 M GuHCl). The 
reason for the lower ∆G at the lower pH is the lower m-value at pH 4 compared to pH 5, which 
indicates a less cooperative unfolding of IFNα2a in this condition. According to the ∆G, 
IFNα2a has lower conformational stability at pH 4.0 compared to pH 5.0. Noteworthy is that 
the dG, Cm and m-value that were determined at pH 5.0 are in excellent agreement with the 
values reported by Bis et al.125. Another interesting observation is that the unfolding behaviour 
(regarding cooperativity and the position of the inflection point) of IFNα2a at pH 4 and 5 during 
heating resembles the unfolding of the protein in guanidine hydrochloride (Figure 9A and 
Figure 12). Only 240 µg of protein were required to obtain one isothermal chemical 
denaturation graph containing 24 points like the graphs depicted in Figure 12. 
 
Figure 12. Isothermal chemical denaturation of IFNα2a with guanidine hydrochloride in 10 mM sodium acetate 
buffer with pH 4 and pH 5. The values for every replicate are shown. The table in the inset shows the calculated 
means and standard deviations for the ∆G, Cm and m-value from the two-state unfolding fit. 
2.4.3.2 Effect of pH and sodium chloride on IFNα2a secondary and tertiary structure    
The amide I band of IFNα2a shows a maximum between 1650 and 1655 cm-1 at both pH 4 and 
pH 5 with or without 70 mM sodium chloride (Figure 13A). This corresponds well to alpha-
helical secondary protein structure which is expected for this protein and is also consistent with 
previously published data122,125,126. Additionally, the characteristic far-UV CD spectra with two 
minima at 209 and 222 nm confirm the presence of alpha-helical protein structure in all four 
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conditions (Figure 13B)127. The near-UV CD spectra of IFNα2a in 10 mM Na-acetate pH 4 or 
5 with or without 70 mM NaCl show the typical negative peaks at 287 nm and 293 nm which 
are assigned to the two tryptophan residues of this protein (Figure 13C)122,124. This indicates 
that the tertiary structure of IFNα2a is the same in the four formulation conditions tested. 
Noteworthy, both CD and FT-IR are non-destructive methods in the way we used them, and 
the sample was recovered after the measurements. 
 
Figure 13. Effect of pH and 70 mM sodium chloride on the IFNα2a secondary structure studied with (A) FT-IR 
and (B) far-UV circular dichroism; and the IFNa2a tertiary structure studied with (C) near-UV circular dichroism; 
2.4.4 Long-term storage stability of IFNα2a 
2.4.4.1 Formation of small soluble aggregates detected by HP-SEC 
The stock solution of IFNα2a contains approximately 1 % high molecular weight species  
(i.e. small soluble aggregates) detectable by HP-SEC already after thawing.  After dialysis 
against acetate buffer with pH 5.0 these aggregates remain in the solution, while after dialysis 
in the buffer with pH 4.0 these aggregates are no longer present (Figure 14). The latter was 
already observed during formulation/deformulation of IFNα2a128. After storage of the samples 
at 25 ⁰C up to 12 months, the relative area of small soluble aggregates increases more at pH 5.0 
compared to the samples with pH 4.0 (Figure 14A). This is in good agreement with the results 
from the biophysical characterisation which shows that both the thermal and colloidal stability 
of IFNα2a is higher in 10 mM sodium acetate with pH 4 compared to pH 5. Interestingly, the 
addition of 70 mM sodium chloride seems to play a small role in the presence of the small 
soluble aggregates of IFNα2a at both pH 4.0 and pH 5.0 (Figure 14A), although it affected the 
aggregation behaviour of the protein in the short-term characterisation (Figures 10 and 11). 
During storage at 4 ⁰C no increase in the amount of small soluble aggregates was observed, 
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although the samples with pH 5.0 contain more aggregates during the entire stability study 
compared to the samples with pH 4.0 (Figure 14B). For a sample chromatogram from the  
HP-SEC method see the Supplementary data to this chapter. 
  
Figure 14. Small soluble aggregates (high molecular weight species) of IFNα2a measured with HP-SEC during 
long-term storage of the samples at 25 ⁰C (A) and 4 ⁰C (B). The values are mean of triplicates from three different 
vials, the bars show the standard deviation. 
2.4.4.2 Formation of larger protein aggregates (sub-visible particles)  
The highest numbers of particles in all three size ranges were measured in IFNα2a formulations 
with 70 mM sodium chloride after storage at 25 ⁰C (Figure 15 – Above). This agrees well with 
the earlier observations that the addition of sodium chloride causes the formation of larger 
aggregates at pH 4 and reduces the thermal and colloidal protein stability (Figures 10 and 11). 
Both formulations with only 10 mM sodium acetate and no sodium chloride contain a very low 
number of particles after storage at 25 ⁰C (Figure 15 – Above). The formulation with pH 4.0 
without NaCl contains fewer particles (specifically in the size range 10 to 25 µm and above 25 
µm) compared to pH 5.0 without NaCl. During storage at 4 ⁰ C fewer particles are formed 
compared to storage at 25 ⁰C (Figure 15 - Below). After storage at 4 ⁰C the IFNα2a formulation 
containing the highest number of particles of any size is with 10 mM sodium acetate pH 5.0 
and 70 mM sodium chloride. The formulation containing only 10 mM sodium acetate at pH 
4.0 without sodium chloride shows the lowest particle numbers after storage at both 4 and  
25 ⁰C (Figure 15). Important to note, this is the condition in which IFNα2a has the highest 
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IP350/330 (Figure 9C), a high Ton (Figure 9F), small aggregate size after heating (Figure 9E) and 
a low Rh and PDI at 25 ⁰C (Figure 9D).  
  
Figure 15. Subvisible particles detected with flow imaging microscopy in IFNα2a solutions during storage at  
25 ⁰C (above) and 4 ⁰C (below). The values are mean of triplicates from three different vials, the error bars are 
the standard deviation. 
2.4.4.3 Formation of impurities detected by RP-HPLC 
Although the chemical protein degradation is a topic outside the scope of this article, we wanted 
to study if there are differences in the chemical degradation of IFNα2a during storage at pH 4 
and pH 5 with or without sodium chloride. We selected RP-HPLC as a well-established 
technique to detect chemically changed species of IFNα2a122,129,130. For a sample RP-HPLC 
chromatogram from the method we used see the supplementary data to this chapter. More 
chemically changed species (i.e. impurities) detected by RP-HPLC form during storage at  
25 ⁰C compared to storage at 4 ⁰C (Figure 16). However, the relative area of impurities formed 
(and the retention time of the impurity peaks) were the same at both pH 4.0 and pH 5.0, 
regardless of the presence/absence of 70 mM sodium chloride. These results indicate that the 
chemical changes of IFNα2a that occur during long-term storage in the four conditions tested 
in Figure 16 are similar and the differences in the protein degradation in these conditions are 
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driven by the different conformational and/or colloidal protein stability. Although the chemical 
changes are not directly assessed by the “1-2-3 Step” protein formulation approach, one could 
additionally perform short-term stress tests (i.e. high temperature, light exposure) coupled to a 
suitable analytical technique on the formulations in Step 2 to get complementary data whether 
a difference in the chemical stability of the lead formulations is expected1,18. 
 
Figure 16. Relative area of all impurities detected by RP-HPLC in IFNα2a solutions during storage at 25 ⁰C (A) 
and 4 ⁰C (B). The values are mean of triplicates from three different vials, the bars show the standard deviation. 
2.4.4.4 Is there a correlation between the rapid sample-saving biophysical 
characterisation and the long-term stability data? 
The aggregation of a protein can be augmented by low conformational or low colloidal protein 
stability, both of which could be influenced by pH and/or ionic strength5,8. Interferon alpha2a 
has lower conformational stability and shows less cooperative thermal and GuHCl-induced 
unfolding at pH 4.0 compared to pH 5.0. However, at low ionic strength in  
10 mM sodium acetate, the colloidal stability of IFNα2a is higher at pH 4 than at pH 5. This is 
in excellent agreement with the less small and large protein aggregates formed during storage 
of IFNα2a at 25 ⁰C and 4 ⁰C at pH 4 without sodium chloride, which indicates that the high 
colloidal stability is crucial to obtain a stable IFNα2a formulation. The addition of sodium 
chloride (i.e. an increase of ionic strength) has an adverse effect on the protein colloidal 
stability (depicted by a reduction of the Tagg, Ton and an increase in the aggregate size formed 
during heating), which also corresponds well with the formation of large protein aggregates 
during storage of IFNα2a in solutions containing 70 mM sodium chloride.  
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2.5 Conclusion 
In this work, we demonstrated how some of the contemporary tools for protein characterisation 
can be used to perform quick and less-sample-demanding formulation studies on interferon 
alpha2a, studied at protein concentrations significantly higher than used in commercial 
formulations. We structured these studies in a 3-step formulation approach, including Step 1 - 
Screen for optimal pH; Step 2 - Screen for the effect of ionic strength (i.e. sodium chloride) on 
the protein stability; Step 3 - Advanced structural characterisation; We validated the results 
from the rapid biophysical protein characterisation by performing long-term stability studies at 
4 ⁰C and 25 ⁰C during which we studied the formation of small and large aggregates of IFNα2a. 
Both the rapid sample-saving biophysical characterisation and the long-term stability data 
indicate that the aggregation of interferon alpha2a is minimal in 10 mM sodium acetate buffer 
with pH 4. The addition of sodium chloride (i.e. an increase of ionic strength) to IFNα2a 
solutions has a negative effect on the protein physical stability. The presented work is important 
in several directions. First, it shows that thanks to technological advancement we can nowadays 
perform quick systematic formulation studies with miniature samples amounts. Second, it 
shows that the rapid sample-saving techniques we apply here were indeed able to find an 
interferon alpha2a formulation that is very stable during long-term storage. Third, the work 
reveals new insights into the stability of interferon alpha2a in different conditions. Finally, it 
shows that the proposed combination of sample-saving techniques could significantly and 
quickly reduce the number of formulations that will move to accelerated or long-term stability 
studies and therefore reduce development costs and time dramatically. 
 
 
 
 
36 
 
2.6 Supplementary data 
 
Figure S1. Comparison of the thermal unfolding of IFNα2a measured by the integrated intrinsic protein 
fluorescence ratio (FI350/FI330) with nanoDSF® (green circles) and the change in the ellipticity at 293 nm with 
the CD spectrometer (red squares). 
 
 
Figure S2. Sample chromatogram showing the monomer peak and the high molecular weight species (HMW) of 
interferon alpha2a detected with the size exclusion chromatography method. 
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Figure S3. Sample chromatogram showing the main peak and the impurity peaks of interferon alpha2a detected 
with the reversed-phase HPLC method. 
Buffer Sodium chloride (mM) Viscosity used for calculating the Rh (cP) 
10 mM sodium acetate with 
pH 4 or 5 
10 0.8930 
20 0.8933 
30 0.8944 
40 0.8947 
50 0.8959 
60 0.8961 
70 0.8971 
80 0.8975 
120 0.8983 
Table S1. Calculated and measured viscosities of the buffers used in this work. The used viscosity for 10 mM 
sodium acetate buffer with pH 3.5 to 5.5 and for 10 mM sodium phosphate is 0.889 cP.  A control experiment 
with a falling ball viscometer and subsequently a capillary viscometer provided values for these buffers which 
were not different than 0.889 cP within the experimental error. The values used calculations of interferon alpha2a 
Rh in 10 mM sodium acetate buffer including different concentrations of sodium chloride are provided in the table.  
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3.1 Abstract 
Various stability indicating techniques find application in the early stage development of novel 
therapeutic protein candidates. Some of these techniques are used to select formulation 
conditions that provide high protein physical stability. Such an approach is highly dependent 
on the reliability of the stability indicating technique used. In this work, we present a 
formulation case study in which we evaluate the ability of differential scanning fluorimetry 
(DSF) and isothermal chemical denaturation (ICD) to predict the physical stability of a model 
monoclonal antibody during accelerated stability studies. First, we show that a thermal 
denaturation technique like DSF can provide misleading physical stability rankings due to 
buffer-specific pH shifts during heating. Next, we demonstrate how isothermal chemical 
denaturation can be used to tackle the above-mentioned challenge. Subsequently, we show that 
the concentration dependence of the Gibbs free energy of unfolding determined by ICD 
provides better predictions for the protein physical stability in comparison to the often-used Tm 
(melting temperature of the protein determined with DSF) and Cm (concentration of denaturant 
needed to unfold 50% of the protein determined with ICD). Finally, we suggest a rational 
approach which includes a combination of DSF and ICD to obtain accurate and reliable protein 
physical stability ranking in different formulations. 
Keywords: Protein formulation; Thermal denaturation; Isothermal chemical denaturation 
Monoclonal antibody; Differential scanning fluorimetry;  
Abbreviations: µDSC - differential scanning microcalorimetry; Cm - concentration (in M) of 
chemical denaturant needed to unfold 50% of the protein (“melting” concentration of 
denaturant); dG - Gibbs free energy of unfolding; Hionisation - enthalpy of ionisation; dpH/dT - 
temperature dependence of pH in pH units per 1 °C; dpKa/dT - temperature dependence of pKa 
in pH units per 1 °C; DSF - differential scanning fluorimetry; HMW - high molecular weight 
species; HP-SEC - high-performance size exclusion chromatography; ICD - isothermal 
chemical denaturation; LMW - low molecular weight species; MWCO - molecular weight cut 
off; pKa - acid dissociation constant; Tm - protein melting temperature; 
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3.2 Introduction 
3.2.1 Therapeutic protein development and formulation 
Therapeutic proteins have been largely successful in the treatment of various severe  
diseases131–133. This success led to the development and market approval of many new biologics 
over the past two decades. Nowadays, almost every big pharmaceutical company has 
therapeutic proteins in its R&D program134. However, the development process of biologics is 
often more complicated in comparison to small molecules. Proteins can exhibit various 
degradation pathways which are intrinsic to their complex structure. One such degradation 
pathway, which is a major quality and safety issue, is the formation of soluble aggregates.  
It has been demonstrated that the presence of soluble aggregates can result in reduced 
biological activity135,136 or trigger immune response followed by the production of anti-drug 
antibodies101,102,137. Even if the immunogenicity is not an issue for a given protein, the 
aggregates are product-related impurities according to the ICH guidelines138, and it is expected 
that during the shelf life aggregate levels remain within an acceptable range set on a  
case-by-case study. The formation of aggregates can be reduced by selection of optimal 
formulation conditions for a new therapeutic protein candidate. Such selection could be based 
on forced degradation studies followed by accelerated stability testing70. However, such studies 
require a lot of time and a large sample amount (both of which are scarce in the early 
development stage). For this reason, various high throughput biophysical methods became 
widespread as tools that can quickly provide data on many formulation conditions with minimal 
sample consumption. Such high throughput methods are usually used to narrow down the 
number of promising formulations to a few that will move on to forced degradation studies and 
accelerated or real-time stability tests47,49,62,139–141. 
3.2.2 Aspects of protein stability 
Protein stability has various aspects (i.e. physical stability, chemical stability), each of which 
can contribute to the formation of aggregates or affect other quality attributes  
(e.g. biological activity). The connection between protein physical stability and aggregate 
formation has been described in detail elsewhere5,38,142. However, the reader should be aware 
that conditions (e.g. pH, ionic strength) that maximise the physical stability of a protein might 
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have a detrimental effect on the protein chemical stability (e.g. oxidation, deamination). 
Therefore, the most stable protein formulation could be a compromise where the physical and 
chemical stability of the protein is not maximal but sufficient to ensure all aspects of product 
quality during the shelf life. The stabilisation of proteins against chemical changes is outside 
the scope of our work, but more information on this topic can be found in the literature18. 
3.2.3 Thermal denaturation techniques to study protein physical stability 
A commonly used technique to screen formulations for protein physical stability is differential 
scanning microcalorimetry (µDSC). Excellent review of the background and applications of 
µDSC can be found elsewhere40. µDSC has been successfully used to measure the melting 
temperatures (Tm) of various proteins in different formulation conditions. The rankings based 
on Tm values are in some cases in good agreement with the outcome of the accelerated stability 
studies48,105,143,144. Although µDSC provides stability indicating data much faster than forced 
degradation studies (or accelerated stability tests), even µDSC devices equipped with an 
autosampler can measure only several samples over 24 h, and few milligrams of protein are 
required to screen different formulation conditions. 
Differential scanning fluorimetry (DSF) is an alternative to the µDSC technique which 
provides physical stability-indicating data based on the protein melting temperatures in 
different formulations140. Hundreds of Tm values can be obtained per day with modern DSF 
methods with as less as few micrograms of protein needed for one measurement. There are two 
main approaches to perform DSF – the first is based on an increase in the (extrinsic) 
fluorescence intensity of a fluorescent dye that interacts with hydrophobic protein patches 
exposed during thermal unfolding145. The second approach is label-free and measures the 
intrinsic tryptophan fluorescence that changes during unfolding due to a change in the 
tryptophan environment116. Excellent agreement was demonstrated between Tm values 
measured by µDSC and DSF with extrinsic fluorescent dye47,140,146,147 or DSF based on intrinsic 
protein fluorescence148. 
Whether µDSC or DSF will be used during protein formulation screening is still a matter of 
debate and preferences of the formulation scientist. An advantage of µDSC is that this 
technique will usually provide a better resolution between protein unfolding transitions in 
comparison to DSF146. Also, the detection of protein unfolding by µDSC is independent on the 
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number of tryptophan residues in the structure or the interaction of the extrinsic fluorescent 
probe with the (partially unfolded) protein. The benefits of DSF techniques are mostly related 
to the lower sample consumption and the high throughput compared to µDSC. 
Regardless whether heat capacity (µDSC) or extrinsic/intrinsic fluorescence (DSF) is measured 
as a physical observable to detect protein unfolding during heating, all thermal denaturation 
methods suffer from the fact that the temperature is increased far above the actual temperature 
of sample preparation and storage. This requires long error-prone extrapolations to lower 
temperatures during thermodynamic evaluation of the data4. Additionally, thermal protein 
denaturation is usually a non-reversible process which makes the thermodynamic evaluation 
of such data invalid and physical stability rankings are based only on apparent Tm values which 
could represent only a small part of the protein conformational stability curve against 
temperature4. On the other hand, aggregation of the protein at high temperatures will also affect 
the accuracy of the measured Tm values
149. These and other challenges to predict protein 
physical stability from thermal denaturation experiments are extensively discussed in the 
following papers4,93. 
In addition to the pitfalls of thermal denaturation techniques mentioned above, it is an often-
ignored fact that not only protein properties but also excipient properties can change during 
heating. A typical example of this is the pKa change of many pharmaceutical excipients during 
heating150,151. This includes two of the most frequently used buffers for protein therapeutics – 
histidine and tris152. 
3.2.4 Isothermal chemical denaturation (ICD) as a tool to study protein physical 
stability in different formulations 
Isothermal chemical denaturation (ICD) was recently proposed as an isothermal method to 
evaluate protein physical stability in different formulations4. A typical ICD experiment 
includes the preparation of protein samples with an increasing concentration of a denaturant 
(usually guanidinium hydrochloride or urea). After sufficient incubation time needed to reach 
an equilibrium, a physical observable is measured (e.g. intrinsic fluorescence) to detect at 
which denaturant concentrations the protein is (partially) unfolded. The approaches to evaluate 
ICD data are described in detail elsewhere4,50,51. Most evaluation methods can extract several 
stability-indicating parameters from chemical denaturation graphs, e.g. the amount of 
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denaturant needed to unfold 50% of the protein (Cm) (sometimes also referred as the “melting” 
denaturant concentration) and the Gibbs free energy of protein unfolding (dG)153. A recently 
proposed approach would also investigate the variation of dG in samples with different protein 
concentration (in the same formulation conditions)154. It should be noted that in this case, the 
dG measured is an apparent value. It is suggested that a lower concentration dependence of dG 
is an indicator for a lower aggregation propensity6. Until now, there is some limited data that 
parameters (i.e. Cm) obtained with ICD can provide reasonable predictions of the outcome of 
accelerated stability studies155. To best of our knowledge, the concentration dependence of dG 
is not directly related to the physical stability of a protein in a wide range of conditions during 
accelerated stability studies. Considering also the high sample consumption and the low 
throughput of ICD, it is still unclear why and how formulation scientists should use ICD to find 
optimal formulation conditions for new therapeutic proteins in early-stage development. 
3.2.5 Problem statement and hypothesis 
The reason we stepped into this work is the trend that high throughput thermal denaturation 
techniques based on Tm measurements are often used on a wide range of formulations to access 
protein physical stability. We hypothesised that such thermal denaturation techniques are not 
an appropriate choice for all formulations, especially such containing excipients that change 
their properties upon heating. We expected that such “inappropriate” use of thermal 
denaturation techniques could result in misleading physical stability rankings and probably 
early rejection of stable protein formulations. As identifying the problem is just the first step 
of the solution, we also wanted to investigate whether isothermal chemical denaturation can 
find a place as a suitable protein physical stability indicating method in cases where high 
throughput thermal denaturation might not be an appropriate choice. 
To test our hypothesis, we developed a classical formulation case study and investigated the 
effect of pH and buffer type on the physical stability of a model monoclonal antibody (mAb1). 
We compared DSF and ICD to see if both methods provide similar physical stability rankings 
with the different conditions we tested. Finally, we performed accelerated stability studies to 
validate the predictions. 
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3.3 Materials and methods 
3.3.1 Model protein and sample preparation 
The model monoclonal antibody (mAb1) used in this work is a human IgG type 1 with a 
molecular weight of 145 kDa. The bulk solution has more than 99.5% relative monomer 
content after thawing (measured by size exclusion chromatography). Further, SDS-PAGE 
shows only bands corresponding to the monomer and antibody fragments (this data is available 
on request). mAb1 was selected as a suitable model protein since it shows Tm dependence 
versus pH which is well described for other IgG type 1 antibodies140. Also, our experience 
shows that the rate of aggregation of mAb1 is highly dependent on the formulation buffer. This 
behaviour makes it a good model protein to compare the prediction quality of stability 
indicating techniques when it comes to buffer selection in a narrow pH range. Different 
formulations of mAb1 were prepared by dialysis at room temperature (20–25 °C) against an 
excess of the respective buffer using a Spectra/Por® 8000 MWCO dialysis tubing from 
Spectrum Laboratories Inc. (Rancho Dominguez, USA). The sample to buffer ratio was 1:200 
and the buffer was exchanged 3 h and 8 h after the start of the dialysis. The total dialysis time 
was 24 h. Protein concentration was measured with a Nanodrop 2000 (Thermo Fisher 
Scientific, Wilmington, USA). Finally, the formulations were sterile filtered with 0.22 µm 
cellulose acetate filters from VWR International (Darmstadt, Germany). Reagent chemicals 
were of analytical grade and were purchased from Sigma Aldrich (Steinheim, Germany) or 
VWR International (Darmstadt, Germany). Highly purified water (Purelab Plus, USF Elga, 
Germany) was used for the preparation of all buffers. 
3.3.2 Differential scanning fluorimetry (DSF) with intrinsic fluorescence and static light 
scattering detection 
Thermal denaturation studies were performed with the Optim® 1000 system (Avacta 
Analytical, United Kingdom). 9 µL of mAb1 formulations with a protein concentration of 
10 g/L were filled in triplicates in microcuvette arrays (Unchained Labs, USA). The samples 
were excited at 266 nm and fluorescence spectra were collected from 30 to 90 °C with a 
temperature ramp of 1 °C/min. The obtained intrinsic fluorescence spectra were further 
processed to create graphs of the fluorescence intensity ratio 350 nm/330 nm (F350/330) versus 
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temperature. The Tm values were determined from the maximum of the first derivatives of these 
graphs using the Optim® 1000 software (Avacta Analytical, United Kingdom). Tm1 was 
assigned to the first transition (at lower temperature) while Tm2 was assigned to the second 
transition (at higher temperature). Simultaneously with the intrinsic fluorescence, static light 
scattering data at 473 nm was collected by the instrument to evaluate if the protein is 
aggregating after unfolding. 
3.3.3 Isothermal chemical denaturation (ICD) with intrinsic fluorescence detection 
8 µL from of each stock solution of mAb1 with concentration 5, 10, 20 or 40 g/L were pipetted 
in triplicates with a 16-channel 12.5 µL Viaflo pipette (Integra Biosciences, Konstanz, 
Germany) and the Viaflo Assist (Integra Biosciences, Konstanz, Germany) into non-binding 
surface 384 well plates (Corning, USA). Next, the respective amount of the formulation buffer 
and subsequently the denaturant stock solution (same as the formulation buffer regarding 
concentration and pH but including 6 M guanidine hydrochloride) were pipetted with a 16-
channel 125 µL Viaflo pipette (Integra Biosciences) and the Viaflo Assist (Integra 
Biosciences). Finally, mixing was performed manually with new tips to minimise cross-
contamination between the wells. After mixing, the well plate was sealed with an EASYseal™ 
sealing film (Steinheim, Germany) and incubated for 24 h at room temperature. A FLUOstar 
Omega microplate reader (BMG Labtech, Ortenberg, Germany) was used to measure the 
intrinsic fluorescence intensity of mAb1 at 330 and 350 nm after excitation at 280 nm. The 
measurements for both wavelengths were performed in multichromatic mode using 50 flashes 
per well and the same gain for each wavelength. The ratio between the fluorescence intensity 
at 350 and 330 nm (F350/330) was calculated for mAb1 in each denaturant concentration. The 
data from the triplicates was fitted to a three-state model and evaluated with the CDpal 
software50. Other models available in the software (e.g. two-state, three-state with dimerisation 
of the intermediates, etc.) were also tested but showed poor fit quality in comparison to the 
three-state model we used. Different starting parameters for the Cm and m-values were tested, 
and the different fits were compared with the f-test function of the software. The best fit was 
used to derive the values for Cm1, Cm2 and dG. The errors for the Cm and dG values are shown 
as the Jackknife error from the fit. ddG was calculated after the dG value for the lowest protein 
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concentration was subtracted from the dG determined for the respective higher protein 
concentration. 
3.3.4 pH measurements at different temperatures 
The pH measurements were performed with an InLab Expert Pro-ISM pH electrode (Mettler 
Toledo, Germany) and a SevenEasy pH meter (Mettler Toledo, Germany). 10 mL of each 
buffer were filled in triplicates in 15 mL Falcon tubes. The Falcon tubes were immersed in a 
water bath and the temperature was increased in a step of 5 or 10 °C. After each increase, the 
samples were equilibrated for at least 5 min to reach constant temperature. Before measurement 
of the samples, the pH electrode was calibrated at each temperature with two calibration buffers 
pH 2 at 25 °C and pH 7 at 25 °C (Bernd Kraft, Germany) using the pH values provided from 
the manufacturer for the respective temperature. 
3.3.5 Accelerated stability study and size exclusion chromatography (SEC) 
mAb1 formulations with a concentration of 10 g/L were sterile filtered with 0.22 µm cellulose 
acetate filters from VWR International (Darmstadt, Germany). Next, 1 mL of each formulation 
was aseptically filled in sterilised type one glass vials (DIN 2R) and closed with sterilised 
rubber stoppers. The samples were incubated for 3 months at 40 °C ± 2 °C. Every four weeks 
50 µL were withdrawn from each replicate in a way that sterility of the solution is preserved. 
The samples were analysed on a Waters Alliance 2695 separation module with a Waters 2487 
UV/Vis detector and a Tosoh TSKgel G3000SWXL 7.8 mm ID × 30.0 cm L column (Tokyo, 
Japan). The flow rate was 1 mL/min, and the protein elution was detected at 280 nm after 25 µg 
protein were injected on the column. The mobile phase consisted of 25 mM sodium phosphate 
and 200 mM sodium chloride; the pH was adjusted to 7.0 ± 0.05 with 2 M sodium hydroxide. 
The chromatograms were integrated with the Chromeleon 6.8 software (Thermo Fisher, 
Dreieich, Germany) and the relative percentage of high molecular weight (HMW) and low 
molecular weight (LMW) species was calculated in relation to the total area of all protein peaks. 
As HMW are evaluated peaks eluting earlier than the monomer, while as LMW are evaluated 
protein peaks eluting later than the monomer (see the supplementary data to this chapter). Next, 
the data was fitted linearly to obtain relative aggregation and fragmentation rates. The values 
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for these rates and the corresponding adj. R2 from the fits are provided (see the supplementary 
data to this chapter). 
3.4 Results and discussion 
3.4.1 Unfolding and aggregation of mAb1 during thermal denaturation 
mAb1 shows two unfolding transitions measured by the change of the intrinsic fluorescence 
ratio F350/330 in the temperature range 30–90 °C in all buffers we tested (Fig. 17A and 17B). 
Previous work on mAbs shows that the first unfolding transition is assigned to the unfolding 
of the CH2 domain, while the second transition is assigned to the Fab and the CH3 domains156. 
Also, static light scattering at 473 nm showed that mAb1 aggregates in all conditions with the 
onset of the second unfolding transition but never during the first transition (see the 
supplementary data to this chapter). 
 
Figure 17. Thermal unfolding of mAb1 detected by intrinsic fluorescence ratio (F350/330) at: (A) pH 5 in 50 mM 
citrate (black) and 50 mM histidine (grey); (B) pH 6 in 50 mM phosphate (black) and 50 mM histidine (grey). An 
overlay of three separate measurements is given for each sample. The place where the Tm values are obtained 
from the first derivative is marked with a cross. 
3.4.2 Melting temperatures of mAb1 in various buffers 
The melting temperatures of mAb1 across the pH range from 4.5 to 8.5 was investigated in 
four different buffers – 50 mM citrate pH 4.5–5.5, 50 mM phosphate pH 6–8.5, 50 mM 
histidine pH 5–6 and 50 mM tris pH 7.5–8.5 (Fig. 18). The general trend shows a sharp decrease 
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in both Tm1 and Tm2 with a decrease in pH below 6.0 in histidine and citrate. Also, both melting 
temperatures slightly decrease when the pH is increased above pH 6.5 in phosphate.  
The highest Tm1 values were measured in 50 mM phosphate in the pH range 6.5–7 and in all 
tris formulations. The highest Tm2 values were measured in 50 mM citrate pH 5.5 and in 50 mM 
phosphate pH 6 and 6.5 as well as in tris formulations with pH 7.5 and 8 (at 25 °C). 
Interestingly, mAb1 shows lower Tm values in histidine compared to formulations with citrate 
or phosphate having the same pH at 25 °C. These differences are more distinct for the second 
melting temperature. On the other hand, mAb1 shows in general higher Tm values in tris 
compared to phosphate in the pH range 7.5–8.5. 
 
Figure 18. Melting temperatures Tm1 (filled symbols) and Tm2 (open symbols) of mAb1 in different buffers 
measured with thermal denaturation and intrinsic fluorescence – 50 mM citrate (squares), 50 mM phosphate 
(circles), 50 mM histidine (triangles), 50 mM tris (diamonds). The pH shown on the graph is measured at 25 °C. 
The provided values are mean of three measurements, and the error is the standard deviation. 
Similar observations with thermal denaturation studies of mAbs can be found in the literature. 
Razinkov et al. reported that the melting temperatures of several mAbs measured by DSC and 
DSF were lower in histidine buffer in comparison to acetate or phosphate, indicating that “at 
pH 5.5, the mAbs were more stable in acetate buffer than in the histidine buffer”140. Menzen et 
al. used DSF with two different extrinsic fluorescent dyes to study the melting temperatures of 
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a model mAb in various formulations157. They showed that the Tms of the mAb were always 
lower in histidine pH 5 when compared to formulations with phosphate pH 5. This was true for 
a wide range of protein concentrations from 0.8 to 40 g/L. Interestingly, in the same work from 
Menzen et al. the melting temperatures of the same antibody were higher in histidine than in 
phosphate at pH 7.2. Another example is a recent work from Kalonia et. al where µDSC was 
used to evaluate the thermal stability of a model mAb and reported that “mAb in pH 4.5 and 
6.5 citrate solutions had higher onset and melting temperatures compared to the mAb in 
histidine solution”95. 
Since histidine is a very common buffer for therapeutic proteins, especially for mAbs152, an 
explanation with the low physical stability of mAb1 in this buffer is unlikely. Therefore, we 
hypothesised that such disagreements between histidine and citrate or phosphate buffers might 
be due to a change in buffer properties, more specifically due to buffer pH shift during heating. 
3.4.3 pH temperature dependence of the tested buffers 
The pH of 50 mM citrate buffer pH 5 (at 20 °C) was measured over the temperature range  
20–80 °C and compared to 50 mM histidine buffer pH 5 (at 20 °C) (Fig. 19A). The pH of 
histidine decreases linearly and reaches 4.2 at 80 °C, while citrate exhibits a slight increase 
from pH 5.05 at 20 °C to pH 5.2 at 80 °C. Similar observations were made when we compared 
50 mM phosphate buffer pH 6 (at 20 °C) with 50 mM histidine buffer pH 6 (at 20 °C)  
(Fig. 19B). The slope of pH decrease (dpH/dT) for histidine was −0.014/1 °C and was the same 
for pH 5 and pH 6 formulations. The pH of citrate and phosphate remained almost unchanged 
over the investigated temperature range (i.e. dpH/dT was close to zero). This revealed that 
although having the same starting pH at 20 °C, when the buffers are heated to about 60–65 °C 
(the approximate temperature of Tm1 for mAb1) there is a difference of 0.7 pH units between 
citrate and histidine (Fig. 19A) and a difference of 0.5 pH units between phosphate and 
histidine (Fig. 19B). This difference becomes even larger at temperatures around 80 °C (where 
approximately Tm2 of mAb1 is). Additionally, we also measured the dpH/dT for tris which was 
−0.022/1 °C for tris buffers with pH 7.5, pH 8.0 and pH 8.5 at 20 °C, indicating that tris 
formulations will exhibit even larger pH shifts than histidine formulations during heating. 
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Figure 19.  (A) pH of 50 mM citrate (squares) and 50 mM histidine (triangles) between 20 and 80 °C, both buffers 
had pH 5 at 20 °C; (B) pH of 50 mM phosphate (circles) and 50 mM histidine (triangles) between 20 and 80 °C, 
both buffers had pH 6 at 20 °C;  
Considering the high pH dependence of the Tms of mAb1 (Fig. 18), especially at a pH  
below 6, such pH shifts during heating can significantly affect the protein melting temperatures. 
This can result in two possible scenarios. In the first case, the pH of the buffer is shifted away 
from the pH of maximum stability during heating, and the Tm values appear lower. This is the 
case for the Tms of mAb1 in histidine in Fig. 18. In the second case, the pH is shifted towards 
the pH of maximum stability of the protein and the Tm values appear higher. This is the case 
for the Tms of mAb1 in tris in Fig. 18. 
It is a well-known fact that the behaviour of a particular buffer during heating will be 
determined mostly by its enthalpy of ionisation dHionisation158. High positive or negative 
dHionisation will indicate high temperature dependence of the acidic constant pKa, while 
ionisation enthalpy close to zero will indicate low temperature dependence of the pKa. 
Subsequently, changes in the pKa will influence the pH of the system according to the 
Henderson–Hasselbalch equation. A quick comparison between the dHionisation and the dpH/dT 
shows that both values are in good agreement for the buffers we tested (for pK2 of histidine 
dHionisation ∼ 30 kJ/mol, for tris dHionisation ∼ 47 kJ/mol; for pKa2 and pKa3 of citrate 
dHionisation ∼ 2 kJ/mol and ∼−3 kJ/mol respectively; for pKa2 of phosphate 
dHionisation ∼ 4 kJ/mol 159). Although, dHionisation and dpKa/dT will indicate if a large dpH/dT can 
be expected, a good practice would be to measure the pH of each formulation for thermal 
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denaturation in the temperature range of interest to determine the exact dpH/dT and avoid 
mistakes arising from comparison of formulations with different dpH/dT. 
Even if the correct pH of a formulation buffer at a given temperature is known, corrections for 
the pH and melting temperatures should be done with great caution. The reason for this is that 
the temperature during thermal denaturation studies is increased relatively quickly (typically 
0.5–1 °C/min) and this might not allow enough time for the protein to reach equilibrium state 
at the new pH before it unfolds. We assume that at the temperature and pH of unfolding the 
protein might be in a state that would not represent its “true” Tm value for a given formulation 
condition. Therefore, a direct comparison of the physical stability of a protein in buffers with 
different dpH/dT would be reliable only with suitable isothermal techniques. 
3.4.4 Unfolding of mAb1 with isothermal chemical denaturation (ICD) 
mAb1 shows a three-state unfolding transition after chemical denaturation with guanidine 
hydrochloride in all formulations tested (Fig. 20). In another work with a monoclonal antibody, 
the first transition was assigned to the unfolding of the CH2 domain while the second transition 
corresponds to the unfolding of the Fab or the CH3 domain160. This unfolding behaviour is also 
in good agreement with the unfolding curves during thermal denaturation. Direct comparison 
of the denaturation graphs (obtained with ICD) of mAb1 in histidine and citrate or histidine 
and phosphate reveals that in most cases higher concentrations of guanidinium hydrochloride 
are needed to unfold the model mAb in histidine which is an indicator for the higher physical 
stability of mAb1 in histidine. 
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Figure 20. Chemical denaturation of mAb1 detected by intrinsic fluorescence ratio (F350/330) at: (A) pH 5 in 
50 mM citrate (squares) and 50 mM histidine (triangles); (B) pH 6 in 50 mM phosphate (circles) and 50 mM 
histidine (triangles). The lines on this graph are to guide the eyes and do not represent a fit to a certain model. 
The denaturation graphs of mAb1 in different formulations were evaluated with CDpal as 
described in the materials and methods section. An example fit of a sample denaturation graph 
can be found in the supplementary data to this chapter. The Cm and dG values obtained from 
the best fit are used for further comparison of the stability of the formulations. The Cm1 was 
derived from the unfolding at the lower denaturant concentration while the Cm2 is derived from 
the unfolding at the higher denaturant concentration. 
3.4.4.1 Cm values of mAb1 in various buffers 
As alkaline pH conditions (pH >7) are known to promote chemical degradation in mAb 
formulations and are thus not practically relevant, ICD and accelerated stability testing were 
limited to the pH range 4.5–7 18. Both the Cm1 and the Cm2 of mAb1 show an increase with the 
increase of pH in all buffers (Fig. 21) which is in good agreement with the increase of the Tm1 
and the Tm2 when the pH is increased from pH 4.5 to pH 6.5 (Fig. 18). The Cm values of mAb1 
in histidine are similar or higher than the Cm values in the citrate or phosphate formulations 
with the same pH, while the Tm1 and Tm2 values of mAb1 in histidine formulations were lower 
compared to their citrate and phosphate counterparts. One reason for this is that ICD is an 
isothermal technique and any pH temperature drift of excipients is avoided. 
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Figure 21. Cm values – Cm1 (filled symbols) and Cm2 (open symbols) – of mAb1 in different buffers measured 
with chemical denaturation and intrinsic fluorescence – 50 mM citrate (squares), 50 mM phosphate (circles),  
50 mM histidine (triangles). The pH shown on the graph is measured at 25 °C. The values are obtained from the 
fit of three denaturation graphs. The error bar represents the Jackknife error from the fit in CDpal. 
3.4.4.2 Concentration dependence of the dG of mAb1 in various buffers 
The Gibbs free energy of unfolding (dG) can be an indicator of the protein conformational 
stability4,153. However, it has recently been demonstrated that the dG is concentration 
dependent and this dependence can change in different formulations of the same protein154. 
Therefore, a comparison of different formulations based on a dG value determined at a single 
protein concentration is rather difficult. On the other hand, the concentration dependence of dG 
is supposed to give indications whether a protein will be more aggregation prone in certain 
conditions154. High concentration dependence of dG indicates a higher aggregation propensity 
of the protein while the low concentration dependence of dG is an indicator for a low 
aggregation propensity of the protein. To evaluate the feasibility of this approach, we 
investigated the concentration dependence of dG of mAb1 in the range of 0.5–4 g/L for several 
formulations. In our experiments, we observed that mAb1 shows the lowest concentration 
dependence (within ±10 kJ/mol) of dG in citrate pH 5.0 and 5.5 (Fig. 22A) and in histidine pH 
6.0 (Fig. 22B). The highest concentration dependence (more than ±25 kJ/mol) of dG was 
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observed in phosphate pH 6 and pH 6.5 (Fig. 22C). This indicates that phosphate is a bad buffer 
choice for mAb1 despite the high Tm and Cm values of mAb1 measured in it. 
 
Figure 22. Concentration dependence of dG for mAb1 in various buffers. A. 50 mM citrate with pH 4.5 (squares), 
pH 5 (circles) and 5.5 (triangles up); B. 50 mM histidine with pH 5 (squares), 5.5 (circles) and 6.0 (triangles up); 
C. 50 mM phosphate with pH 6 (squares), 6.5 (circles) and 7.0 (triangles up). Each point on the graphs is derived 
from three chemical denaturation graphs. The errors are the Jackknife error from the fit to a three-state model. 
3.4.5 Physical degradation of mAb1 during accelerated stability studies 
To validate the predictions made with thermal and chemical denaturation we performed 
accelerated stability studies for 12 weeks at 40 °C. We observed that not only aggregation but 
also fragmentation of mAb1 occurred in the samples we tested. Fragmentation was independent 
of the buffer we used (Fig. 23B) but was highly dependent on the pH showing a minimum at 
pH 5.5 and 6 which is in good agreement with previously published data with mAbs18,161.  
On the other hand, apparent aggregation rates were dependent not only on the pH but also on 
the buffer type (Fig. 23A). Minimal aggregation rates of mAb1 were observed in all histidine 
formulations, followed by citrate formulations with pH 5.0 and 5.5. Highest aggregation rates 
of mAb1 were observed in phosphate pH 6.5 followed by phosphate pH 7 and 6. At this point, 
we should underline that the accelerated stability study in our case did not include analytical 
methods to evaluate chemical degradation (e.g. oxidation, deamination) or changes in the 
biological activity of the protein (both of which can be observed during storage). As already 
discussed in the introduction, such changes can also affect product quality and should be 
studied in parallel with the physical degradation. 
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Figure 23. (A) Apparent aggregation rates of mAb1 in various buffers determined after 12-weeks storage at 40 °C; 
(B) Apparent fragmentation rates of mAb1 in different buffers determined after 12-weeks storage at 40 °C. 
3.4.6 Relationship between stability-indicating parameters and the aggregation rate   
Both the Tm and Cm values indicated that mAb1 should have high stability in phosphate buffer. 
Even worse, due to the pH shift of histidine, it appeared that the physical stability of mAb1 
would be lower in histidine than in citrate or phosphate due to the lower Tm values of mAb1 
measured in histidine. At this point, the only approach that indicated that phosphate is a bad 
buffer for mAb1 was the concentration dependence of dG. Also, all formulations showing a 
minimal concentration dependence of dG in Fig. 22 showed a very low apparent aggregation 
rate (Fig. 23A), but not vice versa. Still, if the formulations with minimal concentration 
dependence of dG were selected, this would have resulted in satisfactory results in the 
accelerated stability studies in this case. However, we should note that the approach to 
determine the concentration dependence of dG requires more sample in comparison to high 
throughput methods like DSF. 
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3.4.7 Rational use of a combination of DSF and ICD to study protein physical stability  
Based on our work, we suggest that a combination of DSF and ICD would be feasible to reduce 
the protein amount required to assess the physical stability in various formulations but still 
provide a sufficient prediction quality. Such a combination would:  
• First – Employ DSF to study the melting temperatures of a new therapeutic protein 
candidate over a wide pH range in buffers with dpH/dT close to zero to determine the pH 
range of maximum Tm values;  
• Second – Use ICD to determine Cm, dG and the concentration dependence of dG of the 
therapeutic protein candidate in the pH range of maximum Tm values in various buffers 
(which can have high dpH/dT e.g. histidine, tris); 
• Third – Perform accelerated stability tests on formulations with the highest Tms, the highest 
Cms and the lowest concentration dependence of dG. 
 
3.5 Final words and recommendations 
High throughput thermal denaturation is a valuable technique to determine the melting 
temperatures of therapeutic protein candidates in early stage development when the amount of 
material is limited. When it comes to formulation studies, thermal denaturation techniques in 
general are (alongside other pitfalls discussed in the introduction) limited by the fact that the 
increase in temperature can change critical excipient properties (i.e. pH of the buffer system). 
Care should be taken when such measurements are conducted. pH screenings based on Tm 
values should be performed only in buffers with dpH/dT close to zero. After the pH range of 
maximum thermal stability of a protein is found, further formulation experiments with a wider 
range of buffers should be performed with isothermal techniques. A suitable isothermal method 
that can be used at this stage is isothermal chemical denaturation. ICD would allow direct 
comparison of a variety of formulation buffers regardless of their dpH/dT. Moreover, the 
concentration dependence of dG seems to be a valuable tool which can allow identification of 
“bad” conditions where the protein has low physical stability during storage. 
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3.6 Supplementary data 
 
Figure S4. Change in intrinsic fluorescence (F350/330) and static light scattering signal at 473 nm during thermal 
denaturation of mAb1 in 50 mM phosphate pH 6. A high increase in the scattering is observed with the onset of 
the second unfolding transition. 
 
Figure S5. Example fit of chemical denaturation graph in CDpal 
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Figure S6. Chromatogram of mAb1 sample from Size Exclusion Chromatography. Integration of the HMW area 
was done from 5 to 8 minutes elution time. Integration for the LMW area was done from 10,5 to 12 minutes 
elution time. 
 
Buffer 50 mM citrate 50 mM phosphate 50 mM histidine 
pH 4,5 5,0 5,5 6,0 6,5 7,0 5,0 5,5 6,0 
Rate of 
HMW 
formation 
(%/week) 
0.18233 0.03808 0.05508 0.20833 0.49792 0.42883 0.02008 0.01425 0.0141 
Error 
from the 
fit 
0.03717 0.01078 0.00691 0.00553 0.09453 0.05566 0.00517 0.0039 0.00422 
Adj. R2 0.8849 0.79273 0.95429 0.99789 0.89914 0.9511 0.82454 0.80482 0.77425 
Rate of 
LMW 
formation 
(%/week) 
0.52508 0.251 0.16558 0.14308 0.1875 0.19633 0.29067 0.16733 0.157 
Error 
from the 
fit 
0.00976 0.02056 0.01085 0.02287 0.01767 0.01386 0.02596 0.01682 0.00914 
Adj. R2 0.99896 0.98014 0.98724 0.92708 0.97382 0.98519 0.97645 0.97029 0.9899 
Table S2. Rate of HMW and LMW formation derived from linear fit of the data in Origin 8.0 with the 
corresponding adjusted R2 values. The adjusted R2 values are used as this is a parameter which describes the 
quality of the regression better than R2. The adj. R2 values are always lower than the corresponding R2 values. 
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Chapter 4 A new approach to study the physical stability of 
monoclonal antibody formulations - Dilution from a denaturant 
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4.1 Abstract 
The early-stage assessment of the physical stability of new monoclonal antibodies in different 
formulations is often based on high-throughput techniques that suffer from various drawbacks. 
Accordingly, new approaches that facilitate protein formulation development can be of high 
value to the industry. In this study, a dynamic light scattering plate reader is used to measure 
the aggregation (by means of the increase in the hydrodynamic radius Rh) of monoclonal 
antibody samples that were subject to incubation, and subsequent dilution from different 
concentrations of a denaturing agent, that is, guanidine hydrochloride. The increase in the Rh 
of the protein samples is dependent not only on the denaturant concentration used but also on 
the buffer in which the incubation/dilution was performed. We also compare the aggregation 
after dilution from a denaturant with other high-throughput stability-indicating methods and 
find good agreement between the techniques. The proposed approach to probe the physical 
stability of monoclonal antibodies in different formulation conditions offers a unique 
combination of features - it is isothermal, probes both the resistance to denaturant-induced 
unfolding and the colloidal protein stability, it is entirely label-free, does not rely on complex 
data evaluation, and requires very short instrument measurement time on standard equipment. 
Keywords: Protein aggregation; Protein formulation; Protein folding/refolding; Light 
scattering (dynamic); Stability; Fluorescence spectroscopy; 
Abbreviations: Cm - concentration of denaturant required to unfold 50% of the protein;  
dG - the Gibbs free energy of unfolding (apparent values in this work); DLS - dynamic light 
scattering; GuHCl - guanidine hydrochloride; ICD - isothermal chemical denaturation; mAb - 
monoclonal antibody; Tm - protein melting temperature; 
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4.2 Introduction 
One of the goals in the (pre-)formulation development of new monoclonal antibodies (mAbs) 
is to find conditions that provide high protein physical stability. Such studies can be performed 
with high-throughput techniques that can be classified as isothermal or non-isothermal. Two 
of the most widely used non-isothermal techniques are differential scanning calorimetry (DSC) 
and differential scanning fluorimetry (DSF)40,63,105,140. In general, non-isothermal techniques 
suffer from drawbacks related to the heating of the sample. For example, aggregation during 
temperature ramps often hinders the thermodynamic evaluation of DSC data and affects the 
accuracy of the determined protein melting temperatures from both DSC and DSF4,149. 
Furthermore, non-isothermal techniques suffer from the fact that the properties of many 
excipients (e.g., the pH of amine buffers like histidine) change during heating, which can affect 
the obtained stability rankings based on protein melting temperatures54. 
Isothermal chemical denaturation (ICD) is a valuable technique that avoids the  
above-mentioned drawbacks of DSC and DSF4,54. Historically, ICD was not the method of 
choice for protein formulation studies mostly due to the tedious sample preparation162. These 
limitations of ICD have recently been overcome by the use of equipment that can  
(semi-)automatically prepare and measure protein samples containing varying concentrations 
of a denaturing agent4,54,162–164. However, the accurate thermodynamic evaluation of ICD data 
assumes that the protein unfolding process is fully reversible, the system is in equilibrium, and 
the denaturation graph fits a known model (e.g., 2-state, 3-state unfolding, etc.)52,165. A recent 
article shows that neither reversibility nor equilibration times in an ICD experiment with mAbs 
are trivial52. In addition, multidomain proteins may also exhibit multiple transitions that can be 
close to each other or (partially) overlap, which can introduce a large error to the parameters 
derived from the fit. 
Last but not least, high-throughput DSF and ICD methods are usually based on intrinsic protein 
fluorescence measurements (i.e. observations due to a change in the tryptophan exposure after 
protein unfolding)4,105,116. This creates complications when no tryptophan is present or when the 
tryptophan in a particular protein domain is already solvent exposed in the native protein 
conformation. 
 
64 
 
Considering the issues mentioned above, we saw a demand for novel approaches that can be 
used in a high-throughput manner to investigate the physical stability of new mAbs in different 
formulations. The hypothesis we present is that isothermal incubation and dilution of mAbs 
from guanidine hydrochloride (GuHCl) solutions with a certain concentration will lead to 
substantial protein aggregation. Furthermore, we propose that the amount and the size of the 
aggregates formed will depend on the formulation conditions and the physical stability of the 
mAbs (Fig. 24) and that this aggregation will be in good agreement with other methods used 
to study the protein physical stability. Previously, dilution from a denaturant was used to probe 
the molten globule states and the stability during refolding of other proteins (e.g., human 
growth hormone4,15, lysozyme166, recombinant human gamma interferon167, and others168–170). 
However, previous work focuses mostly on proteins that are expressed as inclusion bodies in 
bacteria, and the aim of such experiments was usually to achieve higher monomer yields after 
expression, solubilisation, and subsequent refolding. To the best of our knowledge, we are the 
first to propose that the assessment of the aggregation after incubation and dilution from 
different concentrations of a denaturant can be used for high-throughput formulation studies of 
large proteins (i.e., mAbs that are typically not expressed as inclusion bodies). 
 
Figure 24. Schematic explanation of the working hypothesis - Impact of the physical stability of a mAb on the 
protein aggregation after incubation and subsequent dilution from a denaturant. 
In this work, we use a dynamic light scattering (DLS) plate reader to assess the aggregation 
(i.e., the increase in the hydrodynamic radius) of 2 mAbs after dilution from different 
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concentrations of GuHCl in different buffers. We confirm our hypothesis that conditions that 
provide higher physical stability of the protein will require higher GuHCl concentrations to 
induce protein aggregation after dilution of the denaturant. We also show that conditions that 
provide higher protein colloidal stability will result in a smaller increase of the Rh after dilution 
from GuHCl. We compare the proposed approach with other established high-throughput 
methods (e.g. DSF, ICD) to find agreement between the predictions. The method we investigate 
provides a unique combination of features - it is an isothermal technique that simultaneously 
probes the resistance to GuHCl-induced unfolding and the colloidal protein stability (i.e. the 
level of aggregation after dilution from GuHCl). In addition, no complex data evaluation or a 
fitting to a certain protein unfolding model is required (in contrast to ICD). The approach is 
label-free and does not rely on intrinsic protein fluorescence measurements (contrary to DSF 
and ICD). Finally, the proposed approach offers a high potential for scale down and full 
automation with the existing infrastructure in many protein formulation laboratories. 
4.3 Materials and methods 
4.3.1 Monoclonal antibodies 
Both mAbs (LMU-1 and PPI03) used in this work belong to the IgG1 subclass. Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis of the protein bulk shows only bands for the mAb 
monomer and mAb fragments. Relative monomer area of both bulks is >99.5%, measured by 
size exclusion chromatography. 
The mAb buffer was exchanged by dialysis at 20°C-25°C using Spectra/Por® 8000 molecular 
weight cut-off dialysis tubing (Spectrum Laboratories Inc., Rancho Dominguez, CA). The 
sample to buffer ratio was 1:200 and 2 buffer exchanges were performed 3 and 8 h after the 
beginning. After the last change, dialysis was continued for another 16 h. The final buffers of 
both proteins contained 10 mM citrate or 10 mM histidine with pH 5 or 5.75. In addition, all 
LMU-1 samples contained 0.05% w/v polysorbate 20, while all PPI03 samples were free of 
surfactants. 
For the experiment where we compare the effect of additives, 2× stock solution of the 
respective additive (i.e., sucrose, trehalose, arginine hydrochloride or proline) in the respective 
buffer was mixed with the protein to obtain a final concentration of 200 mM sucrose,  
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200 mM trehalose, 200 mM arginine hydrochloride, or 200 mM proline. For the final protein 
concentrations in the different experiments see the Results and Discussion section. 
The protein concentration was measured with a Nanodrop 2000 (Thermo Fisher Scientific, 
Wilmington, DE). Reagent chemicals from the highest grade available were purchased from 
Sigma Aldrich (Steinheim, Germany) or VWR International (Darmstadt, Germany). Highly 
purified water was used for the preparation of all buffers. 
4.3.2 Sample preparation, incubation, and dilution from different concentration of 
guanidine hydrochloride 
Samples containing protein (LMU-1 or PPI03) and 0, 1, 2, 3, or 4 M GuHCl in buffer were 
prepared by mixing 25 μL of protein solution in the respective buffer (or in the respective buffer 
with an additive, i.e., 200 mM sucrose, 200 mM trehalose, 200 mM arginine hydrochloride, or 
200 mM proline) with 75 μL of GuHCl solution in the same buffer (or in the same buffer 
containing an additive - see above). After 24 h of incubation with the denaturant, the samples 
were diluted 10 times by rapid addition of the respective buffer (or the respective buffer 
containing an additive - see above) and incubated for another 24 h. For protein concentration 
in the final samples after the last dilution refer to the Results and Discussion section. The pH 
of the samples was controlled at each step using an appropriately calibrated InLab™ Nano pH 
Electrode with a SevenEasy pH meter (Mettler Toledo, Gießen, Germany). The pH reported is 
the pH of the samples after the final dilution from the denaturant (±0.1 pH units). Finally, the 
samples were centrifuged at 8200 × g for 10 min and measured with a DLS plate reader (see 
next sections). All experiments were performed in triplicates. 
4.3.3 Isothermal chemical denaturation 
Protein in formulation buffer and various amounts of buffer and 6 M GuHCl solution in the 
respective buffer were combined in a 384-nonbinding-well plate (Corning, Corning, NY) using 
the Viaflo Assist pipetting station equipped with a 16-channel 12.5 μL and a 125 μL pipette 
(Integra Biosciences, Konstanz, Germany) as already described54. The pH of the samples was 
controlled after preparation as described in the previous section. Next, the well plate was 
sealed. After 24 h of incubation at room temperature, the protein fluorescence intensity at  
330 nm and 350 nm was measured after excitation at 280 nm with a FLUOstar Omega 
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microplate reader (BMG Labtech, Ortenberg, Germany). The intrinsic fluorescence intensity 
ratio F350/330 (the fluorescence intensity at 350 nm divided by the fluorescence intensity at 
330 nm) was plotted against the denaturant concentration to obtain ICD graphs. All samples 
were prepared in triplicates and the best fit to a 3-state model of each replicate in the CDpal 
software was used to determine the apparent Gibbs free energy of unfolding (dG) and the 
denaturant concentration needed to unfold 50% of the protein (Cm). Other unfolding models 
available in the CDpal software (e.g., 2-state, 3-state with dimerisation of the intermediates, 
etc.) were also investigated but showed worse fit quality than the 3-state model after an f-test 
comparison. The 3-state model was also used by other groups to evaluate ICD data with 
mAbs52,153. Because all samples were evaluated with the 3-state model, two Cm values were 
determined—Cm1 for the transition taking place at lower denaturant concentration and Cm2 for 
the other transition. 
4.3.4 Dynamic light scattering 
Twenty-five microliter of each sample was pipetted in triplicates into a 384-well clear bottom 
plate (Corning), and the plate was centrifuged at 2000 rpm for 2 min using a Heraeus Megafuge 
40 centrifuge equipped with an M-20 well plate rotor (Thermo Fisher Scientific). Next, each 
well was capped with approximately 5 μL of silicone oil and centrifuged again at 2000 rpm for 
2 min. Ten acquisitions of 10 s at 25°C were taken with the DynaPro II DLS plate reader (Wyatt 
Technology Europe, Dernbach, Germany). The Dynamics V7.8 software was used for all the 
calculations. The autocorrelation function of each sample was calculated from the fluctuation 
of the light scattering intensity. Cumulant analysis was used to derive the apparent coefficient 
of self-diffusion (D) and the polydispersity index (PDI). The viscosity of each sample was 
measured with a falling ball viscometer, AMVn (Anton Paar GmbH, Ostfildern-Scharnhausen, 
Germany). The Stokes-Einstein equation was used to calculate the apparent hydrodynamic 
radius (Rh) at 25°C from the D and the sample viscosity. As an additional part of the data 
analysis, the sample size distribution was calculated from the regularisation method. Unless 
otherwise stated, the Rh values reported in this work are derived from the cumulant analysis. 
To determine the interaction parameter kD, different concentrations of LMU-1 (from 1 to  
15 g/L) and PPI03 (from approximately 1 to 10 g/L) in each buffer were prepared and measured 
as described previously.  
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The interaction parameter was calculated using the expansion of the apparent diffusion 
coefficient: 
D=D0(1+kDc) 
where D0 denotes the diffusion coefficient of an isolated scattering solute molecule in a solvent 
and c is the protein concentration. The linear fits of the concentration dependence of D0 from 
which kD was determined can be found in the supplementary data to this chapter. 
4.3.5 Differential scanning fluorimetry 
All samples were diluted to a protein concentration of 1 g/L with the respective buffer and 
filled into 9 μL microcuvette arrays (Unchained Labs, Pleasanton, CA). The Optim® 1000 
system (Unchained Labs) was used to apply a temperature ramp of 1°C/min starting from 25°C 
and ending at 100°C. Protein fluorescence spectra were collected during the ramp after 
excitation at 266 nm. The system software was used to calculate the intrinsic fluorescence 
intensity ratio from the fluorescence intensity at 350 nm and 330 nm (F350/330) against 
temperature. The protein melting temperatures (Tm) were determined from the maximum of 
the first derivatives of these graphs using the Optim® 1000 software (Avacta Analytical, 
Wetherby, UK). Tm1 was assigned to the transition at lower temperature, and Tm2 was assigned 
to the transition at a higher temperature. 
4.3.6 Statistical data analysis and comparison 
The mean values, standard deviations, 95% lower confidence interval (LowCI) and 95% upper 
confidence interval (UpCI) of the means were calculated with Origin 2018. A significant 
difference between 2 values was considered when the 95% CIs of 2 means were not 
overlapping. In the case of slightly overlapping confidence intervals, we could not prove a 
significant difference, although the lack of such cannot be confirmed due to the small samples 
size and the approach we used171. 
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4.4 Results and discussion 
4.4.1 Protein aggregation and Rh after dilution from different concentrations of 
guanidine hydrochloride 
The Rh of LMU-1 and PPI03 after incubation with different concentration of GuHCl and 
subsequent dilution is dependent not only on the denaturant concentration but also on the 
formulation used (Figs. 25a and 25b). The increase in the Rh is due to the formation of more 
(and larger) soluble aggregates, which was confirmed with size exclusion chromatography 
coupled to multiangle light scattering detector (see the supplementary data to this chapter). The 
differences in the Rh are most pronounced after dilution from 3 M GuHCl for both proteins. A 
comparison between the different LMU-1 samples diluted from 3 M GuHCl shows that the 
lowest Rh is measured in 10 mM histidine pH 5.75 with a mean value of 19.43 nm and 95% 
LowCI and UpCI of 18.81 nm and 20.06 nm, respectively, followed by 10 mM citrate, pH 5.75 
(mean = 24 nm with LowCI = 23.1 nm and UpCI = 24.89 nm), 10 mM histidine, pH 5 (mean 
= 29.6 nm with LowCI = 27.86 nm and UpCI = 31.34 nm), and 10 mM citrate, pH 5 (mean = 
43.1 nm LowCI = 40.08 nm and UpCI = 46.11 nm) (Fig. 25a). Similar observations are made 
for PPI03 (Fig. 25b). In the case of PPI03, the following means and 95% CIs of the 
hydrodynamic radius after dilution from 3 M GuHCl were measured—in 10 mM histidine, pH 
5.75 (mean = 5.37 nm; LowCI = 5.22 nm; UpCI = 5.51 nm), in 10 mM citrate, pH 5.75 (mean 
= 5.97 nm; LowCI = 5.82 nm; UpCI = 6.11 nm), in 10 mM histidine, pH 5 (mean = 6.87 nm; 
LowCI = 6.72 nm; UpCI = 7.01 nm), and in 10 mM citrate pH 5 (mean = 7.43 nm; LowCI = 
7.29 nm; UpCI = 7.58 nm). The PDI of all samples is between 0.05 and 0.2 when the proteins 
are diluted from up to 1 M GuHCl, while the PDI of all samples diluted from 3 M or more 
GuHCl is between 0.2 and 0.4. An example of the autocorrelation functions with the 
corresponding cumulant fits and the size distribution from the regularisation analysis can be 
found in the supplementary data to this chapter. Important to mention, none of the samples 
formed a pellet of insoluble matter after dilution and centrifugation. In addition, the absorption 
of the protein in the supernatant was measured at 280 nm and no loss of soluble protein was 
observed (data not shown). Also, the Rh in the samples after 24 h of incubation in GuHCl before 
dilution is measured and can be found in the supplementary data. Furthermore, we studied 
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whether the Rh changes during longer incubation time and found no significant differences in 
the Rh of the samples for up to 1 week after dilution from GuHCl (data not shown). 
 
Figure 25. Hydrodynamic radius Rh from dynamic light scattering of LMU-1 (a) and PPI03 (b) after incubation 
and dilution from different concentrations of guanidine hydrochloride in 10 mM histidine pH 5 (red squares),  
10 mM histidine pH 5.75 (blue circles), 10 mM citrate pH 5 (yellow diamonds), and 10 mM citrate pH 5.75 (green 
triangles). The protein concentration in the measured samples in (a) and (b) is 1 g/L and 0.2 g/L for LMU-1 and 
PPI03, respectively; isothermal unfolding of LMU-1 (c) and PPI03 (d) in presence of different concentrations of 
guanidine hydrochloride measured by the change in the intrinsic protein fluorescence intensity ratio (F350/330). 
The protein concentration in the measured samples in (c) and (d) is 1 g/L and 0.5 g/L for LMU-1 and PPI03, 
respectively. 
4.4.2 Isothermal chemical denaturation 
The ICD graphs obtained with the intrinsic protein fluorescence intensity ratio (F350/330) 
show that both mAbs exhibit complex unfolding behaviour, which fits well to a 3-state 
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transition model (see the supplementary data). Visual observation of the ICD graphs shows that 
higher concentration of GuHCl is needed to unfold both proteins at pH 5.75 compared to pH 5 
(Fig. 25a and Fig. 25b), which indicates higher resistance to the GuHCl-induced unfolding of 
the mAbs at the higher pH. To further support this statement, in the case of LMU-1, the mean 
Cm2 values are significantly higher at pH 5.75 compared to pH 5 with nonoverlapping CIs 
(Table 3). In the case of PPI03, the difference between the Cm2 in 10 mM histidine pH 5 and 
10 mM histidine pH 5.75 is also significant, although the same statement is difficult to make 
for the results in 10 mM citrate due to the slightly overlapping CIs (Table 3). Comparing the 
apparent dG values at different pH values reveals that in the case of LMU-1, there is a 
significant difference (nonoverlapping CIs) between the dG measured in 10 mM citrate pH 5 
and in 10 mM citrate pH 5.75, which indicates higher conformational stability of LMU-1 at the 
higher pH. In the case of PPI03, although the mean values for the dG differ at pH 5 and  
pH 5.75, a significant difference cannot be proved due to the overlapping CIs (Table 3). 
Furthermore, the ICD graphs of the proteins obtained in histidine or citrate with the same pH 
almost completely overlap (Figs. 25c and 25d). Important to note, when comparing the stability 
of the 2 mAbs in 10 mM citrate or 10 mM histidine with the same pH, there is not a single case 
in which a significant difference between ICD data obtained at the same pH can be confirmed 
due to the overlapping CIs (Table 3). 
4.4.3 Colloidal stability of the mAbs in different buffers 
The colloidal stability of both mAbs in citrate and histidine buffers was assessed by means of 
the interaction parameter kD. It has been shown that kD describes the interparticle interaction 
in protein solutions172. Highly positive kD is attributed to repulsive interactions, whereas highly 
negative is related to attractive interactions146. The kD of both LMU-1 and PPI03 is positive in 
histidine buffer and negative in citrate buffer (Table 3). This indicates that both proteins have 
higher colloidal stability in 10 mM histidine buffer compared with 10 mM citrate in the studied 
pH range. However, the kD is not a parameter that can assess the conformational stability of 
the protein, and it is known that both the conformational and colloidal protein stabilities are 
important for the aggregate formation in solution8. 
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Table 3. Physical stability parameters of LMU-1 (A) and PPI03 (B) in different buffers and pH. The apparent 
Gibbs free energy of unfolding (dG) and the melting denaturant concentrations for the first and second unfolding 
(Cm1 and Cm2) are obtained with isothermal chemical denaturation as described in Materials and methods. The 
melting temperatures of the protein (Tm1 and Tm2) are obtained from the maximum of the first derivative of the 
protein unfolding measured with differential scanning fluorimetry as described in Materials and methods. All 
values (except the kD) are means of triplicates, and the 95 % lower and 95 % upper confidence intervals are 
reported in the brackets (Lower CI 95 % - Upper CI 95 %) next to each mean. 
Table 3A 
dG, kJ/mol Cm1, M Cm2, M kD, mL/g Tm1, °C Tm2, °C 
LMU-1 
histidine pH 5 
94.91  
(90.06 - 99.77) 
1.76  
(1.61 - 1.92) 
2.44  
(2.40 - 2.49) 
37.9 
62.20  
(61.56 - 62.83) 
77.5  
(76.90 - 78.20) 
citrate pH 5 
76.84  
(60.35 - 93.34) 
1.67  
(1.21 - 2.13) 
2.38  
(2.33 - 2.43) 
-1.18 
63.52  
(62.17 - 64.88) 
78.5  
(77.41 - 79.58) 
histidine pH 5.75 
106.10  
(98.70 - 113.49) 
1.92  
(1.74 - 2.10) 
2.66  
(2.61 - 2.72) 
40.2 
66.82  
(65.09 - 68.55) 
79.7  
(79.23 - 80.26) 
citrate pH 5.75 
111.84  
(100.98 - 122.7) 
1.94  
(1.80 - 2.08) 
2.60  
(2.56 - 2.63) 
-8.46 
68.29  
(66.41 - 70.18) 
79.3  
(77.45 - 81.15) 
Table 3B 
dG, kJ/mol Cm1, M Cm2, M kD, mL/g Tm1, °C Tm2, °C 
PPI03 
histidine pH 5 
75.06  
(63.83 - 86.29) 
1.86  
(1.62 - 2.09) 
3.00  
(2.99 - 3.01) 
42 
62.87  
(61.48 - 64.25) 
76.4  
(74.67 - 78.13) 
citrate pH 5 
74.84  
(50.41 - 99.27) 
1.99  
(1.79 - 2.21) 
3.01  
(2.81 - 3.20) 
-0.58 
63.88  
(63.31 - 64.44) 
77.99  
(75.84 - 78.29) 
histidine pH 5.75 
87.56  
(74.70 - 100.42) 
2.28  
(1.78 - 2.77) 
3.09  
(3.04 - 3.14) 
46 
68.26  
(68.13 - 68.39) 
77.01  
(77.68 - 78.30) 
citrate pH 5.75 
80.03  
(68.61 - 91.45) 
2.16  
(1.66 - 2.67) 
3.07  
(2.93 - 3.21) 
-4.8 
69.17  
(67.71 - 70.63)  
78.66  
(77.90 - 79.42) 
4.4.4 Thermal stability of the mAbs in different buffers 
Both LMU-1 and PPI03 have higher melting temperatures (Tm1) at pH 5.75 compared with  
pH 5 (Table 3). This indicates higher physical stability of both mAbs at pH 5.75 and 
corresponds well to the higher concentration GuHCl needed to unfold both proteins at higher 
pH. The mean values of the melting temperatures of both proteins in histidine almost always 
appear lower compared with citrate counterparts most probably due to the buffer pH shift of 
histidine during heating54. However, a significant difference between the melting temperatures 
of the mAbs in either 10 mM citrate or 10 mM histidine with the same pH cannot be proved 
due to the small sample size and the overlapping CIs (Table 3). The thermal denaturation graphs 
of each mAb sample can be found in the supplementary data to this chapter. 
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4.4.5 The relation between the Rh after dilution from GuHCl and other parameters 
The increase of Rh after dilution from a certain concentration of GuHCl (in our case 3 M) will 
depend on the degree of protein unfolding at these conditions. In the case of LMU-1 and PPI03 
samples with pH 5, the ICD curves are shifted to lower denaturant concentrations compared to 
samples with pH 5.75, which indicates a lower resistance to the GuHCl-induced unfolding of 
these proteins at the lower pH (Figs. 25c and 25d). Respectively, a higher Rh (more and larger 
aggregates formed) is measured after dilution from 3 M GuHCl in buffers with pH 5 compared 
with dilution in buffers with pH 5.75 (Figs. 25a and 25b). 
When the degree of protein unfolding (or structural perturbation) at a given denaturant 
concentration is the same (e.g., buffers with the same pH or higher denaturant concentrations 
where the protein is fully unfolded regardless of the pH, i.e., at 4 M GuHCl), the protein 
aggregation and the measured Rh after dilution will depend mostly on the colloidal stability 
and the aggregation propensity of the (partially) unfolded protein after dilution in these 
conditions. For example, the ICD curves of LMU-1 in citrate or histidine buffer with the same 
pH almost completely overlap (Figs. 25c and 25d). However, the Rh of LMU-1 after dilution 
from 3 M GuHCl is always lower in histidine buffer compared with citrate counterparts with 
the same pH (Fig. 25a). Similar observations are also made with the other mAb - PPI03  
(Fig. 25b). In addition, at 4 M GuHCl, there is the same degree of unfolding (according to the 
intrinsic protein fluorescence ratio - Figs. 25c and 25d) for both proteins regardless of the 
formulation pH and buffer. We assume that in this case, the aggregation after dilution will be 
driven mostly by differences in the colloidal protein stability and we see that the Rh after 
dilution of the proteins from 4 M GuHCl is always lower in histidine compared with citrate, 
regardless of the pH. This behaviour is in good agreement with the high kD values of both 
proteins in histidine, which indicates a higher protein colloidal stability in this buffer in 
comparison with citrate. 
4.4.6 Effect of different additives on the change in the Rh after dilution from GuHCl 
We further tested if the herein proposed approach could be used to study the effect of different 
additives (i.e., 200 mM sucrose, 200 mM trehalose, 200 mM arginine hydrochloride, or  
200 mM proline) on the increase in Rh (i.e., aggregation) of the mAbs after dilution from 
GuHCl. To study this, we focused on dilution from 3 M GuHCl because this was the 
 
74 
 
concentration of denaturant where we observed the largest differences in the earlier 
experiments. Next, we performed the dilution in a buffer, that is, 10 mM histidine pH 5, in 
which the physical stability of both mAbs is neither the worst nor the best according to the 
different techniques we used in this work. We reported the effect of the additives as the 
difference in the Rh after dilution with the additive compared with dilution without an additive 
(Fig. 26). We observed that for both LMU-1 and PPI03, all additives tested were significantly 
better compared with the histidine buffer alone (Fig. 26). However, in the case of LMU-1,  
200 mM sucrose and 200 mM arginine chloride caused the largest decrease in the Rh, that is, 
the highest stabilizing effect (Fig. 26 - left), while in the case of PPI03, 200 mM sucrose and 
200 mM trehalose were the most stabilising excipients according to the proposed approach 
(Fig. 26 - right). 
 
Figure 26. Effect of various additives on the change in the hydrodynamic radius Rh from DLS of LMU-1 (left) 
and PPI03 (right) after dilution from 3 M guanidine hydrochloride in 10 mM histidine pH 5. All measurements 
were corrected for viscosity as described in Materials and Methods. For clarity reasons, the values with additives 
are represented as a difference from the value without an additive. Negative values indicate that the Rh is lower 
after dilution with the additive compared with dilution without an additive. The circles represent the mean value 
of the measurements, and the bars represent the 95% UpCI and LowCI. The final protein concentration after 
dilution is 1 g/L for both LMU-1 and PPI03. 
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4.5 Conclusion and outlook 
In this work, we demonstrated with 2 mAbs that the DLS assessment of the aggregation (by 
means of the Rh) after dilution from different concentrations of GuHCl is a promising approach 
to probe the protein physical stability in different formulations. A formulator would then aim 
to (1) find buffers and pH that shift the increase in Rh after dilution to higher GuHCl 
concentrations (i.e., find conditions that provide higher resistance to GuHCl unfolding) and (2) 
find conditions that minimize Rh after dilution (i.e., find conditions that provide higher 
colloidal stability and less aggregation during dilution from a denaturant). The proposed 
method could be used alone or as a complementary technique. If used alone, we suggest that at 
least several GuHCl concentrations (in a step of 0.5 or 1 M) are tested to find conditions where 
the increase in the Rh is largest after dilution. Next, this denaturant concentration could be used 
to test the influence of different buffers and additives on the increase in the Rh. In the case of 
the antibodies that we tested, such denaturant concentration is usually around 3 M GuHCl. 
Alternatively, the method we show could be used as a complementary technique to ICD  
(e.g., to distinguish if there is a difference in the protein physical stability in conditions that 
exhibit overlapping curves in an ICD experiment). In such case, we suggest that the 
concentration of GuHCl that can be used is around the denaturant concentration where the 
protein is partially unfolded according to the ICD experiment. 
The approach we propose offers a unique combination of features: (1) the method is isothermal 
(problems arising from sample heating are avoided); (2) it can distinguish between overlapping 
curves in an ICD experiment due to the different colloidal stability and different levels of 
aggregation after dilution from such samples; (3) the method is label-free and independent of 
the intrinsic protein fluorescence; (4) very short instrument measurement time for 1 sample is 
required; (5) there is a high potential for scale-down and automation with the help of already 
available equipment in many protein formulation laboratories. 
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4.6 Supplementary data 
 
 
Figure S7. Unfolding of LMU-1 by guanidine hydrochloride in different buffers and pH values. The black points 
represent the experimentally measured values. The red line is the fit to a three-state unfolding model. The inset 
shows the corresponding residuals from the fit. 
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Figure S8. Unfolding of PPI03 by guanidine hydrochloride in different buffers and pH values. The black points 
represent the experimentally measured values. The red line is the fit to a three-state unfolding model. The inset 
shows the corresponding residuals from the fit. 
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Figure S9. Concentration dependence of the diffusion coefficient of LMU-1 in different buffers and linear fits 
from which the interaction parameter kD was derived. In the order top-down the measurements in  
10 mM histidine pH 5.75, 10 mM histidine pH 5, 10 mM citrate pH 5, and 10 mM citrate pH 5.75.  
 
Figure S10. Concentration dependence of the diffusion coefficient of PPI03 in different buffers and linear fits 
from which the interaction parameter kD was derived. In the order top-down the measurements in  
10 mM histidine pH 5.75, 10 mM histidine pH 5, 10 mM citrate pH 5, and 10 mM citrate pH 5.75. 
 
Figure S11. Thermal unfolding curves obtained from the change in the intrinsic protein fluorescence (F350/330) 
ratio of LMU-1 (left) and PPI03 (right) during heating in different buffers – 10 mM histidine pH 5 (black squares), 
10 mM histidine pH 5.75 (red circles), 10 mM citrate pH 5 (blue triangles up), 10 mM citrate pH 5.75 (green 
triangles down). 
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Figure S12. Chromatograms of LMU-1 in 10 mM histidine pH 5 after dilution from 0 M (black), 1 M (red), 2 M 
(blue) and 3 M (green) guanidine hydrochloride – UV detection at 280 nm (left) and QELS signal (right). The 
aggregate peak and the light scattering from the aggregate peak increases when LMU-1 is diluted from higher 
guanidine hydrochloride concentration, which corresponds well to the increase in the Rh measured by DLS. 
 
Figure S13. Chromatograms of LMU-1 in 10 mM histidine pH 5.75 (black) or 10 mM citrate pH 5.75 (red) after 
dilution from 3 M guanidine hydrochloride - UV detection at 280 nm (left) and QELS signal (right). The relative 
area of the aggregate peak after LMU-1 diluted from either citrate or histidine is similar, but the light scattering 
from the aggregate peak is higher when LMU-1 is diluted in citrate in comparison to histidine buffer, which 
indicates that the aggregates formed after dilution in citrate are larger. This corresponds well with the lower Rh 
measured by DLS after protein dilution in histidine compared to the Rh after dilution in citrate. 
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Description of the SEC–MALS-DLS method used in this chapter.: 
The system consisted of Agilent 1260 infinity II pump (Agilent G7111B, Santa Clara, CA, USA) with an online 
degasser (Agilent G7111B), and a temperature controlled autosampler (Agilent G7129A) at 4°C. The separation 
was performed with a SUPERDEX 200 INCREASE 10/30 GL column. A TREOS II MALS detector (Wyatt 
Technology, Santa Barbara, USA) was connected to the system. The MALS detector measured the intensity of 
the scattered light at 4 scattering angles, 3 angles were used for the static light scattering while the fourth one was 
used to measure the dynamic light scattering.  In addition, a variable wavelength detector (Agilent G7114A) 
operated at 280 nm and a differential refractive index detector (Optilab T-rEX,Wyatt Technology Corp.) were 
connected to the system. Data collection and processing were performed using the ASTRA software, Version 7.1 
(Wyatt Technology, Santa Barbara, USA). The aqueous mobile phase consisted of PBS buffer in HPLC-grade 
water with 200 ppm of sodium azide (Sigma–Aldrich, St. Louis, USA). The reagent was purum grade and the 
mobile phase was filtered through Durapore VVPP 0.1 m membrane filters (Millipore Corporation, Billerica, MA, 
USA). 
 
 
 
 
 
Figure S14. Hydrodynamic radii of LMU-1 (A) and PPI03 (B) measured with DLS after 24 hours of incubation 
in different concentrations of GuHCL and different buffers – 10 mM histidine pH 5 (red), 10 mM histidine pH 
5.75 (blue), 10 mM citrate pH 5 (yellow) and 10 mM citrate pH 5.75 (green). The protein concentration is 10 g/L 
in all LMU-1 samples and 2 g/L in all PPI03 samples. The viscosity of the respective GuHCL concentration was 
measured as described in Materials and methods and used in the calculations of the Rh. The large differences 
between the Rh of the proteins in the absence of GuHCL are due to effects from the kD (see Table 3). 
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Figure S15. Example of autocorrelation functions and the corresponding cumulant fit (black line) from DLS 
measurements of LMU-1 (A) and PPI03 (B) samples after dilution from different GuHCL concentrations. Size 
distributions from the regularisation analysis of the LMU-1 (C) and PPI03 (D) samples after dilution from 
different GuHCL concentrations. All experiments for this figure were performed in 10 mM histidine pH 5. The 
concentration of LMU-1 and PPI03 are 1 g/L and 0.2 g/L respectively. 
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Chapter 5 A study on some variables that affect the isothermal 
denaturant-induced unfolding and aggregation of a monoclonal 
antibody in different formulations 
 
Parts of this chapter are used for the preparation of a manuscript that will be submitted for  
peer-review and publication. 
 
5.1 Abstract 
In this chapter, I investigate several variables in isothermal chemical denaturation (ICD) 
experiments that affect the unfolding and aggregation of a monoclonal antibody in different 
formulations. First, I explore if different denaturants can be used to obtain isothermal chemical 
denaturation curves of an antibody in different formulations. I find that guanidine 
hydrochloride and urea are most suitable for such studies. The use of other denaturants, in this 
case, is obstructed due to various reasons like protein precipitation or low denaturant solubility. 
Second, I study the effect of incubation time on the denaturant-induced unfolding of the 
antibody in two formulations with different pH. I observe that the isothermal chemical 
denaturation curves continuously shift during sample incubation. Third, I investigate more in 
detail how guanidine hydrochloride and urea unfold the antibody in formulations with different 
pH and briefly comment on the differences between these two denaturants. Fourth, I look for 
the reasons behind the shifting protein unfolding curves during incubation and use dynamic 
light scattering and size exclusion chromatography to find that the partially unfolded antibody 
aggregates in the presence of the denaturants. The aggregation of the partially unfolded 
antibody is more pronounced in a formulation with pH 6.5 compared to a formulation with  
pH 5. Finally, I hypothesise that the formulation conditions will affect in the same way  
(1) the aggregation of the partially unfolded antibody in the presence of a denaturant and  
(2) the aggregation of the fully unfolded antibody during refolding from a denaturant. In this 
context, I explore the application of a microdialysis-based unfolding/refolding assay to 
compare the effect of formulation conditions on the aggregation of an antibody.  
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5.2 Introduction 
Isothermal chemical denaturation (ICD) is a technique that employs denaturants to study 
protein conformational stability3,173. In an ICD experiment, increasing denaturant 
concentrations are added to a solution to cause protein unfolding at a constant temperature. 
After some incubation time, the degree of unfolding is assessed by measuring a physical 
observable like protein fluorescence. The data is plotted to obtain isothermal chemical 
denaturation curves which show at which denaturant concentrations the protein is (partially) 
unfolded. Provided that the samples reach an equilibrium and the denaturation is reversible, an 
ICD experiment can give the Gibbs free energy (dG) of protein unfolding which is a direct 
measure for conformational protein stability3,51,174. Most published work using ICD to assess 
conformational stability is on small single-domain proteins. However, there is an increasing 
interest in performing ICD experiments on larger multi-domain proteins like antibodies 
because ICD recently received more attention as a technique for formulation studies of 
therapeutic proteins4,54,165. When using ICD for formulation studies, one must consider 
different questions regarding the experimental variables – Which denaturant should be used? 
How long to incubate the samples with the denaturant? Does the denaturant type affect the 
information obtained for different protein formulations? Are the denaturant-induced partially 
unfolded protein species aggregating and, if yes, does this aggregation depend on the 
formulation conditions? 
Regarding the denaturant selection, most ICD studies on large therapeutic proteins like 
monoclonal antibodies are performed with guanidine hydrochloride or urea. Both have 
drawbacks – for example, guanidine hydrochloride immensely increases the ionic strength of 
the solution, while urea is considered a weaker denaturant than GuHCl and can sometimes 
cause only partial unfolding52,165. Therefore, investigating the application of alternative 
denaturants is important to provide more options to the formulation scientists. Particularly 
interesting are the alkylureas or other guanidine salts which have been successfully used for 
ICD experiments with small model proteins175–179.   
Besides the denaturant choice, the incubation time of the samples is also a variable that is not 
trivial to optimise52. Published work with monoclonal antibodies states incubation times of 15 
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minutes155, 1-3 hours52,154, 8 hours52, 18-30 hours4,154 or even up to several weeks153. Therefore, 
there is a need for a better understanding of how the incubation time affects the protein 
unfolding in different formulation conditions. 
A further important consideration for ICD experiments is whether the partially unfolded 
proteins aggregate in the presence of the denaturant. In this context, ICD was recently used to 
study non-reversibility effects due to the aggregation of the native or unfolded protein154. Such 
experiments look at the protein concentration dependence of dG rather than measuring the 
protein aggregation directly. However, suitable analytical techniques can be used to measure 
this aggregation as earlier reported for small model proteins and recently for an antibody180,181. 
For the purpose of protein formulation studies, the effect of the formulation on the aggregation 
of the partially unfolded proteins is particularly interesting.  
5.3 Materials and methods 
5.3.1 Monoclonal antibodies and chemicals 
The monoclonal antibody (LMU-1) used in this work is a human IgG1. The protein bulk 
contains >99.5% monomer, and the purity of the substance is studied as earlier described55. 
The protein buffer was exchanged to 50 mM histidine/histidine hydrochloride with pH 5 and  
pH 6.5 by extensive dialysis employing materials and steps described in our previous work182. 
The concentration of the protein was determined at 280 nm with a Nanodrop 2000 UV 
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) using the protein extinction 
coefficient. Reagent chemicals were purchased from Sigma Aldrich (Steinheim, Germany), 
VWR International (Darmstadt, Germany) or Fisher Scientific (Schwerte, Germany). Highly 
purified water was used for the preparation of all solutions. The denaturant concentration was 
confirmed by measuring the solution refractive index and calculating the concentration with 
the denaturant calculator from the Sosnick group (http://sosnick.uchicago.edu/gdmcl.html). 
5.3.2 Isothermal chemical denaturation 
The experiment was performed as described in our earlier work55. Briefly, the protein stock 
solution in the formulation buffer was combined with various amounts of formulation buffer 
and denaturant stock solution in formulation buffer. The samples were prepared in 384-
nonbinding well plates (Corning, Corning, NY) with a Viaflo Assist pipetting platform (Integra 
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Biosciences, Konstanz, Germany) equipped with suitable multichannel pipettes. After mixing, 
the well plate was sealed and incubated at room temperature for the desired time. The degree 
of protein unfolding was assessed by measuring the intrinsic protein fluorescence intensity at 
330 nm and 350 nm after excitation at 280 nm with a FLUOstar Omega microplate reader 
(BMG Labtech, Ortenberg, Germany). The intrinsic fluorescence intensity ratio FI350/FI330 
(fluorescence intensity at 350 nm)/(fluorescence intensity at 330 nm) was plotted against the 
denaturant concentration to obtain protein isothermal unfolding curves. The denaturant 
concentration needed to unfold 50% of the protein was calculated for the first (Cm1) and second 
(Cm2) transition from the best fit to a 3-state unfolding model in the CDpal software
50,55. 
5.3.3 Dynamic light scattering 
The samples are centrifuged for 10 minutes at 8200g. Next, ten microliters of each solution 
were pipetted in triplicates into a clear bottom 1534-well plate (Aurora). The plate was 
centrifuged for 2 minutes using a Heraeus Megafuge 40 centrifuge equipped with an M-20 well 
plate rotor (Thermo Fisher Scientific). The plate was then sealed with a transparent foil and 
centrifuged again for 2 minutes. Subsequently, the samples were measured with a DynaPro III 
DLS plate reader (Wyatt Technology Europe, Dernbach, Germany) using 5 acquisitions of 5 
seconds at 25 ºC. The collected data was evaluated with the Dynamics V7.8 software. The 
fluctuations of the scattered light were used to obtain autocorrelation functions. Cumulant 
analysis was used to derive mutual diffusion coefficient (D) and the polydispersity index (PDI). 
The Stokes-Einstein equation was used to calculate the apparent hydrodynamic radius (Rh) at 
25°C from the D and the sample viscosity.   
5.3.4 Size exclusion chromatography with multi-angle light scattering 
The system used includes an Agilent 1100 Series HPLC (Santa Clara, CA, USA), an Agilent 
1100 multiple wavelength detector (Santa Clara, CA, USA), Agilent 1100 refractive index 
detector and a DAWN HELEOS multi-angle light scattering (MALS) detector (Wyatt 
Technology, Santa Barbara, USA). The samples were injected on a TSKgel G3000SWxl, 
7.8x300 mm, 5 µm column (Tosoh Bioscience, Tokyo, Japan) and protein elution was detected 
with the absorption at 280 nm. The running buffer for samples without denaturant consisted of 
100 mM potassium phosphate, 200 mM sodium chloride and 0,05 % w/v sodium azide. The 
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buffer pH was adjusted to 7.0 with 2 M sodium hydroxide. The running buffer for samples with 
denaturant consisted of 50 mM histidine/histidine hydrochloride with pH 5 or pH 6.5 and the 
respective concentration of guanidine hydrochloride. Data collection and processing were 
performed using the ASTRA software v7.1 (Wyatt Technology, Santa Barbara, USA). 
5.3.5 Microdialysis-based unfolding/refolding experiments 
100 µL of LMU-1 solution with a concentration of 1, 5, 10, 25 or 50 g/L in 50 mM histidine 
buffer with pH 5 or 6.5 was filled in Pierce™ microdialysis devices (3.5 kDa MWCO). The 
samples were dialysed in a deep well-plate against 1.5 mL of 8 M guanidine hydrochloride or 
10 M urea solution in the respective formulation buffer. The denaturant solutions were changed 
after 4 and 8 hours to ensure a constant concentration gradient across the membrane. After the 
last change, the dialysis was continued in total for 24 hours. Subsequently, the mAb samples 
dialysed against denaturant were dialysed against 1.5 mL of the respective denaturant-free 
formulation buffer. The buffer was changed after 4 and 8 hours; the dialysis continued in total 
for 24 hours. During the entire dialysis procedure, the deep well plate was agitated at 700 rpm 
with a Thermomixer Comfort (Eppendorf AG, Hamburg, Germany). Subsequently, the 
samples were collected from the dialysis devices, and the weight of each sample was added to 
1.0 g using the respective denaturant-free buffer. Finally, the samples were centrifuged at 10 
000 x g for 10 minutes to remove insoluble protein aggregates. Further measurements were 
performed on the supernatant. 
5.4 Results and discussion 
5.4.1 Effect of denaturant type on the isothermal antibody unfolding 
I investigated if different denaturants can be used to obtain isothermal unfolding curves of a 
model antibody in different formulations. A comparison between isothermal unfolding curves 
of LMU-1 with different denaturants is presented in Fig. 27. GuSCN causes protein unfolding 
at lowest denaturant concentrations but also causes protein precipitation which results in a loop 
in the pre-unfolding baseline. This precipitation was more pronounced in formulations with 
lower pH and at GuSCN concentrations that cause partial protein unfolding (Master thesis, 
Uroš Markoja). This phenomenon could arise from the binding of the weakly hydrated 
guanidine and thiocyanate ions to the protein183. However, the exact mechanism by which 
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GuSCN reduces the solubility of the partially unfolded antibody will be topic of separate 
research. GuHCl unfolds the protein at higher concentrations than GuSCN, and good pre- and 
post-transition baselines are obtained. Dimethylurea causes only partial protein unfolding. Urea 
causes full protein unfolding, but denaturant concentrations up to 9 M are required to obtain a 
good post-transition baseline. I also tested several urea derivatives, i.e. methylurea, ethylurea, 
dimethylurea, that do not cause full unfolding of the protein in the concentration range where 
the denaturant was soluble. Other groups also observed uncomplete protein unfolding of a 
model protein like ribonuclease A in alkylureas184. Another urea derivative, i.e. 
tetramethylurea, precipitated the model antibody. Based on this data, guanidine hydrochloride 
and urea seem to be the most suitable denaturants for ICD experiments with LMU-1. 
 
Figure 27. Effect of denaturant type on the isothermal unfolding of LMU-1. 50 mM histidine with pH 5 is used 
as a sample buffer. The protein concentration is 1 g/L. The samples were incubated for 24 hours at room 
temperature before measurement. The symbols are mean of triplicates; the error bar is the standard deviation. 
5.4.2 Effect of incubation time on the denaturant-induced antibody unfolding 
After identifying guanidine hydrochloride and urea as suitable for further experiments,  
I studied the effect of incubation time with these two denaturants on the isothermal unfolding 
of the antibody in two formulations with different pH - pH 5 and pH 6.5. The isothermal 
chemical denaturation curves in all tested conditions shift quickly in the first hours of 
incubation (Fig 28). I also used circular dichroism on selected samples to confirm that the 
observations from fluorescence measurements arise from structural changes (see 
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supplementary data to this chapter). After 24 hours of incubation, the curve shift is very slow 
but continues for weeks and depends on the formulation buffer and pH (data not shown). This 
shift was already observed for antibodies153 and indicates that the unfolding does not reach 
equilibrium. The shifts mentioned above are a complication in cases when an isothermal 
chemical denaturation experiment aims to accurately determine correct thermodynamic 
parameters like the true Gibbs free energy of unfolding. In the best case, the effect of incubation 
time on the unfolding of the protein should be assessed on a case-by-case basis. 
 
Figure 28. Effect of time and denaturant on the isothermal unfolding of LMU-1 in formulations with different 
pH. Unfolding in (A) pH 5 with guanidine hydrochloride, (B) pH 6.5 with guanidine hydrochloride, (C) pH 5 with 
urea, and (D) pH 6.5 with urea. 
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5.4.3 Effect of guanidine hydrochloride and urea on the isothermal antibody unfolding 
in formulations with different pH 
I was interested to compare more in detail how guanidine hydrochloride and urea unfold the 
model antibody in formulations with different pH because these two denaturants have very 
different properties. Guanidine hydrochloride is a salt and masks the electrostatic interactions 
in solution, while urea does not change the ionic strength and respectively does not largely 
affect the electrostatics. Earlier work employed these differences in the denaturant properties 
to demonstrate that comparing isothermal chemical denaturation data obtained with guanidine 
hydrochloride and urea can be used to provide information about the contribution of 
electrostatic interactions to the conformational protein stability185. From the perspective of 
formulation development, a big change in the ionic strength can affect the protein in different 
ways. To study if using different denaturants affects the results obtained for different protein 
formulations, I tested the effect of urea and guanidine hydrochloride on the unfolding of the 
model mAb in the pH range 5 to 7 (Fig 29). With an increase in pH, higher denaturant 
concentration is needed to unfold the protein with a maximum reached around pH 7. At lower 
pH the protein was unfolded by lower denaturant concentrations. This observation is the same 
when using either guanidine hydrochloride or urea. 
 
Figure 29. Effect of denaturant on the isothermal unfolding of LMU-1 in formulations with different pH. 
Isothermal chemical denaturation curves obtained with (A) guanidine hydrochloride and (B) urea. The samples 
are incubated for 24 hours at 25 ºC. The protein concentration is 1 g/L. 
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I used the obtained curves in Fig 29 to derive the apparent melting denaturant concentrations 
for the first (Cm1) and the second transition (Cm2) (Table 4). The melting denaturant 
concentration shows what denaturant concentration is needed to unfold 50 % of the protein. 
Next, I calculated the ratios between the Cm values for the two unfolding transitions obtained 
in urea and guanidine hydrochloride to assess whether the relationship between the “strength” 
of the two denaturants is the same in all formulations (Fig 30). What is evident from Fig 30 is 
that the ratios of the Cm values obtained with urea or guanidine hydrochloride change with the 
formulation pH. Moreover, the change is different for the two unfolding transitions. The shift 
around pH 6 in Fig 30 could be a result of the change in the protonation state of histidine 
residues in the protein structure, which could change the electrostatics contributing to the 
conformational protein stability. However, the exact reason for these results must be studied in 
detail on smaller model proteins like single antibody domains. 
Table 4. Apparent parameters extracted from the isothermal chemical denaturation graphs of LMU-1. The ± is 
the error from the Jackknife error from the fit to a three-state model in CDpal. 
Denaturant Parameter pH 5.0 pH 5.5 pH 6.0 pH 6.5 pH 7.0 
GuHCl 
Cm1 (M) 1.79 ±0.15 2.08 ±0.12 2.11 ±0.2 2.29 ±0.07 2.50 ±0.07 
Cm2 (M) 2.46 ±0.03 2.64 ±0.01 2.76 ±0.04 2.86 ±0.02 2.86 ±0.02 
Urea 
Cm1 (M) 4.58 ±0.33 5.26 ±0.21 5.74 ±0.32 6.68 ±0.32 7.24 ±0.07 
Cm2 (M) 6.42 ±0.1 6.89 ±0.04 7.2 ±0.21 7.54 ±0.04 7.77 ±0.25 
 
Figure 30. The ration between the melting denaturant concentrations obtained with urea and guanidine 
hydrochloride for the first (squares) and the second (circles) unfolding transition of LMU-1 in formulations with 
different pH 
 
 
92 
 
5.4.4 The impact of the denaturant and formulation pH on the aggregation of a partially 
unfolded antibody 
Earlier, I observed that the isothermal chemical denaturation curves of the model antibody 
continuously shift during incubation. I assumed that the reason for these shifts could be 
aggregation or precipitation that can occur in the samples89,181,186. Such aggregation was 
observed for other monoclonal antibodies, although the effect of denaturant type and pH on 
that phenomenon was not studied in detail53,187.  
 
Figure 31. Effect of pH, denaturant type and denaturant concentration on the aggregation of LMU-1 assessed by 
the change in the apparent hydrodynamic radius Rh from dynamic light scattering. Aggregation in (A) GuHCl at 
pH 5; (B) GuHCl at pH 6.5; (C) urea at pH 5; and (D) urea at pH 6.5; The protein concentration is 10 g/L. 
I wanted to study if the partially unfolded antibody in a denaturant solution aggregates and,  
if so, whether this aggregation is different in formulations with different pH. To investigate 
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that, I used dynamic light scattering to assess the aggregation of the partially unfolded protein 
in two formulations with pH 6.5 and pH 5 over the time course of seven days (Fig 31). A slow 
aggregation was observed at denaturant concentrations that cause partial protein unfolding  
(see Fig 29). This aggregation occurred in both guanidine hydrochloride and urea and was 
significantly more pronounced at pH 6.5 compared to pH 5 (Fig 31). 
To confirm the results from the fluorescence and DLS analysis that the protein unfolds slowly 
(Fig 28) and simultaneously forms aggregates (Fig 31), I used size exclusion chromatography 
coupled to multi-angle light scattering to determine the molecular weight of the eluting species. 
The LMU-1 samples were incubated in the respective denaturant concentration and injected in 
the SEC-MALS system running with the same buffer and denaturant concentration like the 
incubated sample.  
 
Figure 32. Formation of multiple unfolded species with simultaneous formation of aggregates when 10 g/L  
LMU-1 are incubated at 25 ºC in (A) 2.5 M guanidine hydrochloride in 50 mM histidine pH 5; and  
(B) 3 M guanidine hydrochloride in 50 mM histidine pH 6,5; 
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The incubation in the denaturant that induces partial unfolding in Fig 28 causes the formation 
of multiple monomeric species that elute earlier than the native protein (Fig 32). Such species 
have a different degree of unfolding which results in different hydrodynamic radius and 
respectively different elution times. I also observed that aggregates form simultaneously with 
the unfolding of the protein. The DLS and SEC-MALS results both show that the isothermal 
chemical denaturation curves shift during longer incubation due to protein aggregation. 
Important to note, the aggregation of the partially unfolded antibody is more pronounced in a 
formulation with pH 6.5 compared to the counterpart with pH 5 (Fig 33). 
 
Figure 33. Effect of guanidine hydrochloride concentration on aggregation of LMU-1 at (A) pH 5 and  
(B) pH 6.5 measured with SEC-MALS. The protein concertation in the experiment is 10 g/L. The samples are 
incubated at 25 ºC.  
5.4.5 The aggregation during refolding of an antibody depends on the formulation  
I assumed that the formulation conditions (e.g. pH) would affect in the same way the 
aggregation of a partially unfolded antibody in the presence of a denaturant and the aggregation 
of a fully unfolded antibody during refolding from a denaturant. To test this, I performed 
microdialysis unfolding/refolding experiments on the antibody in formulations with pH 5 and 
pH 6.5. Further, I was interested in how the protein concentration (from 1 to 50 g/L) affects the 
antibody aggregation during refolding in the formulations with different pH. Before and after 
refolding, I used size exclusion chromatography to measure the area of the monomer peak in 
each sample. I divided the monomer area after unfolding/refolding by the monomer area before 
unfolding/refolding to obtain a parameter called relative monomer yield (RMY). A RMY of 0 
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shows that no monomer is recovered after refolding, while an RMY of 1 shows that all the 
monomer is recovered after refolding. 
The RMY of the antibody is higher, i.e. less protein is aggregated, when the refolding is 
performed in urea compared to guanidine hydrochloride (Fig 34). This effect is more 
pronounced at protein concentrations less than 25 g/L. The difference between urea and 
guanidine hydrochloride can be explained by the fact that in urea solutions the electrostatic 
interactions between the monomers are not screened and contribute to significant repulsion 
between the molecules, especially in dilute solutions.  The addition of guanidine hydrochloride 
screens these electrostatic repulsions and the antibody aggregates more after refolding. I also 
observed that more monomer was recovered when the refolding was performed in formulations 
with pH 5 compared to counterparts with pH 6.5. These differences were more pronounced 
when urea was used and at lower protein concentration.  
 
Figure 34. Effect of pH and protein concentration on the relative monomer yield of LMU-1 after refolding from 
(A) guanidine hydrochloride, and (B) urea. 
Earlier, I showed that the partially unfolded antibody in urea and guanidine hydrochloride 
aggregates more in a formulation with pH 6.5 compared to a formulation with pH 5. These 
observations agree with the results that the protein aggregates more during refolding from a 
denaturant in formulations with pH 6.5 compared to pH 5. This reveals an interesting 
opportunity that the effect of the formulation on the aggregation of partially unfolded protein 
species can be assessed by microdialysis unfolding/refolding experiments like the one used 
here. 
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5.5 Conclusions 
In this chapter, I explored several variables that affect the unfolding and aggregation of an 
antibody in different formulations. At the beginning, I tested if different denaturants can be 
used for isothermal chemical denaturation studies to find that only guanidine hydrochloride 
and urea were suitable in this work. Other denaturants like alkylureas or guanidine thiocyanate 
had poor solubility in the formulation buffers, induced only partial protein unfolding or caused 
protein precipitation. Next, I studied how the incubation time affects the denaturant-induced 
unfolding of the antibody in two formulations with pH 5 and pH 6.5. The isothermal chemical 
denaturation curves of the antibody shift quickly in the first hours of incubation. After 24 hours, 
the curves continue to shift very slowly, the shift continues for weeks. Further, I used dynamic 
light scattering and size exclusion chromatography coupled to multi-angle light scattering to 
show that the partially unfolded antibody aggregates in the presence of denaturants. The 
aggregation is faster in a formulation with pH 6.5 compared to a formulation with pH 5. Then, 
I hypothesised that the formulation conditions (i.e. pH) would have the same effect on the 
aggregation of the partially unfolded protein in the presence of a denaturant and on the 
aggregation during refolding of the fully unfolded protein from a denaturant. I performed 
microdialysis unfolding/refolding experiments to find that the antibody aggregates more during 
refolding in formulations with pH 6.5 compared to formulations with pH 5, confirming the 
hypothesis mentioned above. 
 
The findings in this chapter indicate that a microdialysis-based unfolding/refolding assay with 
urea could be employed to assess how the formulation affects the aggregation of the partially 
unfolded antibody. In the next two chapters, I explore if such an assay can predict formulations 
that impede protein aggregation during long-term storage. 
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5.6 Supplementary data 
 
Figure S16. Near-UV CD spectra of 10 g/L LMU-1 in 50 mM histidine pH 5 during 24 hours of incubation in 
(A) 1 M guanidine hydrochloride; (B) 2.5 M guanidine hydrochloride; and (C) 4 M guanidine hydrochloride; The 
incubation time step between the different spectra is 2 hours. The measurements are made with a Jasco J-810 
spectrometer (JASCO Deutschland GmbH, Pfungstadt, Germany) using 1 mm quartz cuvettes (Hellma GmbH, 
Muellheim, Germany). Each spectrum is an average of 3 scans measured with 20 min/min scan speed. 
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long-term storage 
 
This chapter is published as: 
Svilenov, H.* and Winter, G. *, 2019. The ReFOLD assay for protein formulation studies and 
prediction of protein aggregation during long-term storage. European Journal of Pharmaceutics 
and Biopharmaceutics, 137, pp. 131-139 
*
Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University, 
Butenandtstrasse 5-13, Munich D-81377, Germany 
 
Author contributions: 
H.S. performed the experiments, evaluated the data and wrote the paper. H.S. and G.W. 
conceived the presented idea and planned the experiments. G.W. supervised the work, provided 
conceptual guidance and corrected the manuscript. 
 
Note from the authors: 
The version included in this thesis is identical with the published article apart from minor 
changes. The reference, figure and table numbers were changed to fit into the coherent 
numbering of this document. The text was edited to meet the norms for British English.  
 
The published article can be accessed online via: 
https://doi.org/10.1016/j.ejpb.2019.02.018 
 
 
 
100 
 
6.1 Abstract 
The formulation of novel therapeutic proteins is a challenging task which aims at finding 
formulation conditions that will minimise protein degradation during long-term storage.  
In this chapter, we suggest a novel approach for the selection of formulations that will suppress 
the formation of protein aggregates during long-term storage. We postulate that conditions (i.e. 
pH, buffer type, ionic strength) that reduce the isothermal aggregation of various denaturant-
induced partially folded protein species will be conditions that impede protein aggregation 
during long-term storage. To test our hypothesis, we developed an isothermal microdialysis-
based unfolding/refolding assay, named ReFOLD, which we use to induce moderate 
aggregation of partially folded proteins. Next, we assessed the relative monomer yield after 
isothermal unfolding/refolding of two monoclonal antibodies, each formulated in 12 different 
conditions. Using the proposed approach, we were able to accurately rank the formulations in 
order of their effect on the amount of protein aggregates detected after storage for 12 months 
at 4 °C and 25 °C, while widely-used stability-indicating parameters like protein melting and 
aggregation onset temperatures failed to provide accurate predictive formulation rankings. 
Keywords - Proteins; Protein formulation; Protein folding; Protein unfolding; Protein 
Aggregation; Monoclonal antibody; Storage Stability; Stability prediction; 
Abbreviations - CD – Circular dichroism; dG – the Gibbs free energy of protein unfolding; 
DLS – Dynamic Light Scattering; DSF - Differential Scanning Fluorimetry; ICD – Isothermal 
Chemical Denaturation; mAb – monoclonal antibody; nanoDSF™ – Microscale Differential 
Scanning Fluorimetry; RMY – Relative Monomer Yield after refolding; SEC-MALS – size 
exclusion chromatography coupled to a multi-angle light scattering detector; Tagg – Protein 
aggregation onset temperature; Tm – Protein melting temperature; 
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Figure 35. Graphical abstract of Chapter 6 - Schematic diagram of the ReFOLD assay 
6.2 Introduction 
Non-native protein aggregation (referred to as just “protein aggregation” in this paper) is a 
major concern during the long-term storage of liquid protein formulations18,47,85,93. This 
pathway of protein aggregation typically occurs through partially unfolded intermediates (often 
termed as reactive species188), which can form irreversible aggregate nuclei that can further 
grow by various mechanisms. The latter are extensively discussed in the literature and are 
outside the scope of this article85,87,90,189,190. Regardless of the exact mechanism of aggregate 
nucleation and growth, the formation and presence of protein aggregates in parenteral products 
should be controlled and minimised for various reasons, e.g. immunogenicity 
concerns101,102,191,192, reduced biological activity135,136 or non-compliance with regulatory 
frameworks103,138,193. The formation of protein aggregates during long-term storage can be 
suppressed by choosing suitable formulation conditions, e.g. pH, buffer type, ionic strength, 
etc.1,104. The process of selecting the optimal formulation for a new therapeutic protein 
candidate usually includes the testing of dozens of different conditions62,194. Screening all these 
formulation conditions with long-term or accelerated stability studies is impractical as this 
would require a lot of resources. Therefore, many researchers turn to short-term biophysical 
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techniques that could provide predictions for the protein aggregation during storage, thereby 
reducing the number of formulations for long-term stability studies.  
Such biophysical techniques usually require small amounts of sample, can be performed in 
short timeframes and are suitable for automatization and high-throughput formats116,139,155,195. 
Two of these techniques that are frequently used in the industry are differential scanning 
fluorimetry (DSF) and dynamic light scattering (DLS)46,47,146,165,196–198. The latter can provide 
the (apparent) protein melting temperature (Tm) and the aggregation onset temperature (Tagg) 
respectively. Earlier publications show that in some cases, and on a limited set of formulation 
conditions, a high Tm or a high Tagg can be an indicator for formulation conditions where protein 
aggregation is suppressed during accelerated stability studies (e.g. 40 ⁰C and 50 ⁰C)47,105,199. 
However, recent work on larger sets of proteins indicates that these parameters show a very 
weak or no correlation with the aggregation behaviour of many therapeutic proteins, especially 
mAbs, during storage at 4 ⁰C and 25 ⁰C62,63,105,200.  
Probably due to the reason mentioned above, researchers have started to explore orthogonal 
techniques that could provide better stability predictions for the aggregation behaviour of novel 
therapeutic proteins during long-term storage. One such technique is isothermal chemical 
denaturation (ICD)4,54,165. Although ICD is the gold standard to obtain the Gibbs free energy 
of protein unfolding (and thereby assess the conformational stability of a protein)162, the data 
evaluation from this method is valid only in cases where the protein of interest undergoes 
reversible unfolding in the denaturant solution52,55,173. Most of the published work including 
ICD experiments is on small globular single-domain proteins174,201,202. However, the vast 
majority of therapeutic proteins under development in the moments have large, multi-domain 
structures (e.g. mAbs, bispecifics, fusion proteins, antibody-drug conjugates) that can undergo 
complex, multi-step unfolding during an ICD experiment which could require sophisticated 
fitting to a model50,165. Furthermore, the reversibility of unfolding of these proteins in different 
formulation conditions might vary52,54,55. Recently, it was suggested that one could use ICD 
experiments to investigate non-reversibility effects during protein unfolding in a 
denaturant6,154. Such experiments study how the apparent Gibbs free energy of protein 
unfolding changes when different protein concentrations are used to obtain the ICD curves. It 
was already demonstrated that the latter approach can provide complementary stability-
 
103 
 
indicating information to DSF and DLS54,203. Still, ICD experiments that study the 
concentration dependence of dG are tedious, require dedicated laboratory equipment and rely 
on the quality of the fitting to a certain unfolding model. 
Rather than using ICD as an “indirect” way to look into the effect of the formulation conditions 
on the reversibility of isothermal protein unfolding, we recently suggested that one could 
directly study the aggregation after dilution from a denaturant55. Shortly after that and 
independently of us, Rowe et al. proposed a similar approach53. In our previous work, we 
showed that when the dilution refolding experiments are performed with certain denaturant 
concentrations, the protein aggregation during refolding can be linked to other stability-
indicating parameters, e.g. the melting denaturant concentration Cm and the interaction 
parameter kD
55. The dilution approach we proposed is valuable to probe which denaturant 
concentrations will cause extensive protein aggregation after dilution refolding and also to 
study if there is a difference in the physical stability of a protein in conditions with overlapping 
ICD curves55.  
However, different concentrations of a denaturant cause different degrees of protein unfolding 
and different aggregation-prone intermediates. Each of the latter could be important for the 
non-native protein aggregation during long-term storage. Rather than diluting the protein from 
dozens of different denaturant concentrations, we decided to perform microdialysis on the 
protein against a denaturant and subsequently against a denaturant-free formulation buffer. 
This procedure will cause various unfolding (refolding) protein intermediates. We 
hypothesised that these intermediates will aggregate depending on the formulation conditions, 
e.g. pH, buffer type, ionic strength, protein concentration. The rationale behind using this 
phenomenon as a protein formulation tool is that formulation conditions which suppress the 
aggregation of various partially folded states would be formulation conditions that would 
suppress protein aggregation during long-term storage. Since the isolation of the individual 
aggregation-prone intermediates or aggregates formed could be a challenging task, we adopted 
an approach where we assess the relative monomer yield (RMY) after the isothermal unfolding 
and refolding is completed. Important to note, determining the RMY after isothermal 
unfolding/refolding of the protein for the purpose of formulation development would be quite 
different compared to unfolding/refolding experiments to increase the monomer yield after 
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protein expression as inclusion bodies. The latter experiments usually include a reduction and 
new formation of disulphide bonds, as well as extremities in the pH, excipient concentration 
and the type of excipients used166,168,169,204,205. Assessing the aggregation during isothermal 
unfolding/refolding of the protein as a formulation tool is focused on a pH range which is 
realistic for long-term storage and administration in patients due to chemical stability and 
tolerability considerations respectively. Furthermore, the excipients used, as well as their 
concentrations, would be approved for parenteral application206.  
To study our hypothesis, we developed a microdialysis unfolding/refolding assay which we 
called ReFOLD. Next, we investigated the effect of realistic for long-term storage formulation 
conditions on the relative monomer yield after isothermal unfolding/refolding of two 
monoclonal antibodies. We validated the predictions from the ReFOLD assay by performing a 
12-month stability study at 4 ⁰C and 25 ⁰C. Additionally, we characterised the antibodies in the 
presence of urea to show that this denaturant causes partially unfolded states and suppresses 
the protein aggregation in all conditions tested. The latter phenomena allow us to see 
formulation-dependent differences in the monomer loss caused by aggregation of partially 
folded protein species during unfolding/refolding.  
6.3 Materials and Methods 
6.3.1 Monoclonal antibodies and chemicals 
Two IgG1 monoclonal antibodies were used in this work - LMU-1 and PPI03. The monomeric 
state and the purity of the proteins in the bulk solution were confirmed as described earlier55. 
The buffer of the mAbs was exchanged by extensive dialysis overnight as previously 
described55. Unless otherwise stated, the final mAb solutions after dialysis contained 10 mM 
histidine/histidine hydrochloride buffer, 10 mM sodium citrate/citric acid buffer with a pH 5, 
5.75 or 6.5. The PPI03 samples containing 70 mM sodium chloride were prepared by spiking 
in the salt from a 10X stock solution. All LMU-1 samples contained 0,05 % w/v polysorbate 
20 which was spiked in the protein solution after dialysis. All PPI03 solutions were free of 
surfactants. For an overview of the formulations see Tables 5 and S4. The protein concentration 
was measured by UV spectrometry at 280 nm with a Nanodrop 2000 (Thermo Fisher Scientific, 
Wilmington, DE) using the respective protein extinction coefficient. Reagent chemicals from 
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the highest grade available were purchased from Sigma Aldrich (Steinheim, Germany), VWR 
International (Darmstadt, Germany) or Fisher Scientific (Schwerte, Germany). Highly purified 
water was used for the preparation of all buffers. 
6.3.2 Isothermal protein unfolding and refolding with microdialysis  
100 µL of formulated mAb solution was filled in Pierce™ microdialysis devices with a 
membrane having 3.5 kDa MWCO. The samples were dialysed in a deep well-plate against 1.5 
mL of 10 M urea solution in the respective formulation buffer. The urea solution was changed 
4 and 8 hours after the beginning. After the last change, the dialysis was continued for another 
16 hours. Next, the mAb samples dialysed against 10 M urea were dialyzed against 1.5 mL of 
the respective urea-free formulation buffer. The buffer was changed 4 and 8 hours after the 
beginning, and the dialysis continued in total for 24 hours. During the entire dialysis procedure, 
the deep well plate was attached to a Thermomixer Comfort (Eppendorf AG, Hamburg, 
Germany) which was adjusted to agitate the plate at 700 rpm. Finally, the samples were 
collected from the dialysis devices and the weight of each sample was added to 1.0 g with the 
respective urea-free buffer to avoid variations in the sample volume that might arise during 
dialysis. Finally, the samples were centrifuged at 10 000 x g for 10 minutes to remove any 
insoluble matter. The supernatant was used for further measurements. 
6.3.3 Size Exclusion Chromatography  
A Dionex Summit 2 system (Thermo Fisher, Dreieich, Germany) and a TSKgel G3000SWxl, 
7,8x300 mm, 5 µm column (Tosoh Bioscience, Tokyo, Japan) were used for the size exclusion 
chromatography. Protein elution was detected at 280 nm unless otherwise stated. The running 
buffer consisted of 100 mM potassium phosphate, 200 mM sodium chloride and 0,05 % w/v 
sodium azide. The buffer pH was adjusted to 7.0 with 2 M sodium hydroxide. The 
chromatograms were integrated with Chromeleon V6.8 (Thermo Fisher, Dreieich, Germany). 
The relative content of the high molecular weight (HMW) species formed after long-term 
storage was calculated by dividing the peak area of the high molecular weight species by the 
total area of all protein peaks in the chromatogram which provides a number representing the 
relative content of high molecular weight species in percentage. Representative chromatograms 
with integration times and more explanations are presented in the supplementary data to this 
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chapter. The relative monomer yield (RMY) of the proteins after isothermal 
unfolding/refolding, i.e. the ReFOLD assay, was calculated by dividing the area of the 
monomer peak of the refolded sample by the area of the monomer peak of the sample before 
unfolding/refolding which gives a value between 0 and 1, where 0 means that no protein 
monomer is recovered in the sample after refolding and 1 means the same amount of monomer 
is recovered after refolding. 
6.3.4 Size Exclusion Chromatography with Multi-angle Light Scattering  
An Agilent 1100 Series HPLC system (Santa Clara, CA, USA) with an Agilent 1100 multiple 
wavelength detector (Santa Clara, CA, USA), Agilent 1100 refractive index detector and a 
DAWN HELEOS multi-angle light scattering (MALS) detector (Wyatt Technology, Santa 
Barbara, USA) were used for the SEC-MALS measurements. Sample elution was monitored 
at 280 nm and with the change in the refractive index. The same column and running buffer 
like for the SEC method above were used. Data collection and processing were performed 
using the ASTRA software, Version 7.1 (Wyatt Technology, Santa Barbara, USA). 
6.3.5 Isothermal Chemical Denaturation (ICD) 
Samples for isothermal chemical denaturation experiments were prepared by combining 
protein stock solution in formulation buffer with different amounts of formulation buffer and 
10 M urea stock solution in formulation buffer in a non-binding 384-well plate as described 
earlier54,55. The samples were incubated for 24 hours at room temperature and the protein 
intrinsic fluorescence intensity at 330 and 350 nm was measured after excitation at 280 nm 
with a FLUOstar Omega microplate reader (BMG Labtech, Ortenberg, Germany). The intrinsic 
protein fluorescence intensity ratio (FI350/FI330) was plotted against the urea concentration to 
obtain isothermal chemical unfolding curves of the mAbs in different buffers54,55,116.  
6.3.6 Microscale Differential Scanning Fluorimetry  
The protein samples were filled in standard nanoDSF™ grade capillaries, the capillaries were 
sealed and the thermal unfolding of the proteins was studied by applying a temperature ramp 
of 1 ⁰C/min from 20 to 100 ⁰C with the Prometheus NT.48 (NanoTemper Technologies, 
Munich, Germany) system that measures the intrinsic protein fluorescence intensity at 330 and 
350 nm after excitation at 280 nm. At the same time, the device detects precipitation of the 
 
107 
 
samples by measuring the back-reflection intensity of a light beam that passes twice through 
the capillary, this signal can be normalised to a value called “Excess Scattering”. The apparent 
protein melting temperatures (Tm) were determined with the PR.ThermControl software V2.1 
(NanoTemper Technologies, Munich, Germany) from the maximum of the first derivatives of 
the thermal unfolding curves148,207.  
6.3.7 Circula Dicroism (CD) Spectroscopy 
Near-UV circular dichroic spectra of the mAb samples were measured at 25 ⁰C with a Jasco J-
810 spectrometer (JASCO Deutschland GmbH, Pfungstadt, Germany). Quartz cuvettes 
(Hellma GmbH, Muellheim, Germany) with 10 mm wavelength path were used for the 
measurements. All measurements were performed with 3 accumulations and a speed of 20 
nm/min. The spectrum of the respective buffer was subtracted for each sample, Savitzky-Golay 
algorithm with 9 smoothing points was applied and the mean residue ellipticity (MRE) of the 
protein at each wavelength was calculated as described elsewhere120. 
6.3.8 Fourier-transform Infrared Spectroscopy  
FT-IR spectra of the mAb samples were collected at 25 °C using a Tensor 27 (Bruker Optik 
GmbH, Ettlingen, Germany) with a BioATR (Attenuated Total Reflectance) cell™ II (Harrick) 
connected to a thermostat (DC30-K20, Thermo Haake). 120 scans with a resolution of 4 cm-1 
were taken to measure each spectrum. The raw data of each sample was analysed with the Opus 
7.5 (Bruker Optik GmbH) software and shown as a vector-normalised second-derivative 
spectrum. The data were smoothed using a Savitzky-Golay algorithm with 17 smoothing 
points119. 
6.3.9 Long-term stability studies 
The mAb solutions with different formulation conditions were sterile filtered with a 0.22 µm 
cellulose acetate filter and aseptically filled into pre-sterilized DIN2R glass type I vials 
(MGlass AG, Germany). Next, the vials were crimped with rubber chlorobutyl stoppers with 
FluroTec® coating (West Pharmaceutical Services, USA) and stored at 4 ⁰C and 25 ⁰C for the 
desired time. Three different vials were used for the SEC analysis of each condition. 
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6.4 Results and Discussion 
6.4.1 The isothermal protein unfolding/refolding leads to a formulation-dependent 
protein aggregation and monomer loss 
Both antibodies used in this work show substantial aggregation after microdialysis against  
10 M urea (unfolding) and subsequently against urea-free formulation buffer (refolding). The 
visual appearance of the samples after refolding is dependent on the formulation conditions in 
which the refolding is performed. For example, after the ReFOLD assay, LMU-1 formulations 
with a concentration 10 g/L in 10 mM histidine buffer with pH 6.5 remain transparent, while 
counterparts with 10 mM citrate buffer show increased turbidity and form a pellet after 
centrifugation. These observations confirm earlier reports that the aggregate formation of 
antibodies after dilution/dialysis from a denaturant is formulation-dependent53,55. SEC-MALS 
analysis of the supernatant of the refolded samples shows that the samples contain a 
considerable amount of high molecular weight species ranging from dimers to oligomers larger 
than 1000 kDa. (Fig 36). The aggregates are not reversible, and their relative area is the same 
even several days after the dialysis (data not shown). A monomer peak having the same 
retention time as the native protein is detected in the refolded samples. The area of the monomer 
peak is largely dependent on the formulation buffer in which the ReFOLD assay is performed. 
Since the evaluation of the exact size, concentration and type of aggregates formed is 
challenging in such a complex mixture, we decided to focus on the fraction of the protein that 
remains monomeric after isothermal unfolding/refolding (i.e. the relative monomer yield - 
RMY) as a parameter providing a comparison between the formulations. 
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Figure 36. SEC-MALS of native and refolded samples of LMU-1 and PPI03 
6.4.2 The relative monomer yield after isothermal protein unfolding/refolding 
correlates with the relative amount of protein aggregates detected after long-term storage 
The relative monomer yield after the ReFOLD assay is highly dependent on the formulation 
conditions of both LMU-1 (Tables 5 and S3) and PPI03 (Table S4). The formulation conditions 
also have an influence on the relative area of high molecular weight (HMW) species, i.e. protein 
aggregates, detected by SEC after storing the respective denaturant-free protein samples for 12 
months at 4 ⁰C and 25 ⁰C (Table 5 and S3). LMU-1 samples contain more HMW species after 
long-term storage compared to PPI03. Both proteins form fewer HMW species when stored at 
4 ⁰C compared to storage at 25 ⁰C. We also used flow microscopy to study the presence of 
subvisible particles in the samples after 12 months of storage at 4 ⁰C and 25 ⁰C (Fig S18). 
Calculations on the monomer recovery from the size-exclusion chromatography method used 
for the stability study are also included in the supplementary data. A very strong correlation 
between the relative monomer yield from the ReFOLD assay and the relative area of high 
molecular weight species detected after 12 months of storage is observed in the case of LMU-
1 (Fig 37). Interestingly, the first and second apparent melting temperatures of LMU-1 
measured nanoDSF™ show reversed correlations with the relative area of HMW species 
detected after storage, therefore providing misleading predictions for the long-term physical 
stability of these samples (Figs S19 and S20). The aggregation onset temperatures of LMU-1 
show only a moderate to weak correlation with the amount of aggregates formed after storage 
for 12 months (Fig S21). In the case of PPI03 the Spearman's R between the RMY from the 
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ReFOLD assay and the aggregates formed after storage at 4 ⁰C and 25 ⁰C is -0.762 and -0.686 
respectively, showing a strong correlation between these parameters (Fig S22). Like the case 
of LMU-1, the melting temperatures of the PPI03 samples show an inverse correlation with the 
aggregates formed after storage, therefore providing wrong predictions for these formulations 
(Figs S23 and S24). The aggregation onset temperatures of the PPI03 samples show a very 
weak correlation with the amount of high molecular species formed after long-term storage at 
4 ⁰C and 25 ⁰C (Fig S25). In general, PPI03 exhibits a very low aggregation propensity and 
small differences between the formulations during long-term storage. The latter observations 
can contribute to the lower correlation between the RMY and the aggregates formed after 12 
months of storage in comparison to LMU-1. Almost all LMU-1 and PPI03 formulations contain 
less than 10 000 particles ≥ 2 µm per mL after 12 months of storage at 25 ⁰C and 4 ⁰C  
(Fig S18). One exception is the LMU-1 formulation with protein concentration 50 g/L 
formulated in 10 mM histidine pH 6.5 which contains around 150 000 particles ≥ 2 µm per mL. 
Interestingly, this is also the formulation with the lowest relative monomer yield after the 
ReFOLD assay (Table 5). There, are small differences, i.e. ± 5 %, in the monomer recovery of 
the antibodies at the end of the stability study. The samples with high RMY from the ReFOLD 
assay show 100 % (± 1 %) monomer recovery after 12-month storage at 4 ⁰C and 25 ⁰C (Tables 
S5 and S6). 
It is important to underline that the RMY-based predictions from the ReFOLD assay provide 
reliable ranking of the formulations in order of their effect on the relative area of protein HMWs 
formed after 12 months of storage at 4 ⁰C and 25 ⁰C, while often-used stability-indicating 
parameters (i.e. apparent protein melting temperatures from nanoDSF™ and the aggregation 
onset temperatures from dynamic light scattering) provided misleading or weak predictions. 
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Table 5. Relative Monomer Yield (RMY) of LMU-1 formulations after the ReFOLD assay and the relative 
content of high molecular weight species after long term storage of the respective LMU-1 formulations. The 
values are mean of triplicates and the error represents the standard deviation. The value from each replicate is 
provided in the supplementary data to this chapter. 
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
Mean StDev Mean StDev Mean StDev 
1 10 histidine 5 0.387 0.0145 0.207 0.0252 0.153 0.0513 
2 10 histidine 5.75 0.378 0.0125 0.167 0.0153 0.197 0.0462 
3 10 histidine 6.5 0.269 0.0035 0.447 0.0907 0.283 0.0808 
4 10 citrate 5 0.241 0.0021 0.51 0.0346 0.313 0.0231 
5 10 citrate 5.75 0.168 0.0032 0.723 0.0651 0.363 0.0586 
6 10 citrate 6.5 0.159 0.0067 0.94 0.1082 0.607 0.0404 
7 50 histidine 5 0.096 0.0032 0.703 0.0289 0.47 0.04 
8 50 histidine 5.75 0.083 0.0046 0.863 0.0306 0.587 0.0723 
9 50 histidine 6.5 0.005 0.0038 1.607 0.0551 0.923 0.0208 
10 50 citrate 5 0.071 0.0052 0.977 0.0808 0.437 0.0643 
11 50 citrate 5.75 0.035 0.0046 1.15 0.0819 0.593 0.0208 
12 50 citrate 6.5 0.021 0.0032 1.757 0.0929 1.01 0.0755 
 
 
Figure 37. Correlation between the relative monomer yield of LMU-1 from the ReFOLD assay and the relative 
content of high molecular weight species, i.e. protein aggregates, detected by size exclusion chromatography after 
12 months of storage at 25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The 
solid red line is linear fit of the data, the dark red zone represents the 95 % confidence interval of the fit and the 
light red zone the 95 % prediction interval. 
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6.4.3 Urea causes partially unfolded species, reduces the melting temperatures and 
suppresses the aggregation of LMU-1 and PPI03 
To study whether the proteins in this work form partially folded states in urea, we performed 
isothermal chemical denaturation experiments on all 24 LMU-1 and PPI03 formulations. The 
isothermal unfolding curves of LMU-1 (Fig 38) and PPI03 (Fig S26) are dependent on the 
formulation conditions (i.e. pH, buffer type, sodium chloride concentration). However, in all 
conditions tested the intrinsic protein fluorescence ratio reached the same value at urea 
concentration of 9.5 M (around 1.3 in the case of LMU-1 and around 1.2 in the case of PPI03). 
This indicates that the unfolding was complete at this concentration of urea. The latter was also 
later confirmed by the loss of the typical peaks in the near-UV CD spectra related to the protein 
tertiary structure (see below). Our aim by performing the isothermal chemical denaturation 
experiments was not to fit the data and extract thermodynamic parameters from it. Our purpose 
was to show that different concentrations of urea cause different states of the unfolding of the 
protein in the formulations tested. 
 
Figure 38. Isothermal unfolding curves of LMU-1 in different formulation buffers. The symbols are means of 
triplicates and the bars represent the standard deviation. The lines are a guide to the eye. The concentration of 
LMU-1 in all samples is 1 g/L. 
Further, we studied how urea affects the melting temperatures and the aggregation behaviour 
of the protein with nanoDSF™. Moderate urea concentrations (up to 4.5 M) shift the apparent 
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melting temperatures of both proteins to a lower temperature, while higher urea concentrations 
(6-7.5 M) cause partial protein unfolding at room temperature (Figs 39 and S27). A similar 
effect of urea on the melting temperatures of a mAb was reported from differential scanning 
calorimetry experiments208. No unfolding upon heating is detected in 9.5 M urea, indicating 
that the proteins are already unfolded at 20 ⁰C in this urea concentration (Figs 39 and S27). 
This is in good agreement with the ICD (Figs 38 and S26) and the Far-UV circular dichroism 
data (see below). The latter observations are consistent among all 24 formulations in this work 
(data not shown). These results confirm our hypothesis that different urea concentrations 
(which the protein will inevitably experience during the ReFOLD assay) cause various partially 
folded protein species in all formulations tested here. 
Additionally, we observed that an increasing concentration of urea suppresses the aggregation 
of the mAbs even at high temperatures (Figs 39 and S27). Similar observations were reported 
earlier for another antibody208. No protein aggregation was detected with the Prometheus 
NT.48 during the temperature ramp when the protein was in solutions with 5 to 9.5 M urea 
(Figs 39 and S27), while rapid aggregation was observed around 70-80 ⁰C in the urea-free 
LMU-1 and PPI03 formulations. We should note that the nature of the aggregate detection with 
the Prometheus NT.48 allows us to see only aggregates with a size starting from about 40-50 
nm. Therefore, we cannot conclude that the aggregate formation is completely absent in the 
presence of urea. However, the aggregation growth is greatly inhibited. Furthermore, the 
isothermal aggregation of the unfolded protein in presence of 9 M urea was very slow at 25 ⁰C 
measured by the change in the apparent hydrodynamic radius of the samples with dynamic 
light scattering (Figure S28).   
Moderate isothermal aggregation of partially unfolded mAbs was already reported in the 
presence of another denaturant - guanidine hydrochloride53,187. This confirms that the 
aggregation of the proteins unfolded in presence of urea is suppressed in comparison to 
aggregation induced by high temperatures. Noteworthy, the moderate aggregation in urea 
allows a large fraction of the (partially) unfolded protein to remain monomeric and allows the 
observation of formulation-dependent differences based on the relative monomer yield after 
refolding. 
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Figure 39. Thermal unfolding traces (left) and aggregation during unfolding (right) of LMU-1 in presence of 
different concentrations of urea. The buffer is 10 mM citrate pH 6.5. The samples were incubated for 24 hours 
in the urea before the measurements. The concentration of LMU-1 in all samples is 1 g/L. 
6.4.4 The samples after isothermal unfolding/refolding have native-like far-UV circular 
dichroic spectra and increased intermolecular beta sheet content  
The near-UV CD spectra of both proteins show typical spectra arising from the signals of the 
tryptophan, tyrosine, phenylalanine and disulphide bonds having a certain environment in the 
tertiary protein structure (Figs 40 and S29)209–211. The formulation conditions (i.e. pH, buffer 
type and sodium chloride concentration) of the native samples do not affect the characteristics 
of the spectra – positive peak around 295 nm and several negative peaks between 280 and 250 
nm. The near-UV CD spectra of LMU-1 and PPI03 samples incubated in 9.5 M urea do not 
contain most of the features of the native samples (Figs 40 and S29). Interestingly, the proteins 
in the supernatant of the refolded samples from the ReFOLD assay have the typical components 
of the near-UV CD spectra of the native monomers (Figs 40 and S29). Hawe et al. reported 
that the near-UV CD spectra of a heat or freeze-stressed mAbs resemble the native protein212. 
Another group showed that the near-UV spectra of thermally-induced mAb oligomers resemble 
the spectra of the native protein213. Additionally, the near-UV spectra of a mAb exhibited the 
same changes during thermal unfolding like the changes we observed during urea-induced 
isothermal unfolding41. 
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Figure 40. Near-UV CD spectra of LMU-1 - native (green solid line), unfolded with 10 M urea (yellow dot and 
dash) and refolded protein (red dot) after the ReFOLD assay was performed with (A) 10 mM histidine pH 5,  
(B) 10 mM histidine pH 6.5, (C) 10 mM citrate pH 5 and (D) 10 mM citrate pH 6.5. The CD spectra of the refolded 
samples represent the mixture of protein aggregates and monomer after refolding without any prior fractionation. 
Further, we used FTIR to investigate the secondary protein structure of the native and refolded 
protein.  A minimum around 1638 cm-1 is observed in the Amide I region of the second-
derivative FTIR spectra of native LMU-1 samples (Fig 41). This is typical for a native beta-
sheet secondary structure and is already reported for monoclonal antibodies80,214,215. The 
refolded LMU-1 samples show a minimum in the Amide I band which is shifted to 1630 cm-1. 
The latter is typical when intermolecular beta-sheets are formed80,214,215. The above-mentioned 
observations were consistent among various formulation conditions we tested in this work. The 
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intermolecular beta-sheets are an often-reported secondary structure of non-native protein 
aggregates216–218.  
 
Figure 41. FT-IR second derivative spectra of native and refolded LMU-1 after the ReFOLD assay was performed 
with (A) 10 mM histidine pH 5, (B) 10 mM histidine pH 6.5, (C) 10 mM citrate pH 5 and (D) 10 mM citrate  
pH 6.5. The CD spectra of the refolded samples represent the mixture of protein aggregates and monomer after 
refolding without any prior fractionation. 
6.5 Conclusions 
This work presents a novel perspective on how to quickly select formulation conditions that 
will suppress the formation of protein aggregates during long-term storage at 4 ⁰C and 25 ⁰C. 
The proposed approach is based on the hypothesis that formulation conditions which suppress 
the isothermal aggregation of various partially folded species would be formulation conditions 
that suppress protein aggregation during long-term storage. An isothermal microdialysis-based 
 
117 
 
unfolding/refolding assay, named ReFOLD, is presented and used to assess the relative 
monomer yield after isothermal unfolding/refolding with 10 M urea of two mAbs, each in 12 
different formulation conditions. The relative monomer yield of the proteins in different 
formulation conditions from the ReFOLD assay shows a very strong to strong correlation with 
the amount of aggregates formed by the proteins after storage for 12 months at 4 ⁰C and 25 ⁰C. 
Other stability-indicating parameters like the apparent protein melting temperatures and 
aggregation onset temperatures show inverse or weak correlations with the amount of 
aggregates formed after storage. The refolded protein samples have a native-like near-UV 
circular dichroic spectra and a peak position in the Amide I band which is typical for aggregated 
beta-sheets.   
The concept of the ReFOLD assay presented here opens several directions for future work. 
First, the ReFOLD assay must be tested with more proteins and on a larger set of formulation 
conditions to study whether the technique can be used as a universal tool for formulation 
development. Second, it will be interesting to study in detail the effect of various excipients, 
i.e. sugars, polyols, amino acids, surfactants, on the relative monomer yield of different proteins 
and investigate whether excipients that inhibit the aggregation of partially folded species are 
the excipients that stabilize the proteins during long-term storage. Third, the aggregates and 
monomers formed after unfolding and refolding in urea can be fractionated and their 
morphology and structure can be studied more in detail. It would be interesting to see whether 
the aggregates formed during long-term storage exhibit the same characteristics with the 
aggregates formed after refolding. Finally, development of dedicated devices for fully 
automated and controlled microdialysis with online detection of aggregation and protein 
unfolding will pave the way for a more comprehensive understanding of the concept behind 
the ReFOLD assay.  
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6.6 Supplementary data 
 
Determination of aggregation onset temperature with dynamic light scattering 
25 µL of protein solution was filled in a 384 well plate (Corning) and the plate was centrifuged 
at 2200 rpm for 2 minutes using a Heraeus Megafuge 40 centrifuge equipped with an M-20 
well plate rotor (Thermo Fisher Scientific, Wilmington, USA). Next, a drop of silicone oil was 
used to seal each well and the samples were centrifuged again at 2200 rpm for 2 minutes. 
Unless otherwise stated, the well plate was placed in a Dyna Pro DLS plate reader (Wyatt 
Technology, Santa Barbara, USA) and a temperature ramp of 0.25 °C/min was applied from 
25 to 80 °C. During the temperature ramp, the samples were measured with 3 acquisitions of 3 
seconds. The autocorrelation function (ACF) of each sample was calculated from the 
fluctuation of the light scattering intensity using the Dynamics V7.8 software. Cumulant 
analysis was performed with the same software to derive the apparent coefficient of self-
diffusion (D) and the polydispersity index (PDI). Next, the apparent protein hydrodynamic 
radius from DLS (Rh) was calculated using the Stokes-Einstein equation. The aggregation onset 
temperature (Ton) from the increase in the Rh from DLS was determined using the Dynamics 
V7.8 software. All measurements were performed in triplicates. 
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Table S3. Relative Monomer Yield (RMY) of LMU-1 formulations after the ReFOLD assay and the relative 
content of high molecular weight species after long term storage of the respective LMU-1 formulations 
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
1 10 histidine 5 0.401 0.387 0.372 0.21 0.23 0.18 0.11 0.14 0.21 
2 10 histidine 5.75 0.378 0.365 0.390 0.15 0.18 0.17 0.25 0.17 0.17 
3 10 histidine 6.5 0.269 0.272 0.265 0.38 0.55 0.41 0.27 0.21 0.37 
4 10 citrate 5 0.239 0.243 0.240 0.47 0.53 0.53 0.34 0.30 0.30 
5 10 citrate 5.75 0.17 0.164 0.169 0.79 0.66 0.72 0.32 0.43 0.34 
6 10 citrate 6.5 0.153 0.166 0.157 0.91 0.85 1.06 0.57 0.65 0.60 
7 50 histidine 5 0.098 0.097 0.092 0.67 0.72 0.72 0.43 0.47 0.51 
8 50 histidine 5.75 0.082 0.079 0.088 0.87 0.89 0.83 0.54 0.67 0.55 
9 50 histidine 6.5 0.003 0.009 0.002 1.66 1.61 1.55 0.90 0.93 0.94 
10 50 citrate 5 0.065 0.074 0.074 0.93 0.93 1.07 0.39 0.51 0.41 
11 50 citrate 5.75 0.036 0.030 0.039 1.08 1.13 1.24 0.57 0.61 0.60 
12 50 citrate 6.5 0.022 0.023 0.017 1.68 1.73 1.86 1.08 1.02 0.93 
 
Table S4. Relative Monomer Yield (RMY) of PPI03 formulations after the ReFOLD assay and the relative 
content of high molecular weight species, i.e. protein aggregates, after long term storage* of the respective PPI03 
formulations. The concentration of PPI03 is 5 g/L in all 12 formulations. 
Form. 
number 
Buffer pH NaCl RMY after refolding 
from 10 M urea 
% HMW after 12 
months at 25 ⁰C 
% HMW after 12 
months at 4 ⁰C 
1 histidine 5 No 0.519 0.535 0.553 0.11 0.11 0.14 0.16 0.16 0.14 
2 histidine 5.75 No 0.47 0.47 0.495 0.15 0.13 0.13 0.15 0.13 0.14 
3 histidine 6.5 No 0.514 0.474 0.461 0.18 0.18 0.18 0.14 0.16 0.16 
4 histidine 5 70 mM 0.352 0.359 0.355 0.22 0.24 0.26 0.17 0.16 0.17 
5 histidine 5.75 70 mM 0.334 0.338 0.335 0.23 0.24 0.24 0.17 0.17 0.17 
6 histidine 6.5 70 mM 0.336 0.305 0.317 0.41 0.46 0.43 0.24 0.26 0.24 
7 citrate 5 No 0.418 0.417 0.397 0.5 0.44 0.43 0.24 0.23 0.22 
8 citrate 5.75 No 0.303 0.294 0.296 0.55 0.48 0.46 0.31 0.33 0.32 
9 citrate 6.5 No 0.255 0.284 0.285 0.65 0.67 0.64 0.56 0.54 0.54 
10 citrate 5 70 mM 0.431 0.399 0.421 0.5 0.45 0.48 0.24 0.23 0.22 
11 citrate 5.75 70 mM 0.364 0.339 0.323 0.41 0.44 0.44 0.29 0.3 0.29 
12 citrate 6.5 70 mM 0.337 0.346 0.353 0.63 0.63 0.6 0.55 0.55 0.56 
*The relative content of high molecular weight species of PPI03 after storage was measured with the same SEC 
method described in materials and methods. However, the elution of the protein was detected with a Dionex 
RF2000 fluorescence detector (Thermo Fisher, Dreieich, Germany) using the following parameters - excitation at 
280 nm, emission at 343 nm, gain 4.0 and medium sensitivity. There is a linear correlation (R2>0.98) between the 
relative area of high molecular weight species of PPI03 detected by UV absorption at 280 nm and by intrinsic 
fluorescence (data not shown). However, in the case of PPI03 many of the samples contained less than 0.2 % 
aggregates and the use of the fluorescence detector provided a better signal-to-noise ratio compared to the UV 
detector. 
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Table S5. Monomer recovery of LMU-1 after 12 months of storage at 25 ⁰C and 4 ⁰C. The monomer recovery 
was calculated by dividing the area of the monomer peak in the SEC chromatograms after 12 months of storage 
by the area of the monomer peak at the beginning of the stability study, and finally multiplying this value by 100. 
A value of 100 % therefore indicates that the same monomer area was fond after storage, while a value lower than 
100 % indicates that the area of the monomer was smaller. 
Formulation 
number 
Protein 
conc. 
[g/L] 
Buffer pH SEC monomer 
recovery (%) after 12 
months at 25 ⁰C 
SEC monomer 
recovery (%) after 
12 months at 4 ⁰C 
Mean StDev Mean StDev 
1 10 histidine 5 99.96 0.05 100.54 0.22 
2 10 histidine 5.75 100.91 1.46 100.24 0.08 
3 10 histidine 6.5 100.43 1.14 99.99 0.14 
4 10 citrate 5 101.23 0.65 101.18 0.20 
5 10 citrate 5.75 100.15 0.66 100.13 0.38 
6 10 citrate 6.5 99.94 0.17 100.02 0.18 
7 50 histidine 5 96.15 1.17 99.50 0.54 
8 50 histidine 5.75 96.34 0.41 99.56 0.25 
9 50 histidine 6.5 95.48 1.20 99.06 0.26 
10 50 citrate 5 95.29 1.05 97.94 0.24 
11 50 citrate 5.75 95.38 0.51 98.36 0.41 
12 50 citrate 6.5 95.36 0.22 97.68 0.77 
 
Table S6. Monomer recovery of PPI03 after 12 months of storage at 25 ⁰C and 4 ⁰C. The monomer recovery 
was calculated by dividing the area of the monomer peak in the SEC chromatograms after 12 months of storage 
by the area of the monomer peak at the beginning of the stability study, and finally multiplying this value by 100. 
A value of 100 % therefore indicates that the same monomer area was fond after storage, while a value lower than 
100 % indicates that the area of the monomer was smaller. 
Formulation 
number 
Buffer pH NaCl 
SEC monomer  
recovery (%) after  
12 months at 25 ⁰C 
SEC monomer 
recovery (%) after  
12 months at 4 ⁰C 
Mean StDev Mean StDev 
1 histidine 5 No 99.57 0.57 100.15 0.36 
2 histidine 5.75 No 98.87 0.37 99.48 0.20 
3 histidine 6.5 No 99.14 0.10 98.97 0.40 
4 citrate 5 70 mM 98.39 0.08 98.88 0.24 
5 citrate 5.75 70 mM 99.21 1.50 98.77 0.45 
6 citrate 6.5 70 mM 98.80 0.34 98.99 0.18 
7 histidine 5 No 96.91 0.34 98.67 0.36 
8 histidine 5.75 No 96.86 0.35 97.82 0.37 
9 histidine 6.5 No 98.11 0.60 98.47 0.35 
10 citrate 5 70 mM 96.78 0.45 98.19 0.62 
11 citrate 5.75 70 mM 96.76 0.92 96.86 0.55 
12 citrate 6.5 70 mM 98.32 0.53 98.67 0.79 
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Figure S17. Representative chromatograms of LMU-1 and PPI03 obtained with the size-exclusion 
chromatography method used during the long-term stability studies. The area of high molecular weight (HMW) 
species is integrated between 5 and 15.1 minutes retention time. The protein monomer is integrated between 15.1 
and 22 minutes. 
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Figure S18. Subvisible particles in the LMU-1 and PPI03 formulations after 12 months of storage at 25 ⁰C. The 
numbers represent cumulative particles larger than 2 µm in 1 mL. After 12 months of storage at 4 ⁰C, all 
formulations contained less than 5000 particles ≥ 2 µm per mL (data not shown). The measurements were 
performed with a FlowCAM® 8100 (Fluid Imaging Technologies, Inc., Scarborough, ME, USA). The system was 
equipped with a 10x magnification cell (81 µm x 700 µm). Before each measurement, the cleanliness of the cell 
was checked visually. 200 µL of sample were used for the analysis and the images are collected with a flow rate 
of 0.15 mL/min, auto image frame rate of 29 frames/second and a sampling time of 74 seconds. The following 
settings were used for particle identification - 3 µm distance to the nearest neighbour, particle segmentation 
thresholds of 13 and 10 for the dark and light pixels respectively. The particle size was reported as the equivalent 
spherical diameter (ESD). The VisualSpreadsheet® 4.7.6 software was used for data collection and evaluation. 
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Figure S19. Correlation between the first melting temperature Tm1 of LMU-1 and the relative content of high 
molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C (left) 
and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the data, 
the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
 
Figure S20. Correlation between the second melting temperature Tm2 of LMU-1 and the relative content of high 
molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C (left) 
and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the data, 
the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
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Figure S21. Correlation between the aggregation onset temperature from DLS of LMU-1 and the relative content 
of high molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C 
(left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the 
data, the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
 
Figure S22. Correlation between the relative monomer yield of PPI03 from the ReFOLD assay and the relative 
content of high molecular weight species detected by size exclusion chromatography after 12 months storage at 
25 ⁰C (left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of 
the data, the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % 
prediction interval. 
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Figure S23. Correlation between the first melting temperature Tm1 of PPI03 and the relative content of high 
molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C (left) 
and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the data, 
the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
 
Figure S24. Correlation between the second melting temperature Tm2 of PPI03 and the relative content of high 
molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C (left) 
and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the data, 
the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
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Figure S25. Correlation between the aggregation onset temperature from DLS of PPI03 and the relative content 
of high molecular weight species detected by size exclusion chromatography after 12 months of storage at 25 ⁰C 
(left) and at 4 ⁰C (right). The value of each replicate is shown on the graph. The solid red line is linear fit of the 
data, the dark red zone represents the 95 % confidence interval of the fit and the light red zone the 95 % prediction 
interval. 
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Figure S26. Isothermal unfolding curves of PPI03 in histidine (A) and citrate (B) buffer with different pH and 
different ionic strength. The symbols are means of triplicates and the bars represent the standard deviation. The 
lines are a guide to the eye. The protein concentration in all samples is 0.5 g/L. 
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Figure S27. Thermal unfolding traces (left) and aggregation during unfolding (right) of PPI03 in presence of 
different concentrations of urea. The buffer is 10 mM histidine pH 6.5 with 70 mM sodium chloride. The protein 
concentration in all samples is 0.5 g/L. 
 
Figure S28. Isothermal aggregation of LMU-1 in presence of 9 M urea in different formulation conditions 
measured by the change in the apparent protein hydrodynamic radius from DLS. The samples are prepared, 
measured and evaluated as described in the Supplementary data. The measurements are performed at 25 ⁰C with 
5 acquisitions of 5 seconds. The samples are corrected for viscosity using a value of 1.93 cP for the 9 M urea 
solutions. 
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Figure S29. Near-UV CD spectra of PPI03 native (green solid line), unfolded with 10 M urea (yellow dot and 
dash) and refolded protein (red dot) after the ReFOLD assay was performed with 10 mM histidine pH 5 (A),  
10 mM histidine pH 6.5 (B), 10 mM citrate pH 5 (C) and (D) 10 mM citrate pH 6.5. 
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7.1 Abstract 
Additives like sucrose and arginine salts can have effects on protein long-term storage stability. 
Predicting these effects with prompt biophysical characterisation could accelerate the 
therapeutic protein development process. In this work, we apply several high-throughput 
methods to study the thermal unfolding and aggregation of a model antibody at pH 5 and  
pH 6.5 in the presence of 280 mM sucrose, 140 mM arginine hydrochloride, and  
70 mM arginine glutamate. The colloidal protein stability is reduced upon addition of the 
arginine salts which results in reduced protein aggregation onset temperature, reduction in the 
interaction parameter kD and lower relative monomer yield after refolding from urea. The low 
colloidal stability in the presence of arginine salts together with the thermal unfolding at a 
lower temperature at pH 5 concurs with the formation of subvisible particles during storage for 
12 months at 25 ºC. 280 mM sucrose does not affect the colloidal protein stability, shifts the 
thermal protein unfolding to a higher temperature and increases the relative monomer yield 
after refolding from urea which agrees with a stabilising effect during long-term storage. This 
study shows how contemporary techniques for protein characterisation can be applied to select 
additives for stable therapeutic protein formulations. 
Keywords - Proteins; Protein formulation; Protein folding; Protein unfolding; Protein 
Aggregation; Monoclonal antibody; Storage Stability; Stability prediction; Excipients; 
Abbreviations - DLS - Dynamic Light Scattering; mAb - monoclonal antibody;  
nanoDSF™ - Microscale Differential Scanning Fluorimetry; RMY - Relative Monomer Yield 
after refolding; SEC - size exclusion chromatography; Tagg - Protein aggregation onset 
temperature from DLS; IP1 - Inflection point of the thermal unfolding transition at a lower 
temperature; IP2 - Inflection point of the thermal unfolding transition at a higher temperature;  
kD - interaction parameter; A2 - second osmotic virial coefficient; SLS – static light scattering; 
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7.2 Introduction 
One fundamental aim during the development of therapeutic proteins is finding formulations 
that increase protein stability during long-term storage. Some of the critical variables in these 
formulations are solution pH, ionic strength, and the presence of additives. The additives 
usually belong to the group of sugars, polyols, amino acids or polymers219,220. Among these, 
sucrose is the most frequently used in marketed therapeutic protein formulations219. From the 
amino acids, arginine is of considerable interest as in some cases it can suppress protein 
aggregation or reduce the viscosity of highly concentrated protein solutions221,222. Also, the use 
of different arginine salts is a topic of intense research since the arginine counterion can 
determine the effect on protein stability199,222–224.  
Sucrose and arginine salts can affect the thermal protein unfolding and aggregation in different 
directions depending on the protein molecule199,225–228. Especially arginine can have complex 
effects on the protein unfolding, aggregate formation and aggregate growth229. The 
concentration of the additive is also essential but limited by the osmotic pressure of the 
formulation that typically should be close to physiological230. Many of the studies with sucrose 
and arginine salts observe effects on protein stability that depend on the additive 
concentration199,225,226,228. Often, 0.5-1 M  of sucrose or arginine have beneficial effects on 
protein stability8,169,225,231,232. However, such solutions are hypertonic and thus unsuitable for 
the development of therapeutic protein formulations that will be injected undiluted in patients. 
Further, published work about the effect of additives on protein stability is typically not 
supported by long-term stability data to confirm that an additive will have a stabilising or 
destabilising effect during storage at temperatures relevant for therapeutic proteins. 
Here, we apply high-throughput methods to study the effect of three additives, 280 mM 
sucrose, 140 mM arginine hydrochloride, and 70 mM arginine glutamate, on the thermal 
unfolding and aggregation of a model monoclonal antibody at pH 5 and pH 6.5. In addition, 
we assess the impact of the additives on the colloidal protein stability, and on the protein 
aggregation during refolding from urea using a new assay, named ReFOLD. Finally, we 
perform long-term stability for 12 months at 4 ºC and 25 ºC to see if the prompt biophysical 
characterisation can predict the effects of the additives on the protein storage stability. 
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7.3 Materials and methods 
7.3.1 Monoclonal antibodies and chemicals 
The monoclonal antibody PPI13 used in this work is a human IgG1κ with a molecular mass of 
148.9 kDa and an isoelectric point around 9. The protein bulk solution is surfactant-free and 
contains 98 % monomer and 2 % dimer, assessed with size exclusion chromatography. The 
bulk buffer was exchanged to 10 mM histidine/histidine hydrochloride with pH 5, pH 5.75 and  
pH 6.5 using extensive dialysis as described earlier182. The absorption of PPI13 at 280 nm was 
measured with a Nanodrop 2000 UV spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE) and the protein concentration was calculated using the protein extinction 
coefficient. Stock solutions of the additives (sucrose, arginine hydrochloride, arginine 
glutamate, guanidine hydrochloride and sodium chloride) were prepared in the respective 
histidine buffer and spiked to the dialysed protein solution. All chemicals were high purity 
grade and were purchased from Sigma Aldrich (Steinheim, Germany), VWR International 
(Darmstadt, Germany) or Fisher Scientific (Schwerte, Germany). Highly purified water was 
used to prepare all solutions.  
7.3.2 Long-term stability study 
PPI13 samples with protein concentration 5 g/L in the respective buffer (or buffer plus additive) 
were sterile filtered with a 0.22 µm cellulose acetate filter, aseptically filled into sterilised 
DIN2R glass type I vials (MGlass AG, Germany), crimped with FluroTec® coated rubber 
chlorobutyl stoppers (West Pharmaceutical Services, USA), and stored at 4 ⁰C and 25 ⁰C for 
the desired time. Three different vials were used for the analysis of each condition and time. 
7.3.3 Dynamic light scattering 
Before DLS measurements, all samples were centrifuged at 10 000g for 10 minutes. Next,  
10 µL of PPI13 solution with 5 g/L protein concentration unless otherwise stated were filled in 
a 1534 microwell plate (Aurora, Whitefish, USA). The plate was centrifuged at 2200 rpm for 
2 minutes using a Heraeus Megafuge 40 centrifuge equipped with an M-20 well plate rotor 
(Thermo Fisher Scientific, Wilmington, USA). Each well was subsequently sealed with 5 µL 
silicon oil and the plate was centrifuged again. The samples were then measured on a DynaPro 
plate reader III (Wyatt Technology, Santa Barbara, USA) using 3 acquisitions of 3 seconds 
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during a linear temperature ramp of 0.1 °C/min from 25 to 85 ºC. The Dynamics V7.8 software 
was used to create autocorrelation functions (ACF) and to apply cumulant analysis giving the 
mutual self-diffusion coefficient (D) and the polydispersity index (PDI). The apparent protein 
hydrodynamic radius (Rh) was calculated with the Stokes-Einstein equation from the D and the 
sample viscosity. The sample viscosity was measured with a falling ball viscometer. The 
aggregation onset temperature (Tagg) was determined using the Dynamics V7.8 software from 
the Rh increase during heating.  
To derive the interaction parameter kD, PPI13 samples with different protein concentration (see 
the results section) were filled in 1534 microwell plates as described above. The samples were 
then measured at 25 ºC with 10 acquisitions of 5 seconds. The mutual self-diffusion coefficient 
D was calculated as described above and the following equation was used to extract kD: 
D=D0(1+kDc) 
where D0 is the diffusion coefficient at infinite dilution and c is the protein concentration. All 
DLS measurements were performed in triplicates. 
7.3.4 High-throughput Fluorimetric Analysis of Thermal Protein Unfolding 
The thermal unfolding of 5 g/L PPI13 in different formulations was studied with 
nanoDSF®116,117. The samples were filled in standard glass capillaries, the capillaries were 
sealed and placed in a Prometheus® NT.48 (NanoTemper Technologies, Munich, Germany). 
The device was used to linearly change the sample temperature from 25 to 100 °C with a ramp 
of 0.1 °C/min. During the temperature increase, the intrinsic protein fluorescence intensity at 
330 nm and 350 nm was measured after excitation at 280 nm. Simultaneously, the back-
reflection intensity of a light beam that passes through the capillary was measured to detect 
protein aggregation/precipitation. The scattering signal was normalised to a value called 
“Excess Scattering”. The fluorescence intensity ratio (F350/F330) was plotted versus 
temperature, and the first (IP1) and second (IP2) inflection points of the protein thermal 
unfolding curve were determined from the maxima of the first derivative using the 
PR.ThermControl V2.1 software (NanoTemper Technologies, Munich, Germany).  
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7.3.5 Isothermal unfolding and refolding with urea (ReFOLD assay) 
The assay was performed as described earlier182. Briefly, 50 µL of 5 g/L PPI13 solution in the 
respective buffer (or buffer plus additive) were filled in Pierce™ microdialysis devices  
(3.5 kDa MWCO). The samples were dialysed in a deep well-plate against 1.5 mL of 9 M urea 
dissolved in the respective formulation buffer (or buffer plus additive). The urea solution was 
changed after 4 and 8 hours and the dialysis continued for 24 hours in total. Next, the PPI13 
samples in 9 M urea were dialysed using the same procedure against 1.5 mL of the respective 
urea-free formulation buffer (or buffer plus additive). During dialysis, the deep well plate was 
agitated at 700 rpm with a Thermomixer Comfort (Eppendorf AG, Hamburg, Germany). 
Subsequently, the samples were collected from the dialysis devices, and the weight of each 
sample was added to 250 mg on a microbalance. Finally, the samples were centrifuged at  
10 000g for 10 minutes, and the supernatant was used for further measurements. 
7.3.6 Size exclusion chromatography 
A Dionex Summit 2 system equipped with a UVD170U UV/Vis detector (Thermo Fisher, 
Dreieich, Germany) was used to inject PPI13 samples on a TSKgel G3000SWxl, 7,8x300 mm, 
5 µm column (Tosoh Bioscience, Tokyo, Japan). The mobile phase with pH 7.0 consisted of 
100 mM potassium phosphate, 200 mM sodium chloride and 0,05 % w/v sodium azide. The 
elution of the samples was detected at 280 nm. The chromatograms were collected and 
integrated with Chromeleon V6.8 (Thermo Fisher, Dreieich, Germany). The relative monomer 
yield (RMY) of the protein after isothermal unfolding/refolding in urea was calculated after 
dividing the area of the monomer peak of the refolded sample by the area of the monomer peak 
of the sample before unfolding/refolding182. The relative area of aggregates and the monomer 
recovery of PPI13 during long-term storage were calculated as earlier described182. 
7.3.7 Flow imaging microscopy 
The subvisible particles formed during long-term storage of PPI13 were measured with a 
FlowCAM® 8100 (Fluid Imaging Technologies, Inc., Scarborough, ME, USA) equipped with 
a 10x magnification cell (81 µm x 700 µm). Particle images were obtained using 150 µL sample 
volume, a flow rate of 0.15 mL/min, an auto image frame rate of 29 frames/second and a 
sampling time of 74 seconds. The particle identification settings were 3 µm distance to the 
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nearest neighbour, particle segmentation thresholds of 13 and 10 for the dark and light pixels 
respectively. The particle size reported represents the equivalent spherical diameter (ESD). The 
data was collected and processed with the VisualSpreadsheet® 4.7.6 software. 
7.4 Results and discussion 
7.4.1 Effect of pH and additives on the thermal unfolding and aggregation of PPI13 
PPI13 shows two unfolding transitions detected by the change in the intrinsic protein 
fluorescence ratio (Fig 42A). These transitions correspond well to the temperatures of circular 
dichroism changes in the near-UV protein spectra (Fig S30).  
 
Figure 42. Simultaneous thermal unfolding and aggregation of 5 g/L PPI13 in 10 mM histidine with  
pH 5 (squares), 5.75 (circles) and 6.5 (triangles) assessed by the change in the (A) intrinsic protein fluorescence 
intensity ratio from nanoDSF®, (B) apparent hydrodynamic radius Rh from DLS, and (C) the excess scattering 
from nanoDSF®; In A and C the datapoint density is reduced to improve clarity. 
Increasing pH from 5 to 6.5 shifts the inflection point of the first unfolding transition to a higher 
temperature, while the effect on the second inflection point is minimal. At pH 5, the protein 
aggregation onset temperature measured with dynamic light scattering is around 78 ºC and the 
Rh does not become larger than 7-8 nm up to 85 ºC (Fig 42B). Correspondingly, no precipitation 
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or formation or large aggregates is detected with the Prometheus NT.48® up to 100 ºC  
(Fig 42C). At pH 6.5, the Tagg from DLS is slightly lower (76.7 ºC), and the sample Rh and 
excess scattering rapidly increase which indicates the formation of large aggregates and 
precipitation (Figs 42B and 42C). Such pH dependence of thermal unfolding and aggregation 
is already reported for several monoclonal antibodies54,116,140,233. We then focused on the effect 
of several additives on the stability of PPI13 at pH 5 and pH 6.5 since the protein behaves 
differently in these conditions concerning its thermal unfolding and aggregation. The addition 
of 280 mM sucrose shifts the inflection points of the unfolding transitions and the aggregation 
onset to a slightly higher temperature independent of pH and without affecting the aggregate 
growth (Figs 43 and 44) (for values see Table 6). The stabilisation effect of sucrose is known 
and can be explained by preferential exclusion140,233–236. 
  
Figure 43. Simultaneous thermal unfolding and aggregation of 5 g/L PPI13 in 10 mM histidine pH 5 with no 
additive (squares), 280 mM sucrose (circles), 140 mM arginine hydrochloride (triangles up), 70 mM arginine 
glutamate (triangles down) assessed by the change in the (A) intrinsic protein fluorescence intensity ratio from 
nanoDSF®, (B) apparent hydrodynamic radius Rh from DLS, and (C) the excess scattering from nanoDSF®; In 
A and C the datapoint density is reduced to improve clarity. 
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Contrary to sucrose, the addition of 140 mM arginine hydrochloride at pH 5 shifts the protein 
aggregation onset and the inflection points of both unfolding transitions to lower temperatures 
(Figs 43 and 44) (Table 6). 70 mM arginine glutamate has a more complex effect on the stability 
of PPI13 at pH 5, reducing the aggregation onset temperature, but in most cases slightly 
increasing the temperature of both thermal unfolding inflection points (Table 6). The addition 
of arginine salts causes the formation of larger protein aggregates at pH 5 (Figs 43B and 43C). 
At pH 6.5, 140 mM arginine hydrochloride and 70 mM arginine glutamate affect the Tagg, IP1 
and IP2 of PPI13 in a similar direction but with a smaller magnitude compared to pH 5 (Table 
6). The early onset of protein aggregation induced by ArgHCl at pH 5 (indicated by an arrow 
in Fig 43B) is not observed at pH 6.5. Our findings agree well with published data about the 
effect of arginine hydrochloride on the thermal unfolding of other proteins47,226,237. 
 
Figure 44. Simultaneous thermal unfolding and aggregation of 5 g/L PPI13 in 10 mM histidine pH 6.5 with no 
additive (squares), 280 mM sucrose (circles), 140 mM arginine hydrochloride (triangles up), 70 mM arginine 
glutamate (triangles down) assessed by the change in the (A) intrinsic protein fluorescence intensity ratio from 
nanoDSF®, (B) apparent hydrodynamic radius Rh from DLS, and (C) the excess scattering from nanoDSF®; In 
A and C the datapoint density is reduced to improve clarity. 
 
 
140 
 
The unfavourable effect of arginine salts on the aggregation onset temperature of PPI13 
encouraged us to further investigate how the additives affect the colloidal protein stability. 
Table 6. Stability-indicating parameters of PPI13 in 10 mM histidine buffer with pH 5 and pH 6.5 in presence of 
different additives. 
 Additive 
From nanoDSF® From DLS 
IP1, ⁰C IP2, ⁰C Tagg, ⁰C kD (mL/g) D0 (cm2/s) 
pH 5 
No 58.2 ±0.05 80.17 ±0.07 78.11 ±0.29 34.20 4.70E-07 
280 mM Sucrose 59.32 ±0.06 81.04 ±0.05 78.86 ±0.14 16.70 4.16E-07 
140 mM ArgHCl 55.43 ±0.06 76.99 ±0.03 60.76 ±0.86 -13.90 4.48E-07 
70 mM ArgGlu 59.7 ±0.09 80.37 ±0.01 73.32 ±0.24 -11.10 4.48E-07 
pH 6.5 
No 64.33 ±0.10 80.11 ±0.04 76.68 ±0.38 27.30 5.01E-07 
280 mM Sucrose 65.86 ±0.11 81.24 ±0.03 77.38 ±0.42 10.40 4.62E-07 
140 mM ArgHCl 62.25 ±0.06 78.97 ±0.04 73.26 ±0.50 -15.80 4.55E-07 
70 mM ArgGlu 63.84 ±0.02 80.36 ±0.01 74.11 ±0.45 -16.80 4.47E-07 
7.4.2 Effect of additives on the colloidal stability of PPI13 
Dynamic light scattering was used to study the effect of the additives on the colloidal stability 
of PPI13. In 10 mM histidine buffer with pH 5 and pH 6.5, the mutual diffusion coefficient of 
the protein increases with an increase in protein concentration (Fig 45). The addition of  
280 mM sucrose does not change the sign of this concentration dependence. However, when 
140 mM arginine hydrochloride or 70 mM arginine glutamate is added, the mutual diffusion 
coefficient of the protein decreases with protein concentration (Fig 45). This effect can be 
explained with the increase in ionic strength upon addition of the arginine salts which leads to 
screening of the electrostatic repulsion between the protein molecules57. We also used the data 
in Fig 45 to derive the interaction parameter kD of PPI13 in these formulations (Table 6). Here, 
we would like to make a note that the kD values obtained at pH 6.5 without arginine salts could 
be overestimated due to the low ionic strength of the solution59, but their sign should not be 
affected. To confirm the observations in Fig. 45, we used microwell plate-based static light 
scattering method to measure second virial coefficients A2 of PPI13 in presence of the additives 
and found good agreement between kD and A2 (Figure S31) that is already reported earlier
56.  
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Figure 45. Concentration dependence of the mutual diffusion coefficient of PPI13 at pH 5 (A) and pH 6.5 (B) in 
presence of no additive (squares), 280 mM sucrose (circles), 140 mM arginine hydrochloride (triangles up) and 
70 mM arginine glutamate (squares down). The data is overlay of triplicates. The lines present a linear fit to the 
points. 
Based on the kD and A2 data we could confirm that the addition of both arginine salts reduces 
the repulsive protein interactions, thus reducing the colloidal stability of PPI13 which 
corresponds well with the lower aggregation onset temperatures (Table 6) and the larger 
aggregate growth at pH 5 (Figs 43B and 43C). 280 mM Sucrose has a much smaller effect on 
the kD and A2 of PPI13 compared to the arginine salts (Tables 6 and S7). 
7.4.3 Do arginine salts reduce the colloidal and thermal stability of PPI13 only due to 
an increase in ionic strength? 
Looking for a better understanding how the additives affect the stability of PPI13, we assessed 
the IP1, IP2, Tagg, kD and A2 of PPI13 in guanidine hydrochloride and sodium chloride solutions 
having the same molar concentration as the arginine salts used above (Table S7). Both 140 mM 
guanidine hydrochloride and 140 mM sodium chloride cause PPI13 unfolding and aggregation 
at a lower temperature in a similar way to arginine hydrochloride (Table S7).  Although there 
are some differences between the effects of ArgHCl, GuHCl and NaCl, these results indicate 
that the negative impact on PPI13 is not exclusively due to the arginine cation but also due to 
an increase in ionic strength and subsequent reduction in the colloidal protein stability. 
Interestingly, 70 mM arginine glutamate has a less negative impact on the thermal protein 
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unfolding and aggregation compared to 70 mM guanidine hydrochloride or 70 mM sodium 
chloride. This indicates once again the advantage of ArgGlu over ArgHCl but also raises the 
question of whether ArgGlu is superior to ArgHCl due to the glutamate counterion or ArgHCl 
is inferior to ArgGlu due to the chloride ion. A hint about the answer to this question can be 
found in a recent study showing that arginine acetate stabilises proteins as good as arginine 
glutamate and that both are better than arginine hydrochloride224. In addition, we measured the 
osmotic pressure of the solutions. The osmolarity of the formulations with all salts tested 
corresponds to the expected osmolarity of strong binary electrolytes (Table S8), indicating that 
the ionic strength of formulations including salts with the same molar concentration will be 
similar. Small differences from the expected osmolarity were observed in some cases, e.g. for 
arginine hydrochloride and guanidine hydrochloride. These differences could be due to the way 
of interaction of the excipients with the protein238. In future, we will explore if we can use 
vapour pressure osmometry to assess quantitatively the interaction of the additives with PPI13. 
7.4.4 Effect of additives on the aggregation during refolding of PPI13 
We recently developed an unfolding/refolding assay, named ReFOLD, that can be used to 
assess the aggregation of urea-induced partially unfolded protein species182. We applied this 
assay to see whether the additives tested here suppress the aggregation of the partially unfolded 
protein at pH 5 and pH 6.5. The 9 M concentration of urea was selected since it causes 
significant perturbations in the protein structure as shown by the change in the circular 
dichroism protein spectra (Fig S32). Also, 280 mM sucrose, 140 mM ArgHCl and 70 mM 
ArgGlu can be dissolved in this urea concentration.  
After isothermal unfolding and refolding of PPI13, there is a significant reduction in the 
monomer peak detected by size exclusion chromatography (Fig 46A). This decrease is due to 
protein aggregation during refolding from urea as we reported earlier for two other monoclonal 
antibodies182. We then calculated the relative monomer yield (RMY) after refolding and 
observed that the RMY was lowest when the refolding was performed at pH 5 in the presence 
of 140 mM ArgHCl or 70 mM ArgGlu (Fig 46B). This corresponds well with the detrimental 
effect of these salts on the colloidal stability of PPI13. The addition of 280 mM sucrose results 
in higher RMY at both pH 5 and pH 6.5 which agrees with the stabilising effect of this sugar 
during thermal denaturation of PPI13 (Figs 46B and 46C). In addition, the mean values of 
 
143 
 
RMY are slightly higher at pH 6.5 compared to their counterparts at pH 5. That concurs with 
the other stability-indicating parameters measured earlier at these pH values (Table 6). The 
near-UV CD spectra of the refolded PPI13 resembled the spectra of the native PPI13 in all 
formulation that we tested (Fig S32). 
 
Figure 46. (A) SEC chromatogram of native and refolded PPI13 in 10 mM histidine pH 5. In a separate 
experiment, the peak at 14.2 minutes was identified as a dimer using SEC coupled to multi-angle light scattering. 
Relative monomer yield of PPI13 when the protein is refolded from 9 M urea at pH 5 (B) and pH 6.5 (C) with no 
additive, 280 mM sucrose, 140 mM arginine hydrochloride or 70 mM arginine glutamate. The values in B and C 
are mean of triplicates, the error bar is the standard deviation.  
The results that arginine salts reduce the relative monomer yield after refolding from urea might 
appear surprising at first since arginine is often used at high concentrations (i.e. 0.5-1.0 M) to 
suppress aggregation during refolding239. However, the formulations of PPI13 present an 
interesting case. As we showed earlier, PPI13 has high colloidal stability at low ionic strength 
in 10 mM histidine with pH 5 or pH 6.5. The addition of salts in concentration 70-140 mM 
negatively affects the colloidal protein stability and reduces the repulsive protein-protein 
interactions as shown by the reduction in the interaction parameter kD and the aggregation onset 
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temperature (Tables 6 and S7). Published work shows that the protein-protein interactions are 
directly linked to the aggregation during refolding of some proteins169,240. This reveals that the 
effects of additives on the protein colloidal stability should be carefully considered from case 
to case to have a better understanding why specific concentrations of some additives have a 
negative impact on protein aggregation during heating and refolding. 
7.4.5 Effect of additives on the aggregation during long-term stability of PPI13 
The stability of PPI13 during long-term storage at 4 ºC and 25 ºC was assessed with size 
exclusion chromatography and flow imaging microscopy. PPI13 presents a peculiar case in 
which the amount of soluble aggregates detected by SEC remained constant or decreased a 
little bit during storage (Fig S33). These aggregates were present in the bulk solution which 
has about ten-fold higher protein concentration than the 5 g/L we used in our stability studies. 
The observation with SEC that the amount of soluble aggregates in the samples does not 
increase after storage were confirmed with dynamic light scattering (data not shown). Future 
work can focus on the aggregation mechanism and type of aggregates formed by PPI13, and 
how the aggregation depends on protein concentration. 
A decrease in the monomer recovery of PPI13 was observed after storage which indicated a 
loss of soluble protein probably due to the formation of larger aggregates that are filtered out 
by the SEC column (Fig 47). The decrease in monomer recovery was more pronounced at  
pH 5 compared to pH 6.5, and during storage at 25 ºC compared to 4 Cº. The formulations 
including 280 mM sucrose showed the highest recovery at both storage temperatures and both 
at pH 5 and pH 6.5. Interestingly, the formulations with 70 mM arginine glutamate had 
monomer recoveries close to 100 % at pH 6.5 but not at pH 5. 
We confirmed our hypothesis for the monomer loss due to the formation of larger aggregates 
by observing the formation of subvisible particles in PPI13 formulations (Fig 48).  At pH 5, 
the two arginine salts induced the formation of the largest number of particles in all three size 
ranges. 280 mM sucrose reduced the number of particles formed at pH 5 compared to no 
additive. These results concur well with the monomer recovery in Fig 47A. At pH 6.5 the 
particle counts were very low independent of the presence of additives. The samples stored at 
4 ºC showed very low particle numbers at both pH 5 and pH 6.5, and no clear difference 
between effect of different additives could be observed (Fig S34). 
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Figure 47. Effect of additives on the monomer recovery of PPI13 from size exclusion chromatography after 12 
months of storage. (A) storage at 25 ºC at pH 5, (B) storage at 25 ºC at pH 6.5, (C) storage at 4 ºC at pH 5, (D) 
storage at 4 ºC at pH 6.5; 
 
Figure 48. Subvisible particles of PPI13 measured during storage for 12 months at 25 ºC 
 
 
146 
 
7.4.6 Correlation between stability-indicating parameters and long-term stability 
To conclude the study, we looked for correlations between the different biophysical parameters 
and the monomer recovery and particle numbers after long-term storage at 25 ºC. Almost all 
parameters indicated that the formulations comprising arginine salts at pH 5 will have inferior 
stability compared to others. The rankings from the first thermal unfolding inflection point and 
the relative monomer yield after refolding from urea showed the strongest correlation with 
long-term stability data (Fig S35). In general, some of the correlations (Fig S35 – A, B, C, D, 
E) are weak due to the low particle numbers and small differences between most of the 
formulations that causes the points to cluster in a narrow range.  The least stable formulations 
during long-term storage were the two formulations where the protein unfolds at lower 
temperature and has the lowest aggregation onset temperature, the lowest relative monomer 
yield after refolding from urea, and a negative interaction parameter kD. 280 mM sucrose 
increase the temperature of thermal unfolding and the relative monomer yield after refolding 
from urea at pH 5. This corresponds well to the stabilising effect of sucrose observed during 
storage compared to no additive. Many of the formulations, e.g. at pH 6.5, exhibit high 
monomer recovery and low particle numbers independent of the presence of an additive. It 
remains an open question, whether a difference between these formulations would be seen after 
longer storage time. Here, we should note that the although the strength of the correlations in 
Fig S35 differ, there was good agreement between the stability-indicating techniques, and they 
were all useful for identifying the two PPI13 formulations that were least stable during long-
term storage. Taking a decision which protein formulations should (or should not) be developed 
is easier in cases like this due to the consensus between the stability-indicating techniques. 
An interesting observation is that during long-term stability studies with PPI13 we did not 
detect an increase in the amount of soluble aggregates but found that the protein aggregates by 
forming large particles which contributes to monomer loss. When the protein is refolded from 
9 M urea using the ReFOLD assay, we observe substantial monomer loss but only a small 
increase in the soluble aggregates, identified as dimers (Fig 46). For a comparison, two other 
antibodies form much more soluble aggregates with various sizes after refolding from urea182. 
These results indicate that the aggregation mechanisms of PPI13 during long-term storage and 
during refolding from urea in different formulations are probably similar. 
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7.5 Conclusion 
In this work, we applied orthogonal high-throughput techniques to probe the effect of 280 mM 
sucrose, 140 mM arginine hydrochloride and 70 mM arginine glutamate on the stability of a 
monoclonal antibody named PPI13. We found good agreement between various parameters 
showing that sucrose stabilises the protein, while arginine salts in this concentration reduce the 
colloidal protein stability at both pH 5 and pH 6.5. This reduction can be explained with the 
increase in ionic strength and the screening of electrostatic repulsion between the protein 
monomers. We also performed long-term stability studies to validate the observations from the 
prompt biophysical characterisation. The two parameters that show the strongest correlation 
with the long-term stability data are the temperature of the first thermal unfolding inflection 
point and the relative monomer yield after isothermal refolding from urea. Formulations in 
which PPI13 unfolds at lower temperature and has low colloidal stability are the formulations 
in which a considerable amount of subvisible particles were formed after 12-month storage at 
25 ºC.  Our work is important in two directions. First, it shows that the effect of additives on 
the long-term stability of PPI13 can be predicted with the biophysical techniques used here. 
And second, we show that a more comprehensive approach is needed to predict whether 
arginine salts will inhibit or promote aggregation. Although arginine can undoubtedly bring 
benefits in formulations where the short-ranged hydrophobic interactions are important (e.g. at 
high protein concentration), arginine salts can have a detrimental effect on the protein colloidal 
stability in protein formulations where electrostatic repulsion is important to suppress protein 
aggregation (e.g. dilute protein solutions with low ionic strength). 
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7.6 Supplementary data 
 Additive 
From nanoDSF® From DLS From SLS 
IP1, ⁰C IP2, ⁰C Tagg, ⁰C kD (mL/g) D0 (cm2/s) 
A2 
(mol.mL/g2) 
pH 5 
No 58.2 ±0.05 80.17 ±0.07 78.11 ±0.29 34.20 4.70E-07 3.6296E-4 
280 mM Sucrose 59.32 ±0.06 81.04 ±0.05 78.86 ±0.14 16.70 4.16E-07 3.9649E-4 
140 mM ArgHCl 55.43 ±0.06 76.99 ±0.03 60.76 ±0.86 -13.90 4.48E-07 2.5636E-5 
140 mM GuHCl 54.41 ±0.05 76.21 ±0.01 60.35 ±0.93 -15.40 4.66E-07 2.1202E-5 
140 mM NaCl 55.25 ±0.02 76.78 ±0.04 57.37 ±0.08 -33.40 4.56E-07 -7.8494E-5 
70 mM ArgGlu 59.7 ±0.09 80.37 ±0.01 73.32 ±0.24 -11.10 4.48E-07 1.0445E-4 
70 mM GuHCl 55.55 ±0.03 77.5   ±0.05 65.76 ±0.89 -16.50 4.67E-07 1.7217E-5 
70 mM NaCl 55.95 ±0.04 77.81 ±0.04 61.13 ±0.18 -28.70 4.55E-07 -1.7224E-5 
pH 
6.5 
No 64.33 ±0.10 80.11 ±0.04 76.68 ±0.38 27.30 5.01E-07 2.8685E-4 
280 mM Sucrose 65.86 ±0.11 81.24 ±0.03 77.38 ±0.42 10.40 4.62E-07 4.4982E-4 
140 mM ArgHCl 62.25 ±0.06 78.97 ±0.04 73.26 ±0.50 -15.80 4.55E-07 2.3052E-5 
140 mM GuHCl 61.93 ±0.07 78.1   ±0.08 71.76 ±0.29 -18.70 4.72E-07 1.4398E-5 
140 mM NaCl 63.33 ±0.06 79.3   ±0.03 71.46 ±0.62 -35.70 4.63E-07 -1.9252E-4 
70 mM ArgGlu 63.84 ±0.02 80.36 ±0.01 74.11 ±0.45 -16.80 4.47E-07 2.6366E-5 
70 mM GuHCl 62.95 ±0.02 79.13 ±0.11 72.08 ±0.53 -24.70 4.73E-07 -1.1819E-5 
70 mM NaCl 64.08 ±0.14 79.2   ±0.05 69.75 ±0.72 -40.80 4.61E-07 -9.2413E-5 
Table S7. Stability indicating parameters of PPI13 at pH 5 and pH 6.5 in the presence of different additives 
 
 
 
 
 
 
 
149 
 
Additive No 
280 mM 
sucrose 
140 mM 
ArgHCl 
140 mM 
GuHCl 
140 mM 
NaCl 
70 mM 
ArgGlu 
70 mM 
GuHCl 
70 mM 
NaCl 
pH 5 13 (±5.5) 287 (±2.3) 244 (±3.5) 261 (±5.6) 274 (±1.5) 138 (±6.7) 138 (±2.9) 143 (4.6) 
pH 6.5 2 (±1) 294 (±7.8) 235 (±5.7) 259 (±3.8) 254 (±2.5) 123 (±3.8) 134 (±4.5) 134 (±5.5) 
Table S8. Osmolarity of 5 g/L PPI13 solutions in 10 mM histidine buffer with pH 5 and pH 6.5 including different 
additives. The values are mean of triplicates, the error is the standard deviation. The osmolarity was measured 
with a VAPRO® Vapor Pressure Osmometer using 10 µL sample volume. The device was calibrated before use 
according to the manual from the manufacturer. 
 
Circular dichroism (CD) spectroscopy method used in this work: 
The 5 g/L PPI13 solution was filled in a quartz cuvette with 1 mm wavelength path and placed 
in a Jasco J-810 spectrometer (JASCO Deutschland GmbH, Pfungstadt, Germany). The sample 
temperature was increased with a gradient of 0.1 ⁰C/min. In 10 ⁰C interval, the near-UV spectra 
were collected with 3 accumulations and a speed of 20 nm/min. The spectra we smoothed using 
Savitzky-Golay algorithm with 9 smoothing points and plotted against temperature. 
 
Figure S30. Near-UV CD spectra of 5 g/L PPI13 in 10 mM histidine pH 5 at different temperatures. 
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Static light scattering method used in this work: 
Different concentrations of PPI13 in the respective buffer and additive were filled in 1532 
microwell plates as described for the dynamic light scattering measurements. The static light 
scattering measurements were performed with the DynaPro plate reader III using 2 % laser 
power, 0 % attenuation level and 30 acquisitions of 3 seconds. The light scattering of the pure 
buffers without protein was measured to determine the solvent offsets. The microwell plate 
was calibrated using concentration series of dextran solutions with known molecular weight 
and second virial coefficient.  
 
Figure S31. Correlation between the interaction parameter kD from dynamic light scattering and the second virial 
coefficient A2 from static light scattering. 
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Figure S32. Effect of pH and additives on the near-UV CD spectra of native PPI13 (green line), PPI13 incubated 
for 24 hours in 9 M urea (yellow dash and dot), and PPI13 refolded from 9 M urea (red dots). (A) pH 5 with no 
additive; (B) pH 5 with 280 mM sucrose; (C) pH 5 with 140 mM arginine hydrochloride; (D) pH 5 with 70 mM 
arginine glutamate; (E) pH 6.5 with no additive; (F) pH 6.5 with 280 mM sucrose; (G) pH 6.5 with 140 mM 
arginine hydrochloride; (H) pH 6.5 with 70 mM arginine glutamate; The addition of 9 M urea perturbs the 
structure of PPI13 as seen by the change in the near-UV CD spectra (yellow dash and dot). The refolded PPI13 
(red dots) has the typical near-UV CD spectrum of the native protein (green line) in all tested formulations. 
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Figure S33. Relative area of aggregates detected by size exclusion chromatography during storage of PPI13 with 
different additives at (A) 25 ºC and pH 5, (B) 25 ºC and pH 6.5, (C) 4 ºC and pH 5, (D) 4 ºC and pH 6.5.  
 
Figure S34. Subvisible particles of PPI13 measured during storage for 12 months at 4 ºC 
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Figure S35. Correlations between long-term stability data and stability indicating parameters and long-term 
stability data obtained after storage for 12 months at 25 C. Correlation between the number of subvisible particles 
after storage and (A) the first thermal unfolding inflection point, (B) the second thermal unfolding inflection point 
(C) the aggregation onset temperature, (D) the interaction parameter kD, (E) the relative monomer yield after 
refolding from 9M urea; Correlation between the monomer recovery after storage and (F) the first thermal 
unfolding inflection point, (G) the second thermal unfolding inflection point (H) the aggregation onset 
temperature, (I) the interaction parameter kD, (J) the relative monomer yield after refolding from 9M urea; 
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Chapter 8 Summary of the thesis  
The primary aim of this thesis was to investigate whether techniques used for prompt 
biophysical characterisation can be used to accurately rank and select therapeutic protein 
formulations stable during long-term storage. 
In Chapter 1, I started the thesis with a brief overview of protein stability from the perspective 
of a protein formulation scientist. This chapter can serve as an introduction to people that are 
new to the topic and that want to learn about the various aspects that must be considered to 
obtain a stable protein formulation. In Chapter 2, I applied some of the state-of-the-art protein 
characterisation techniques on interferon alpha2a. Using these techniques and a systematic 
approach I selected four leading formulations and performed long-term stability studies on 
them. The formulation indicated as most stable by the largest number of stability-indicating 
parameters was also the most stable during long-term storage. I then moved to Chapter 3, where 
I discussed some disadvantages of the thermal denaturation techniques. I demonstrated that 
using these methods on formulations that exhibit a change in their properties (i.e. pH) during 
heating can lead to misleading stability rankings. These findings also explained some 
observations in the literature that proteins have lower melting temperatures in histidine buffer 
compared to acetate and citrate buffer, for example. To tackle the problems arising from sample 
heating, I developed a microwell plate-based method for isothermal chemical denaturation in 
our laboratory and applied it to investigate non-reversibility unfolding effects (i.e. the 
concentration dependence of the Gibbs free energy of unfolding) and by this to find antibody 
formulations stable during storage. Encouraged by the agreement between storage stability data 
and the non-reversibility effects measured with isothermal chemical denaturation, I started 
Chapter 4 in which I studied the aggregation of two antibodies after dilution from different 
concentrations of a denaturant. I showed that there is a connection between several stability-
indicating parameters and the level of aggregation after refolding by dilution in different 
formulations. Based on the results in Chapter 4, I developed a hypothesis that the aggregation 
of the partially folded proteins will depend on the formulation conditions.  
In Chapter 5, I prove this hypothesis by systematically studying the effect of denaturants on 
the unfolding and aggregation of an antibody. I demonstrate with orthogonal techniques that a 
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partially unfolded antibody exhibits more aggregation at pH 6.5 compared to pH 5. I then show 
that the aggregation of the partially unfolded protein in the presence of denaturants agrees well 
with the aggregation of the protein during isothermal refolding from denaturants. From these 
observations, I assumed that the aggregation during refolding from urea in different 
formulations could be used to rank formulations in order of their effect on the aggregation of 
the protein during long-term storage. To study this, in Chapter 6, I develop a microdialysis-
based unfolding/refolding assay, named ReFOLD. I show that the parameters obtained from 
the ReFOLD assay correlate very well with the aggregation of two antibodies, each in 12 
different formulations, during storage at 4 ºC and 25 ºC. Until that point, most of the work in 
this thesis was focused on the effect of pH, buffer type, ionic strength and protein concentration. 
Besides these variables, another essential part of formulation development is the inclusion of 
additives. Such additives are typically sugars or amino acids, and their effect on protein 
stability can be either positive or negative. To cover this aspect, I included Chapter 7 in which 
I investigate the effect of sucrose and arginine salts on the stability of a model antibody. A 
combination of complementary techniques, including the newly developed ReFOLD assay, 
was able to determine and explain the effect of these additives on the different aspects of protein 
stability and the predictions were confirmed by long-term stability data. The thesis is concluded 
with this summary and general suggestions for rational therapeutic protein formulation 
approach. 
This thesis is relevant to both basic and applied research as it shows several protein formulation 
case studies. Most of the techniques I used require small sample amounts which makes the 
approaches presented here especially interesting for people involved in the early-stage 
development of therapeutic protein candidates. Also, the presented ReFOLD assay is a new 
stability-predicting tool that can become an integral part of protein formulation design and the 
concept behind it carries the potential of many creative follow-up studies. The part of the thesis 
which is rarely seen in published work and therefore carries particularly high value are the 
comparisons between stability-indicating parameters and long-term stability data after storage 
at 4 ºC and 25 ºC of the proteins in different formulations.  
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A rational approach to develop protein formulations stable during long-term storage 
Stepping into formulation studies of a new therapeutic protein raises two questions: 
1. What techniques should be used? and 2. What formulation variables should be studied? 
Regarding the first question, the main message from this thesis is that no single technique can 
provide a reliable prediction for protein aggregation in all cases.  Attempts to correlate a single 
parameter to long-term stability data will sometimes succeed and sometimes fail depending on 
the protein. The best formulation approach is to apply a combination of several orthogonal 
methods to study the protein thermal unfolding, aggregation, colloidal stability, monomer 
recovery after refolding, and, if necessary, other relevant parameters like viscosity. An 
approach that employs a combination of many techniques in the very early-stage development 
of proteins was unthinkable several years ago since many of the methods like differential 
scanning microcalorimetry required large sample amounts and suffered from low throughput. 
Fortunately, the technological progress has greatly decreased the sample volume and increased 
the throughput of most machinery enabling us to make the formulation development of 
therapeutic proteins more efficient. 
Regarding the second question, as discussed in Chapter 1, protein formulation is a compromise. 
Much like in diplomacy, the formulation scientists are looking for conditions where all aspects 
of protein stability are satisfied. This compromise can be achieved by optimising several 
formulation variables. These variables are typically solution pH and ionic strength; the type 
and concentration of buffer, osmolytes, surfactants, antioxidants; protein concentration; and 
the primary package. Some directions how to investigate these variables are listed below: 
Study the effect of pH - A successful and effective pH screen starts with a sound theoretical 
preparation before the experiments. Most of the chemical changes that I briefly discussed in 
Chapter 1 are greatly accelerated at very acidic or basic pH. This means that typically only the 
pH range of 3.5 to 8.0 is feasible for long-term protein storage at 4 ºC and 25 ºC. Good 
knowledge of the molecule can narrow this pH range even more. For example, if the protein 
under development is an IgG1 antibody, it is known that the optimal pH range for storage of 
these proteins is between 5 and 7. Next, several complementary techniques can be applied to 
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study the unfolding and aggregation of the protein in the selected pH range. If the sample 
amount is limited, a combination of sample-saving high-throughput techniques like the ones 
used in Chapter 2 can be applied. In case more sample is available, isothermal methods like 
isothermal chemical denaturation (Chapter 3) and isothermal refolding from denaturant 
(Chapter 6) can be used. The aim during the pH screen is to discard formulations that have very 
low melting and aggregation onset temperatures, as well as formulations that have low Gibbs 
free energy of unfolding or low monomer yield after refolding from urea. Although it is difficult 
to define a threshold for these values that will be valid for all proteins, one could, for example, 
adopt an approach where the worst 25-50 % of all formulations are discarded. 
Study the effect of different buffers – After the pH range (±1 pH unit) of optimal stability is 
defined, different buffer systems must be tested. The main requirement is to select buffers that 
have a high buffer capacity in the desired pH range. To keep the ionic strength of the buffer 
low, the buffer concentration typically should be low (e.g. ≤ 50 mM) and the final pH should 
be achieved by combining the appropriate amounts of the two buffer components. Further, the 
buffer molecules are not inert towards the protein and as I show in Chapter 6 a change from 
citrate to histidine can have a positive effect on the protein stability during storage. It is 
important that buffers having different pH shift with temperature are not compared with each 
other using non-isothermal techniques as we show in Chapter 3. The effect of the buffers on 
the protein stability can be studied by assessing parameters like the interaction parameter kD, 
the second osmotic virial coefficient A2, the Gibbs free energy of protein unfolding, or the 
relative monomer yield after refolding from urea. 
Study the effect of ionic strength – the ionic strength of the solution can have a significant 
influence on the protein aggregation during storage when electrostatic interactions between the 
monomers are contributing to high colloidal protein stability. The effect of an increase in ionic 
strength on the protein unfolding and aggregation can be studied with thermal denaturation 
techniques as I demonstrate in Chapter 2 or with isothermal methods like the ReFOLD assay 
in Chapter 6 and dynamic light scattering in Chapter 7. These studies will aim to define if low 
(e.g. ≤20 mM), moderate (e.g. 20 – 140 mM) or high (e.g. ≥ 140 mM) ionic strength will have 
favourable effects on the protein stability-indicating parameters. 
 
159 
 
Study the effect of additives – After the optimal pH, buffer and ionic strength are defined, the 
formulation scientist can include various additives, e.g. osmolytes, in the formulation. Such 
additives might not always be needed to stabilise the protein but, for example, could be used 
to adjust the tonicity of the solution. Additives can positively or negatively affect protein 
stability as we also show in this thesis. A systematic approach with stability-indicating 
techniques like the one in Chapter 7 is needed to assess the effects of additives on protein 
stability and to predict their impact on protein aggregation during long-term storage.   
Effect of protein concentration – Increasing protein concentration typically results in more 
aggregation during storage as also we show with the antibody LMU-1 in Chapter 6. These 
effects were predictable by assessing the aggregation onset temperature of the protein and the 
relative monomer yield after refolding from urea. A critical point here is that there is an 
increased demand for highly concentrated protein formulations, e.g. 150-200 g/L for 
antibodies. The development of such formulations brings additional challenges that were 
unfortunately outside the scope of this thesis. Such complications are, for example, related to 
high viscosity, phase separation and aggregation driven by short-ranged hydrophobic 
interactions. Studying and tackling these phenomena requires the adoption of more methods 
and the use of viscosity-lowering agents. Future work will have to address these challenges. 
Study the effect of surfactants – Although outside the scope of this thesis, the interfacial protein 
stability is another important aspect of protein formulation. The impact of several surfactants, 
e.g. polysorbates and poloxamers, on the protein stability should be studied by a combination 
of appropriate analytical techniques mentioned in Chapter 1 and suitable mechanical stress like 
agitation, shaking, freeze/thaw and after repetitive drops.  
Study the effect of antioxidants – after several leading formulations with optimised pH, ionic 
strength, osmolyte and surfactant are selected, the sensitivity to oxidation of the protein should 
be tested. This can be done by stress like light exposure, the addition of oxidants, purging with 
oxygen or exposure to high temperature coupled to a suitable analytical technique  
(see Chapter 1). It is essential that these studies are also done after the surfactants and all other 
excipients are added since they can impact the oxidation rates. If needed, an antioxidant like 
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methionine can be included in the formulation or the solution can be filled and closed under 
oxygen-poor atmosphere. 
Study the effect of the primary package – Finally, the effect of the primary package on the 
protein stability should be extensively studied. The package material, transparency, fill volume, 
type of overhead gas, presence of tungsten or silicon oil can all affect the stability of the protein 
in the lead formulations. In the best case, several primary packages should be tested with stress 
and accelerated stability studies to access their impact on the product.  
 
The suggestions above can serve as some starting points for protein formulation studies.  
One should not look at all these steps of protein formulation development separately but always 
think about the connection between them and how changing one variable positively or 
negatively affects different aspects of protein stability. Complex and non-evident relationships 
between variables can be better studied by applying design of experiments (DoE). Although 
the application of DoE was not part of this thesis, this concept can also be applied to 
simultaneously and quickly study the effect of various formulation variables (e.g. pH, ionic 
strength, buffer system) on several stability-indicating parameters. For example, a screen for 
optimal pH and ionic strength like the one in Chapter 2 can also be integrated into DoE and 
can be completed in a couple of days by consuming only several micrograms of protein. The 
presented ReFOLD assay can also be used in the design of protein formulation studies as an 
orthogonal stability-indicating technique that provides good predictions which formulations 
will impede protein aggregation during storage.  
 
Finally, the selection of the leading formulations should be performed also considering the 
entire life cycle of a potential therapeutic protein drug starting from protein expression and 
finishing with the administration in patients. 
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